denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Ha, X.
1774 - Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial
3098 - Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study
4408 - Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study
3098 - Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study
4408 - Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study
Haack, S.
Haaf, T.
Haake, A.
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
1442 - Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
1442 - Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
Haaland, B.
Haarer, E. L.
Haas, O. A.
Haas, S.
860 - Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
2554 - Unraveling and Visualizing the Interactions of Acute Myeloid Leukemia with the Bone Marrow Microenvironment in Vitro and In Vivo
3928 - Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML
- Combined Single-Cell and Spatially Resolved Mapping of Lymph Node Ecosystems Reveals Fundamental Principles of Lymphoma Tissue Organization
2554 - Unraveling and Visualizing the Interactions of Acute Myeloid Leukemia with the Bone Marrow Microenvironment in Vitro and In Vivo
3928 - Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML
- Combined Single-Cell and Spatially Resolved Mapping of Lymph Node Ecosystems Reveals Fundamental Principles of Lymphoma Tissue Organization
Haase, D.
3100 - Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
Habenicht, K. M.
Haberichter, S. L.
Habermann, T. M.
545 - A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study
724 - Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
793 - Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
798 - Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
2860 - Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)
2889 - Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
2957 - Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium
2966 - Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study
4156 - Molecular Landscape of Primary Refractory DLBCL
4207 - Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group
4216 - Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
4437 - Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
724 - Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
793 - Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
798 - Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
2860 - Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)
2889 - Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
2957 - Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium
2966 - Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study
4156 - Molecular Landscape of Primary Refractory DLBCL
4207 - Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group
4216 - Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
4437 - Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
Habib, R.
Habibi, A.
Hablesreiter, R.
Habte, H.
Hachem, N.
Hachfeld, C. M.
Hachimi, M.
Hack, J.
Hackett, L. R.
Hackworth, R.
Haddad, B.
Haddad, C.
Haddad, F.
213 - Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
333 - Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis
619 - Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia
944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
1378 - Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia
1384 - Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)
1695 - Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia
1696 - More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
4224 - Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia
4330 - Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy
333 - Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis
619 - Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia
944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
1378 - Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia
1384 - Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)
1695 - Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia
1696 - More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
4224 - Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia
4330 - Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy
Haddad, P. A.
1577 - Splenic Diffuse Red Pulp Small B-Cell Lymphoma Descriptors and Clinicopathologic Determinants of Clinical Outcomes: Analysis of a Pooled Database
1601 - Primary Cutaneous Gamma-Delta T-Cell Lymphoma (PCGDTCL) Descriptors and Clinicopathologic Determinants of Survival: Analysis of a Pooled Database
2505 - Risk of Intracranial Hemorrhage with Direct Oral Anticoagulants (DOACs) Versus Low Molecular Weight Heparin (LMWH) in Primary and Secondary Brain Cancers: An up-to-Date Meta-Analysis of Comparative Studies
2934 - Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma (PCAECTCL) Descriptors and Clinicopathologic Determinants of Survival: Analysis of a Pooled Database
4246 - Clinicopathologic Determinants of Subcutaneous Panniculitis-like T-Cell Lymphoma (SPTCL) Clinical Outcomes: Analysis of a Pooled Database
4947 - Comparative Efficacy of Targeted Therapies in Old Unfit Intermediate to High-Risk Patients with Acute Myeloid Leukemia: A Meta-Analysis of Comparative Studies
1601 - Primary Cutaneous Gamma-Delta T-Cell Lymphoma (PCGDTCL) Descriptors and Clinicopathologic Determinants of Survival: Analysis of a Pooled Database
2505 - Risk of Intracranial Hemorrhage with Direct Oral Anticoagulants (DOACs) Versus Low Molecular Weight Heparin (LMWH) in Primary and Secondary Brain Cancers: An up-to-Date Meta-Analysis of Comparative Studies
2934 - Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma (PCAECTCL) Descriptors and Clinicopathologic Determinants of Survival: Analysis of a Pooled Database
4246 - Clinicopathologic Determinants of Subcutaneous Panniculitis-like T-Cell Lymphoma (SPTCL) Clinical Outcomes: Analysis of a Pooled Database
4947 - Comparative Efficacy of Targeted Therapies in Old Unfit Intermediate to High-Risk Patients with Acute Myeloid Leukemia: A Meta-Analysis of Comparative Studies
Haddadi, S.
Hader, C.
Hadidi, Y. F.
Hadjur, S.
Hadland, B.
Hadzijusufovic, E.
Haebe, S.
Haegele, F.
Haenel, M.
212 - Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
742 - Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
759 - Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial
877 - Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
968 - Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
1438 - Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
2786 - Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
742 - Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
759 - Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial
877 - Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
968 - Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
1438 - Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
2786 - Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
Haertle, L.
1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
1882 - Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase (PSMC) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP/ATP Binding Pocket
3146 - Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
1882 - Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase (PSMC) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP/ATP Binding Pocket
3146 - Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma
Haferlach, C.
228 - AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages?
438 - A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
787 - Machine Learning Algorithm Correctly Identifies 95% of Cells in Differential Count of Blood Smears: A Prospective Study on >29,000 Cases and >17 Million Single Cells
790 - Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases
856 - Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS
1281 - RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
1373 - Evaluation of Analysis Strategy for Cytoplasmic Lineage-Associated Markers in Mixed-Phenotype Acute Leukemia (MPAL) As Devised By Who Classification 2022
1477 - IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing
1769 - Application of a Flow Cytometric Core Marker Set in the Diagnostic Workup of Patients with Suspected Myelodysplastic Syndromes
1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
2823 - Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
3487 - Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL
3861 - Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
4118 - Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup?
4813 - A Fully Automated Digital Workflow for Assessment of Bone Marrow Cytomorphology Based on Single Cell Detection and Classification with AI
438 - A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
787 - Machine Learning Algorithm Correctly Identifies 95% of Cells in Differential Count of Blood Smears: A Prospective Study on >29,000 Cases and >17 Million Single Cells
790 - Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases
856 - Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS
1281 - RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
1373 - Evaluation of Analysis Strategy for Cytoplasmic Lineage-Associated Markers in Mixed-Phenotype Acute Leukemia (MPAL) As Devised By Who Classification 2022
1477 - IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing
1769 - Application of a Flow Cytometric Core Marker Set in the Diagnostic Workup of Patients with Suspected Myelodysplastic Syndromes
1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
2823 - Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
3487 - Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL
3861 - Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
4118 - Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup?
4813 - A Fully Automated Digital Workflow for Assessment of Bone Marrow Cytomorphology Based on Single Cell Detection and Classification with AI
Haferlach, T.
85 - Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
228 - AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages?
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
787 - Machine Learning Algorithm Correctly Identifies 95% of Cells in Differential Count of Blood Smears: A Prospective Study on >29,000 Cases and >17 Million Single Cells
790 - Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases
791 - Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia
856 - Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS
857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
1281 - RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
1373 - Evaluation of Analysis Strategy for Cytoplasmic Lineage-Associated Markers in Mixed-Phenotype Acute Leukemia (MPAL) As Devised By Who Classification 2022
1477 - IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing
1741 - Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
1750 - Cooperative Effects of SRSF2 and STAG2 mutations on Development of Myelodysplastic Syndrome and Its Related Disorders
1769 - Application of a Flow Cytometric Core Marker Set in the Diagnostic Workup of Patients with Suspected Myelodysplastic Syndromes
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
2643 - Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
2779 - Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
2823 - Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3064 - Splicing Analysis Unveils Convergent Transcriptomic Pathways in U2AF1 S34 and Q157 Mutant Myeloid Neoplasia
3070 - Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
3487 - Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL
3861 - Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression
3887 - Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
3917 - Molecular and Clinical PHF6 Mutant Myeloid Neoplasia Provides Clues As to Their Pathogenesis and Therapeutic Targeting
3955 - Role of MBD4 Mutation in Neoplastic Evolution of Acute Myeloid Leukemia
4016 - Identification of Phenotypic Subgroups of Acute Myeloid Leukemia, Defined By Differentiation According to Who 2022 Classification
4017 - Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
4118 - Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup?
4378 - Synthetic Data Generation By Artificial Intelligence to Accelerate Translational Research and Precision Medicine in Hematological Malignancies
4379 - Dead and Deah-Box Helicases Other Than DDX41 Are Mutated in Myeloid Neoplasia
4415 - Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms
4813 - A Fully Automated Digital Workflow for Assessment of Bone Marrow Cytomorphology Based on Single Cell Detection and Classification with AI
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
228 - AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages?
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
787 - Machine Learning Algorithm Correctly Identifies 95% of Cells in Differential Count of Blood Smears: A Prospective Study on >29,000 Cases and >17 Million Single Cells
790 - Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases
791 - Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia
856 - Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS
857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
1281 - RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
1373 - Evaluation of Analysis Strategy for Cytoplasmic Lineage-Associated Markers in Mixed-Phenotype Acute Leukemia (MPAL) As Devised By Who Classification 2022
1477 - IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing
1741 - Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
1750 - Cooperative Effects of SRSF2 and STAG2 mutations on Development of Myelodysplastic Syndrome and Its Related Disorders
1769 - Application of a Flow Cytometric Core Marker Set in the Diagnostic Workup of Patients with Suspected Myelodysplastic Syndromes
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
2643 - Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
2779 - Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
2823 - Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3064 - Splicing Analysis Unveils Convergent Transcriptomic Pathways in U2AF1 S34 and Q157 Mutant Myeloid Neoplasia
3070 - Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
3487 - Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL
3861 - Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression
3887 - Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
3917 - Molecular and Clinical PHF6 Mutant Myeloid Neoplasia Provides Clues As to Their Pathogenesis and Therapeutic Targeting
3955 - Role of MBD4 Mutation in Neoplastic Evolution of Acute Myeloid Leukemia
4016 - Identification of Phenotypic Subgroups of Acute Myeloid Leukemia, Defined By Differentiation According to Who 2022 Classification
4017 - Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
4118 - Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup?
4378 - Synthetic Data Generation By Artificial Intelligence to Accelerate Translational Research and Precision Medicine in Hematological Malignancies
4379 - Dead and Deah-Box Helicases Other Than DDX41 Are Mutated in Myeloid Neoplasia
4415 - Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms
4813 - A Fully Automated Digital Workflow for Assessment of Bone Marrow Cytomorphology Based on Single Cell Detection and Classification with AI
Hafsaoui, A. Y.
Hagberg, H.
Hagedoorn, R. S.
1104 - Sars-Cov-2-Specific CD4+ and CD8+ T Cell Responses Can Originate from Cross-Reactive CMV-Specific T Cells
1961 - Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain
4600 - Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia
4625 - T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma
1961 - Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain
4600 - Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia
4625 - T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma
Hagelaar, R.
Hageman, L.
119 - Specific Clonal Mutations Are Predictive of Therapy-Related Myeloid Neoplasms (tMN) after Autologous Peripheral Blood Stem Cell Transplantation (aPBSCT) for Lymphoma
492 - Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)
903 - Poverty during Maintenance and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): A Report from Children’s Oncology Group Study (COG-AALL03N1)
2253 - Individual Prediction of Cardiovascular Events in Blood or Marrow Transplant Survivors - a BMT Survivor Study Report
2304 - Processing Speed Improvement in Hematologic Cancer Survivors Treated with Allogeneic Blood or Marrow Transplantation– a Randomized Online Cognitive Training Intervention
492 - Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)
903 - Poverty during Maintenance and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): A Report from Children’s Oncology Group Study (COG-AALL03N1)
2253 - Individual Prediction of Cardiovascular Events in Blood or Marrow Transplant Survivors - a BMT Survivor Study Report
2304 - Processing Speed Improvement in Hematologic Cancer Survivors Treated with Allogeneic Blood or Marrow Transplantation– a Randomized Online Cognitive Training Intervention
Hagemeister, F. B.
Haggarty, N.
Haggenburg, S.
808 - Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
3120 - Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients with Chronic Lymphocytic Leukaemia
3736 - Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies
3120 - Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients with Chronic Lymphocytic Leukaemia
3736 - Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies
Haghverdi, L.
Hagihara, M.
Hagl, C.
Hagner, P.
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
1682 - Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial
3143 - Suppression of Myeloid Cell–Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)
1682 - Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial
3143 - Suppression of Myeloid Cell–Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)
Hagstroem-Andersson, A.
Hahn, C. N.
1754 - Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
4730 - Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
4730 - Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
Hahn, C. K.
3128 - Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia
4432 - Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter’s Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia
4432 - Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter’s Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia
Hahn, S.
Hahn, T. E.
270 - Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation
385 - Risk Factors Beyond Chemo-Radiotherapy Exposure for Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML) Development in Breast Cancer Survivors: A 15-Year SEER-Medicare Analysis
1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
4760 - Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT
385 - Risk Factors Beyond Chemo-Radiotherapy Exposure for Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML) Development in Breast Cancer Survivors: A 15-Year SEER-Medicare Analysis
1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
4760 - Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT
Haigney, M.
Hailan, Y. M.
Haiman, C. A.
270 - Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation
1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT
4760 - Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT
1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT
4760 - Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT
Haimed, A.
Haims, A.
3151 - Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy
3249 - Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
3249 - Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
Haingartner, S.
842 - Loss of Nr4a1 Causes an Elevated Expression of Co-Inhibitory Receptor:Ligand Axes and Results in a Diminished T Cell-Mediated Lymphoma Cell Killing in Aggressive Lymphoma
2159 - The Flavonoid Brusatol Induces Apoptosis in Aggressive Lymphoma Cells and Exhibits Synergistic Effect with Venetoclax
2159 - The Flavonoid Brusatol Induces Apoptosis in Aggressive Lymphoma Cells and Exhibits Synergistic Effect with Venetoclax
Haioun, C.
542 - Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
2026 - CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry
2026 - CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry
Haioun, C.
312 - EBV Dictates Lower Tumor Neoepitopes Scores and Intra-Tumoral Repertoire Diversity in NHL from Immuno-Compromized Patients
449 - Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa
767 - Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
2883 - Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study
449 - Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa
767 - Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
2883 - Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study
Hait, A.
Hajducek, D. M.
Hájek, R.
1859 - Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study
1922 - Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years
1926 - Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years
4491 - Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1–3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study
1922 - Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years
1926 - Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years
4491 - Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1–3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study
Haji, M.
Hajj Ali, A.
3211 - Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant
4748 - Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4748 - Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
Hajj, C.
557 - Initial Treatment Response Is Prognostic and Predictive of Relapse Patterns: Outcomes of >500 Patients Treated for Primary CNS Lymphoma
1573 - “Big Boom” (4 Gy x 1) Radiation Treatment (RT) Versus “Big Boom” (2 Gy x 2) for Non-Hodgkin Lymphoma (NHL)
2854 - Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma
2974 - Radiotherapy for Secondary CNS Lymphoma: Patterns of Utilization and Clinical Outcomes
4292 - Safety and Efficacy of Splenic Irradiation for Non-Hodgkin Lymphoma
4539 - Predictors of Response to Radiation Therapy and of Progression to Multiple Myeloma in Patients with Solitary Bone and Extramedullary Plasmacytomas
1573 - “Big Boom” (4 Gy x 1) Radiation Treatment (RT) Versus “Big Boom” (2 Gy x 2) for Non-Hodgkin Lymphoma (NHL)
2854 - Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma
2974 - Radiotherapy for Secondary CNS Lymphoma: Patterns of Utilization and Clinical Outcomes
4292 - Safety and Efficacy of Splenic Irradiation for Non-Hodgkin Lymphoma
4539 - Predictors of Response to Radiation Therapy and of Progression to Multiple Myeloma in Patients with Solitary Bone and Extramedullary Plasmacytomas
Hajj, K.
Hajmirza, A.
Hakim, H.
Hakim, N.
Hakim, S.
Häkkinen, A.
Hakobyan, M.
Hakobyan, N.
Hakobyan, Y.
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
Hakonardottir, G. K.
3188 - Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
Hakre, S.
Halaburda, K.
Halbsguth, T. V.
Haldar, S. D.
Hale, C.
Hale, S.
Halene, S.
530 - U2AF1 Splicing Factor Mutations Affect RNA Subcellular Compartmentalization in Myeloid Malignancies
2170 - Harmonizing the Annotation of Hematopoietic Populations in Single-Cell Atlases with the Cell Marker Accordion
2540 - Chronic Inflammation Drives p53 Mutant Clonal Hematopoiesis Via Activating the NLRP1 Inflammasome
2779 - Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
3151 - Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy
3249 - Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
3936 - Repressive β-Catenin-Ikaros Complexes Are Essential to Prevent Clonal Evolution of Human Lymphopoiesis
4017 - Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
4091 - A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure
4385 - Single-Cell Multiomics Reveal Hypomethylating Agent Partially Restores Hematopoiesis in a LR-MDS Patient at the Cost of Leukemic Transformation
4671 - Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel
2170 - Harmonizing the Annotation of Hematopoietic Populations in Single-Cell Atlases with the Cell Marker Accordion
2540 - Chronic Inflammation Drives p53 Mutant Clonal Hematopoiesis Via Activating the NLRP1 Inflammasome
2779 - Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
3151 - Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy
3249 - Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
3936 - Repressive β-Catenin-Ikaros Complexes Are Essential to Prevent Clonal Evolution of Human Lymphopoiesis
4017 - Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
4091 - A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure
4385 - Single-Cell Multiomics Reveal Hypomethylating Agent Partially Restores Hematopoiesis in a LR-MDS Patient at the Cost of Leukemic Transformation
4671 - Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel
Halfond, A.
Halka, J.
2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
Halkes, C. J.
2065 - Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3446 - Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia
4576 - Large Scale Identification and Validation of 85 New HLA Class I-Restricted Minor Histocompatibility Antigens for Immune Monitoring and Modulation after Allogeneic Stem Cell Transplantation
3446 - Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia
4576 - Large Scale Identification and Validation of 85 New HLA Class I-Restricted Minor Histocompatibility Antigens for Immune Monitoring and Modulation after Allogeneic Stem Cell Transplantation
Halkidis, K.
Hall, A. C.
1930 - Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial
2717 - Impact of Early Hospitalization, Medical Comorbidities and Allogeneic Stem Cell Transplantation on Survival in Acute Myeloid Leukemia Patients Treated with Venetoclax Based Therapy – a Single Institution Experience from an Academic Center
4863 - A Quality Improvement Initiative to Improve Implementation of Guideline-Concordant Hereditary Myeloid Malignancy Syndrome Evaluation
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
2717 - Impact of Early Hospitalization, Medical Comorbidities and Allogeneic Stem Cell Transplantation on Survival in Acute Myeloid Leukemia Patients Treated with Venetoclax Based Therapy – a Single Institution Experience from an Academic Center
4863 - A Quality Improvement Initiative to Improve Implementation of Guideline-Concordant Hereditary Myeloid Malignancy Syndrome Evaluation
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
Hall, C.
Hall, J. W.
Hall, J.
Hall, K.
Hall, K. H.
Hall, R. P.
Halladay, D.
Hallal, M.
Hallböök, H.
Hallek, M.
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
343 - Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
345 - Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment – Outcome Results from the CLL13/GAIA Trial
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
1536 - Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing
4419 - Proteogenomic Analysis of SF3B1mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways
4436 - Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
343 - Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
345 - Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment – Outcome Results from the CLL13/GAIA Trial
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
1536 - Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing
4419 - Proteogenomic Analysis of SF3B1mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways
4436 - Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
Haller, G.
Halperin, E.
Halpern, A. B.
57 - Time-Dependent Prediction of Relapse in Patients with Acute Myeloid Leukemia
496 - Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)
740 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
1385 - Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse
2694 - Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison
2708 - Time to Count Recovery after Post-Remission Chemotherapy in AML Patients
4057 - Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
496 - Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)
740 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
1385 - Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse
2694 - Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison
2708 - Time to Count Recovery after Post-Remission Chemotherapy in AML Patients
4057 - Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
Halsey, C.
Hama, A.
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission
2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission
Hamad, N.
75 - Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4728 - Ibrutinib for Steroid Refractory Chronic Graft Vs Host Disease - Real World Experience
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4728 - Ibrutinib for Steroid Refractory Chronic Graft Vs Host Disease - Real World Experience
Hamada, E.
Hamadani, J.
Hamadani, M.
65 - Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features
387 - Blood and Marrow Transplantation (BMT) within Four Weeks of Sars-Cov-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2018 - A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies
2851 - MRD Status By Clonoseq ® Is a Poor Predictor of Long-Term Outcomes after Bispecific LV20.19 CAR T-Cell Therapy for Relapsed, Refractory B-Cell NHL
2888 - Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404
2960 - Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
3331 - 8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma
3598 - Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy
4198 - Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma
4297 - CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort
4709 - Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
4806 - Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis Is an Effective Surveillance Tool in Patients with Mantle Cell Lymphoma
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
387 - Blood and Marrow Transplantation (BMT) within Four Weeks of Sars-Cov-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2018 - A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies
2851 - MRD Status By Clonoseq ® Is a Poor Predictor of Long-Term Outcomes after Bispecific LV20.19 CAR T-Cell Therapy for Relapsed, Refractory B-Cell NHL
2888 - Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404
2960 - Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
3331 - 8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma
3598 - Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy
4198 - Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma
4297 - CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort
4709 - Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
4806 - Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis Is an Effective Surveillance Tool in Patients with Mantle Cell Lymphoma
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
Hamadeh, I. S.
Hamamoto, K.
Hamard, P. J.
Hamashima, A.
Hamdy, A.
2650 - VIP943 Is a Novel CD123 Antibody Drug Conjugate with in Vitro and In Vivo Efficacy in Acute Myeloid Leukemia (AML) Models
4256 - Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
4793 - Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma
4256 - Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
4793 - Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma
Hamdy, M.
Hamed, A.
Hamer-Maansson, J. E.
Hamerschlak, N.
1609 - Does Prompt Access to Healthcare Impact the Outcomes of Hodgkin Lymphoma? a Comparison between Public and Private Patients Sharing the Same Infrastructure
2080 - Impact of Donor Age in the Selection of a Haploidentical or a Matched-Related Donor: A Secondary Analysis of a CIBMTR Database
2151 - Clinical Validation of Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of B Neoplasia
3129 - Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
2080 - Impact of Donor Age in the Selection of a Haploidentical or a Matched-Related Donor: A Secondary Analysis of a CIBMTR Database
2151 - Clinical Validation of Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of B Neoplasia
3129 - Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
Hamid, S.
Hamidi, H.
Hamidi, R.
Hamilton, A.
730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
4222 - Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
4222 - Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation
Hamilton, B. K.
375 - Association between Patient-Reported Social Determinant of Health Outcomes and a Social Genomics Profile in Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
573 - Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial
778 - Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
2037 - Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers
2221 - Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4719 - The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease
4731 - Quality of Life in Patients Undergoing Double Umbilical Cord Blood Vs. Haploidentical Marrow Transplantation: A QOL Analysis Report of BMT CTN 1101
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4908 - Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study
573 - Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial
778 - Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
2037 - Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers
2221 - Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4719 - The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease
4731 - Quality of Life in Patients Undergoing Double Umbilical Cord Blood Vs. Haploidentical Marrow Transplantation: A QOL Analysis Report of BMT CTN 1101
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4908 - Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study
Hamilton, C.
Hamilton, E.
Hamilton, III, J.
Hamilton, J.
Hamilton, J. R.
Hamilton, M.
3153 - Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
Hamilton, M. P.
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
Hamilton, Z. P.
Hamilton-Dutoit, S.
614 - Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial
1534 - Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation
2864 - Characterization and Clinical Impact of the Tumor Microenvironment of Post-Transplant Large B-Cell Lymphoma
1534 - Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation
2864 - Characterization and Clinical Impact of the Tumor Microenvironment of Post-Transplant Large B-Cell Lymphoma
Hamladji, R. M.
266 - Outcome of Haematopoietic Cell Transplantation in 813 Children with Fanconi Anaemia: A Study on Behalf of the EBMT Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
3443 - Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study
4895 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
3443 - Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study
4895 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study
Hamlin, P. A.
730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
4222 - Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
4222 - Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation
Hamm, C.
Hammami, M. B.
Hammer, M. J.
Hammer, Q.
Hammer, S.
Hammerschmidt, D.
Hammond, D.
1758 - Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients
3090 - Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)
4392 - Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure
3090 - Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)
4392 - Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure
Hammond, D.
596 - Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia
1432 - Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials
1756 - RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia
2701 - Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment
3889 - Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy
4074 - Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study
4401 - Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome
4411 - A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
1432 - Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials
1756 - RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia
2701 - Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment
3889 - Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy
4074 - Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study
4401 - Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome
4411 - A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Hammond, N.
Hammons, L.
3210 - Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (allo-HCT) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
3588 - Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy
3588 - Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy
Hamoda, A. M.
Hamouche, R.
Hamouda, D. M.
Hampel, P. J.
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
4276 - Prognosis Score for Overall Survival with CAR-T Therapy in Aggressive Lymphoma
4437 - Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
4276 - Prognosis Score for Overall Survival with CAR-T Therapy in Aggressive Lymphoma
4437 - Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
Hampp, C.
2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
2310 - Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
4896 - Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)
2310 - Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
4896 - Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)
Hampton, H. R.
3080 - In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial
4381 - Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment
4381 - Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment
Hampton, K.
Hampton, K.
351 - Malignant Plasma Cell Derived Mitochondrial Damps Activate Macrophages Via Sting Signalling to Promote Myeloma Development
2548 - LC3-Associated Phagocytosis Is Impaired in Bone Marrow Macrophages during Ageing Leading to Defective Processing of Apoptotic Cells and Suppression of Sting Activation
3852 - Mitochondrial Membrane Potential Defines the HSC Population with Serial Repopulating Potential in Young but Not Aged Animals
2548 - LC3-Associated Phagocytosis Is Impaired in Bone Marrow Macrophages during Ageing Leading to Defective Processing of Apoptotic Cells and Suppression of Sting Activation
3852 - Mitochondrial Membrane Potential Defines the HSC Population with Serial Repopulating Potential in Young but Not Aged Animals
Hampton, K.
Hampton, O.
646 - Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
1306 - Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes
1848 - A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data
2661 - Acid Ceramidase (ASAH1) Is a Key Mediator of Drug Resistance in Refractory Multiple Myeloma
1306 - Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes
1848 - A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data
2661 - Acid Ceramidase (ASAH1) Is a Key Mediator of Drug Resistance in Refractory Multiple Myeloma
Hamre, J.
Hamsher, H.
Hamulyák, E.
Han, B.
1766 - Alterations of Gut Microbiota in Myelodysplastic Syndromes and Aplastic Anemia: Potential Relationship with Inflammatory Response
2572 - Immunosuppressive Therapy-Response Predicting Scoring System for Severe Aplastic Anemia
2574 - Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study
2572 - Immunosuppressive Therapy-Response Predicting Scoring System for Severe Aplastic Anemia
2574 - Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study
Han, G.
Han, H.
1197 - Continuous Platelet Infusion Is an Effective Alternative to Conventional Transfusion in Reducing Platelet Transfusions in Critically Ill Pediatric Patients with Refractory Thrombocytopenia
3857 - Clonal Competition: Cisplatin Treatment Drives Dominance of TP53- over Tet2-Mutant Stem Cell Clones
3857 - Clonal Competition: Cisplatin Treatment Drives Dominance of TP53- over Tet2-Mutant Stem Cell Clones
Han, J.
2200 - COVID-19 Vaccination Status and Disease Burden in Patients with Sickle Cell Disease
2391 - Diabetes, Diabetic Control, and Kidney Dysfunction in Adults with Sickle Cell Disease
3704 - Association of Community-Level Socioeconomic Distress with Nutritional Status in People with Sickle Cell Anemia
2391 - Diabetes, Diabetic Control, and Kidney Dysfunction in Adults with Sickle Cell Disease
3704 - Association of Community-Level Socioeconomic Distress with Nutritional Status in People with Sickle Cell Anemia
Han, J. W.
Han, K.
Han, L.
919 - Mutational Permutations of a Single Amino Acid Exert Divergent Phenotypic Effects in Human, Mice, and Cellular Models of SAMD9L Bone Marrow Failure Disorder
1265 - Germline Loss-of-Function Mutations in MDM4 Cause p53-Dependent Hematopoietic Cell Death in Patients with Variable Bone Marrow Failure Phenotypes
1265 - Germline Loss-of-Function Mutations in MDM4 Cause p53-Dependent Hematopoietic Cell Death in Patients with Variable Bone Marrow Failure Phenotypes
Han, L.
Han, M.
989 - Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
4695 - The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients
4695 - The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients
Han, M. M.
3569 - Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy
4891 - Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy
4891 - Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy
Han, N. R.
Han, Q.
Han, S.
1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
Han, S.
Han, S.
1600 - Rituximab and Lenalidomide Plus Chidamide Can be an Effective Chemotherapy Regimen for Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma
4255 - “Gentle Initiation” Rituximab, Lenalidomide and Zanubrutinib Chemo-Free Regimen Followed By Immunochemotherapy for Elderly/Frail Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Investigator Initiated, Single Arm, Phase 2 Trial
4255 - “Gentle Initiation” Rituximab, Lenalidomide and Zanubrutinib Chemo-Free Regimen Followed By Immunochemotherapy for Elderly/Frail Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Investigator Initiated, Single Arm, Phase 2 Trial
Han, T.
780 - Development and Validation of a Prognostic Model Based on Clinical Biomarkers for Heart Failure in Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
2081 - Efficacy and Safety of MSCs Plus Basiliximab for the Treatment of Steroid-Resistant aGVHD after Haploidentical Stem Cell Transplantation: A Multicenter, Randomized, Open-Label Trial
2081 - Efficacy and Safety of MSCs Plus Basiliximab for the Treatment of Steroid-Resistant aGVHD after Haploidentical Stem Cell Transplantation: A Multicenter, Randomized, Open-Label Trial
Han, T.
2051 - Thrombopoietin Levels Predict the Response to Avatrombopag Treatment in Patients with Persistent Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplantation
2454 - Real-World Study of the Use of Iguratimod to Treat Chronic/Refractory ITP
3270 - Exploring the Effects of G-CSF Mobilization on the Immune Function of Mucosal-Associated Invariant T Cell Subsets By Single-Cell RNA-Seq
2454 - Real-World Study of the Use of Iguratimod to Treat Chronic/Refractory ITP
3270 - Exploring the Effects of G-CSF Mobilization on the Immune Function of Mucosal-Associated Invariant T Cell Subsets By Single-Cell RNA-Seq
Han, W.
780 - Development and Validation of a Prognostic Model Based on Clinical Biomarkers for Heart Failure in Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
3424 - Machine Learning Algorithm As a Prognostic Tool for Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation
3424 - Machine Learning Algorithm As a Prognostic Tool for Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation
Han, W.
Han, W.
Han, W.
407 - Dnmt3a Loss-of-Function Enhances DNA Repair in Proliferative HSCs Under Inflammatory Stress
3002 - Using a Humanized Animal Model to Determine the Minimum JAK2V617F Mutant Allele Burden Required to Generate MPN Pathologies
3851 - The PRC2 Co-Factor JARID2 Regulates Hematopoiesis through Non-Canonical Mechanisms
3942 - DNMT3A Mutations Enhance T-ALL Survival, Which Is Reversed By JAK/STAT Inhibition
3002 - Using a Humanized Animal Model to Determine the Minimum JAK2V617F Mutant Allele Burden Required to Generate MPN Pathologies
3851 - The PRC2 Co-Factor JARID2 Regulates Hematopoiesis through Non-Canonical Mechanisms
3942 - DNMT3A Mutations Enhance T-ALL Survival, Which Is Reversed By JAK/STAT Inhibition
Han, X.
Han, X.
Han, X.
Han, X.
Han, Y.
Han, Y.
1722 - Comparison of the Efficacy and Safety of Pegylated Interferon Alpha-2b and Common Interferon Alpha in Patients with Myeloproliferative Neoplasms
4373 - Mild Fibrosis (MF-1) Increases the Risk of Secondary Cancers in Patients with Myeloproliferative Neoplasms-Clinical Characteristics of 1060 Myeloproliferative Neoplasms Patients with Secondary Cancers
4373 - Mild Fibrosis (MF-1) Increases the Risk of Secondary Cancers in Patients with Myeloproliferative Neoplasms-Clinical Characteristics of 1060 Myeloproliferative Neoplasms Patients with Secondary Cancers
Han, Y.
Han, Y.
Han, Y.
Han, Z.
Hana, C.
Hanackova, V.
Hanafee Alali, T.
Hanash, A. M.
475 - Donor-Derived Amphiregulin Drives CD4+ T Cell Expansion and Promotes Tissue Pathology after Experimental Allogeneic BMT
480 - Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39
2077 - Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations
480 - Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39
2077 - Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations
Hancock, B.
Hancock, H.
Hancock, J.
Handa, H.
Handgretinger, R.
872 - Tcrαβ+/CD19+-Depletion in Hematopoietic Stem Cells Transplantation from Matched Unrelated and Haploidentical Donors in Pediatric Acute Lymphoblastic Leukemia Patients in Complete Remission
2010 - Allogeneic Donor-Derived Myeloid Antigen Directed CAR-T Cells – for Relapsed/Refractory Acute Myeloid Leukemia in Children after Allogeneic Hematopoietic Stem Cell Transplantation: Report of Three Cases
2060 - Hypofibrinolysis in Pediatric Patients with Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation
4913 - A Multidimensional Approach to Measuring Distress in Children Undergoing Hematopoietic Stem Cell Transplantation: Three Raters’ Perspectives and Stress Biomarkers in Saliva and Blood
2010 - Allogeneic Donor-Derived Myeloid Antigen Directed CAR-T Cells – for Relapsed/Refractory Acute Myeloid Leukemia in Children after Allogeneic Hematopoietic Stem Cell Transplantation: Report of Three Cases
2060 - Hypofibrinolysis in Pediatric Patients with Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation
4913 - A Multidimensional Approach to Measuring Distress in Children Undergoing Hematopoietic Stem Cell Transplantation: Three Raters’ Perspectives and Stress Biomarkers in Saliva and Blood
Hanekamp, D.
Haneke, T.
Hänel, G.
Hanel, W.
Hanenberg, H.
Hanes, V.
Hang, Y.
Haniffa, M.
Hankins, J. S.
181 - Hydroxyurea Dosing in Very Young Children with Sickle Cell Anemia: A Multicenter, Randomized, Controlled Trial (HUGKISS)
786 - Treatment of Individuals with Severe Sickle Cell Disease with OTQ923, an Autologous, Ex Vivo, CRISPR/Cas9-Edited, CD34+ Hematopoietic Stem and Progenitor Cell Product, Leads to Durable Engraftment and Fetal Hemoglobin Induction
883 - Optimizing the Frequency of Transcranial Doppler (TCD) Exams in Children with Sickle Cell Anemia
1074 - Baseline Patient and Provider Reports of Quality of Care and Confidence Providing ED Management of Vaso-Occlusive Episodes
1082 - Mortality in Adults with Sickle Cell Disease: Results from the Sickle Cell Disease Implementation Consortium (SCDIC) Registry
2252 - Efficacy of Interventions to Build Transition Readiness for Youth with Sickle Cell Disease: A 13-Year Evaluation of a Healthcare Transition Program
- Sickle Cell Disease
- Blood Drop: Sickle Cell Disease
786 - Treatment of Individuals with Severe Sickle Cell Disease with OTQ923, an Autologous, Ex Vivo, CRISPR/Cas9-Edited, CD34+ Hematopoietic Stem and Progenitor Cell Product, Leads to Durable Engraftment and Fetal Hemoglobin Induction
883 - Optimizing the Frequency of Transcranial Doppler (TCD) Exams in Children with Sickle Cell Anemia
1074 - Baseline Patient and Provider Reports of Quality of Care and Confidence Providing ED Management of Vaso-Occlusive Episodes
1082 - Mortality in Adults with Sickle Cell Disease: Results from the Sickle Cell Disease Implementation Consortium (SCDIC) Registry
2252 - Efficacy of Interventions to Build Transition Readiness for Youth with Sickle Cell Disease: A 13-Year Evaluation of a Healthcare Transition Program
- Sickle Cell Disease
- Blood Drop: Sickle Cell Disease
Hanley, M. J.
Hanley, P. J.
Hanley, P. J.
Hanna, M.
Hanna, N.
Hanna, R.
986 - Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
Hannah, G.
Hannun, Y. A.
Hannunen, T.
Hanoun, C.
Hanoun, M.
51 - Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL
212 - Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
1438 - Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
1442 - Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
212 - Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
1438 - Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
1442 - Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
Hanrahan, J. R.
Hansbury, E.
Hänselmann, S.
Hansen, B. S.
919 - Mutational Permutations of a Single Amino Acid Exert Divergent Phenotypic Effects in Human, Mice, and Cellular Models of SAMD9L Bone Marrow Failure Disorder
1265 - Germline Loss-of-Function Mutations in MDM4 Cause p53-Dependent Hematopoietic Cell Death in Patients with Variable Bone Marrow Failure Phenotypes
3983 - Genetic and Epigenetic Cis-Regulatory Disruptions Impacting the Canonical Wnt Signaling Repressor TLE1 Gene Promote Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia
1265 - Germline Loss-of-Function Mutations in MDM4 Cause p53-Dependent Hematopoietic Cell Death in Patients with Variable Bone Marrow Failure Phenotypes
3983 - Genetic and Epigenetic Cis-Regulatory Disruptions Impacting the Canonical Wnt Signaling Repressor TLE1 Gene Promote Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia
Hansen, B. T.
Hansen, D. L.
743 - Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial
3768 - Use of Psychotropic Prescription Drugs and Mental Health in Adult Patients with Primary Immune Thrombocytopenia – a Danish Nationwide Cohort Study
3768 - Use of Psychotropic Prescription Drugs and Mental Health in Adult Patients with Primary Immune Thrombocytopenia – a Danish Nationwide Cohort Study
Hansen, D. K.
252 - Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
2043 - Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
2118 - Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience
2268 - Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma
3343 - The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
3355 - Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient’s Monitoring after CAR T-Cell Therapy
3412 - Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4668 - High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4706 - Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
4903 - Associations between Patient-Reported Outcomes and 90-Day Response to Chimeric Antigen Receptor T-Cell Therapy: A Bayesian Network Analysis
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
2043 - Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
2118 - Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience
2268 - Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma
3343 - The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
3355 - Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient’s Monitoring after CAR T-Cell Therapy
3412 - Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4668 - High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4706 - Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
4903 - Associations between Patient-Reported Outcomes and 90-Day Response to Chimeric Antigen Receptor T-Cell Therapy: A Bayesian Network Analysis
Hansen, E.
1802 - Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy
2234 - Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)
3183 - Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data
2234 - Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)
3183 - Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data
Hansen, J. B.
Hansen, J.
Hansen, K. D.
Hansen, N.
Hansen, R.
Hanson, C. A.
Hanson, G.
Hanson, P. J.
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
Hansson, M.
Hansson, M.
Hantash, F.
Hantrakool, S.
917 - Improvement of Platelet Count after Helicobacter Pylori Screening and Eradication in Immune Thrombocytopenia Patients: A Randomized Open-Label Study
1032 - Plasma Metabolomic Profiles Are Imbalanced in Adults Thalassemia Patients with Malnutrition and That Imbalance Is Alleviated By Oral Nutritional Supplements: A Prospective Randomized Controlled Trial
3815 - Profiling of Heparin-Induced Thrombocytopenia Antibodies in Thai People Who Received ChAdOx1 Ncov-19 Vaccination
1032 - Plasma Metabolomic Profiles Are Imbalanced in Adults Thalassemia Patients with Malnutrition and That Imbalance Is Alleviated By Oral Nutritional Supplements: A Prospective Randomized Controlled Trial
3815 - Profiling of Heparin-Induced Thrombocytopenia Antibodies in Thai People Who Received ChAdOx1 Ncov-19 Vaccination
Hantrakun, N.
917 - Improvement of Platelet Count after Helicobacter Pylori Screening and Eradication in Immune Thrombocytopenia Patients: A Randomized Open-Label Study
1032 - Plasma Metabolomic Profiles Are Imbalanced in Adults Thalassemia Patients with Malnutrition and That Imbalance Is Alleviated By Oral Nutritional Supplements: A Prospective Randomized Controlled Trial
3815 - Profiling of Heparin-Induced Thrombocytopenia Antibodies in Thai People Who Received ChAdOx1 Ncov-19 Vaccination
1032 - Plasma Metabolomic Profiles Are Imbalanced in Adults Thalassemia Patients with Malnutrition and That Imbalance Is Alleviated By Oral Nutritional Supplements: A Prospective Randomized Controlled Trial
3815 - Profiling of Heparin-Induced Thrombocytopenia Antibodies in Thai People Who Received ChAdOx1 Ncov-19 Vaccination
Hanyok, J.
225 - Quantum-First Trial: FLT3-ITD–Specific MRD Clearance Is Associated with Improved Overall Survival
878 - Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3–Internal Tandem Duplication: Results from the Quantum-First Trial
878 - Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3–Internal Tandem Duplication: Results from the Quantum-First Trial
Hao, D.
2790 - Single Cell RNA-Seq Reveals Intra-Tumoral Heterogeneity Relevant to Differentiation States and Outcomes Among Newly Diagnosed Acute Myeloid Leukemia Patients
4119 - Single-Cell Profiling of CD8 Landscape in Treatment Naïve and Relapsed/Refractory AML Patients Reveals Distinct Effector Cellular States Predictive of Outcomes
4119 - Single-Cell Profiling of CD8 Landscape in Treatment Naïve and Relapsed/Refractory AML Patients Reveals Distinct Effector Cellular States Predictive of Outcomes
Hao, M.
350 - PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment
3161 - Multiple Myeloma-Derived Mir-27b-3p Facilitates Tumor Progression Via Promoting Tumor Cell Proliferation and Immunosuppressive Microenvironment
4482 - Immune Profiling of MM Microenvironment at Single-Cell Resolution
3161 - Multiple Myeloma-Derived Mir-27b-3p Facilitates Tumor Progression Via Promoting Tumor Cell Proliferation and Immunosuppressive Microenvironment
4482 - Immune Profiling of MM Microenvironment at Single-Cell Resolution
Hao-Shen, H.
1687 - Combination of 5-Azacytidine and Pegifna Is Able to Overcome Resistance in JAK2-V617F Positive MPN with Loss of Dnmt3a
2992 - The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)
4310 - Disrupting the Socs2-Mediated Negative Feedback to JAK-STAT Signaling Boosts Molecular Responses Induced By Interferon-α in a Mouse Model of Myeloproliferative Neoplasms
2992 - The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)
4310 - Disrupting the Socs2-Mediated Negative Feedback to JAK-STAT Signaling Boosts Molecular Responses Induced By Interferon-α in a Mouse Model of Myeloproliferative Neoplasms
Happ, L.
Haq, Q. S.
Haque, S.
Hara, Y.
Hara, Y.
Harada, S.
321 - Novel Simple Prognostic Index (NJHSG-PI) Can Effectively Predict Prognosis in Patients with Newly Diagnosed DLBCL : A Real World Analysis across 14 Cancer Centers in Japan
324 - Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma
478 - Calcineurin Inhibitors Inhibit Tolerance Induction By Suppressing Terminal Differentiation of Donor Exhausted T Cells after Allogeneic SCT
974 - Intercellular Mitochondrial Transfer Enhances Metabolic Fitness and Anti-Tumor Effects of CAR T Cells
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
324 - Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma
478 - Calcineurin Inhibitors Inhibit Tolerance Induction By Suppressing Terminal Differentiation of Donor Exhausted T Cells after Allogeneic SCT
974 - Intercellular Mitochondrial Transfer Enhances Metabolic Fitness and Anti-Tumor Effects of CAR T Cells
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
Harada, Y.
Haradhvala, N. J.
102 - Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology
108 - Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy
354 - Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
108 - Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy
354 - Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
Harbi, S.
Hardesty, B.
Hardi, L.
Hardin, J. W.
Harding, M.
Harding, R.
Harding, S.
103 - Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
972 - Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis
3216 - Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4538 - Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
972 - Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis
3216 - Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4538 - Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Hardison, R. C.
799 - Let-7 Inhibits HIC2 to Control BCL11A Transcription and Hemoglobin Switching
802 - Examining the Role of Individual Baf Chromatin Remodeling Complex Components in Globin Gene Regulation
1041 - Regulation of Fetal Hemoglobin Production in Adult Erythroid Cells By Protein Phosphatase 6C (PPP6C)
2361 - Mechanisms of Polycomb Group Protein-Mediated Fetal Hemoglobin Silencing
802 - Examining the Role of Individual Baf Chromatin Remodeling Complex Components in Globin Gene Regulation
1041 - Regulation of Fetal Hemoglobin Production in Adult Erythroid Cells By Protein Phosphatase 6C (PPP6C)
2361 - Mechanisms of Polycomb Group Protein-Mediated Fetal Hemoglobin Silencing
Hardouin, G.
Hardy, N. M.
Hardy, S. J.
888 - Preliminary Feasibility and Efficacy of the Balance Program to Reduce Pain-Related Disability in Pediatric Sickle Cell Disease
3523 - A New Phen X Collection: Sickle Cell Disease Psychosocial and Social Determinants of Health Protocols
4827 - Implementing ASH Guidelines: Clinical Utility of a Signaling Question for Detecting Cognitive Deficits in Pediatric Sickle Cell Disease
4888 - Reliability of Parent Proxy-Report Measures of Quality of Life and Cognitive Functioning in Pediatric Sickle Cell Disease
3523 - A New Phen X Collection: Sickle Cell Disease Psychosocial and Social Determinants of Health Protocols
4827 - Implementing ASH Guidelines: Clinical Utility of a Signaling Question for Detecting Cognitive Deficits in Pediatric Sickle Cell Disease
4888 - Reliability of Parent Proxy-Report Measures of Quality of Life and Cognitive Functioning in Pediatric Sickle Cell Disease
Hare, J.
Harel, S.
Hari, P.
361 - KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation
1930 - Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3210 - Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (allo-HCT) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
3237 - Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial
3331 - 8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma
4198 - Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma
4521 - Association of Human Leukocyte Antigen Variants with Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
1930 - Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3210 - Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (allo-HCT) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
3237 - Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial
3331 - 8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma
4198 - Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma
4521 - Association of Human Leukocyte Antigen Variants with Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
Haridas, N. K.
Harigae, H.
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
1024 - Altered Transcription By GATA1 Impairs Autophagy and Prevents Ferroptosis in X-Linked Sideroblastic Anemia
1024 - Altered Transcription By GATA1 Impairs Autophagy and Prevents Ferroptosis in X-Linked Sideroblastic Anemia
Hariharan, N.
Hariharan, S.
Harila-Saari, A.
Harker-Murray, P.
Härkönen, J.
Harlev, S.
1658 - Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
2907 - Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia
2907 - Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia
Harmon, A.
1955 - Engineered Stem Cell Antibody Paired Evasion 1 (ESCAPE-1): Paired HSC Epitope Engineering and Upregulation of Fetal Hemoglobin for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Hemoglobinopathies
4585 - Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease
4585 - Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease
Harmon, C.
Harms, C.
Harnett, J.
2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
4896 - Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
4896 - Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)
Harnois, M.
Haroche, J.
Harousseau, J. L.
Harper, J. S.
Harrer, T.
Harrington, A. M.
Harrington, B.
Harrington, B. K.
Harrington, C. C.
3239 - A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
Harrington, T. J.
Harris, C. E.
1259 - Targeting a Putative Intronic Splicing Silencer Salvages Expression from the Recurrent SBDS C.258+2T>C Mutant Allele in Shwachman-Diamond Syndrome Patient Cells and Mouse Model
3856 - Septin-6 Regulates Murine and Human Hematopoiesis, and Its Dysregulation Is Associated with Pediatric Myelodysplasia
3856 - Septin-6 Regulates Murine and Human Hematopoiesis, and Its Dysregulation Is Associated with Pediatric Myelodysplasia
Harris, D.
Harris, E. I.
154 - Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
Harris, E. M.
Harris, F. R.
Harris, H.
Harris, J.
Harris, L.
Harris, M. H.
Harris, N. L.
Harris, N.
Harris, R. M.
Harris, R. E.
Harrison, C. J.
1387 - Whole Genome Sequencing for Detection of Prognostically Relevant Genetic Abnormalities in Paediatric Acute Myeloid Leukaemia
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
2827 - Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
2827 - Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia
Harrison, C. N.
238 - Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24
239 - Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study
628 - Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
630 - Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib
739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
740 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
899 - Identification and Successful Targeting of a Larger Than Expected Health Literacy Gap in Young People with Sickle Cell Disease Transitioning from Pediatric to Adult Care
1683 - Mylox-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis
1711 - Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
1712 - Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden
1729 - The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States
1733 - Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib
2312 - The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
3037 - MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
4316 - PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
4344 - Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
4348 - Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
4351 - The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study
4361 - Modulation of TGF-β Superfamily Signaling to Treat Myelofibrosis and Mitigate JAK Inhibitor Toxicity: A Report on the Phase 2 Study of Ker-050 in Participants with Myelofibrosis
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
4369 - Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib
239 - Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study
628 - Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
630 - Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib
739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
740 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
899 - Identification and Successful Targeting of a Larger Than Expected Health Literacy Gap in Young People with Sickle Cell Disease Transitioning from Pediatric to Adult Care
1683 - Mylox-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis
1711 - Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
1712 - Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden
1729 - The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States
1733 - Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib
2312 - The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
3037 - MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
4316 - PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
4344 - Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
4348 - Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
4351 - The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study
4361 - Modulation of TGF-β Superfamily Signaling to Treat Myelofibrosis and Mitigate JAK Inhibitor Toxicity: A Report on the Phase 2 Study of Ker-050 in Participants with Myelofibrosis
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
4369 - Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib
Harrison, K.
Harrison, K.
Harrison, K. R.
Harrison, L.
Harrison, S. J.
161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
567 - Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
1847 - Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
1912 - Infectious Complications of Bispecific Antibody Therapy in Patients with Multiple Myeloma
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
3232 - An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
567 - Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
1847 - Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
1912 - Infectious Complications of Bispecific Antibody Therapy in Patients with Multiple Myeloma
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
3232 - An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
Harrivel, V.
1398 - Standard Risk-Assessment of AML Doesn’t Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy
2793 - AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network
3886 - Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study
2793 - AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network
3886 - Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study
Harroche, A.
Harrop, E.
1659 - Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Harrop, S.
849 - Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers
4237 - Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study
4237 - Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study
Harrup, R.
Harsløf, M.
Harstead, E.
Harstrick, A.
Hart, A. C.
21 - Do Children with Immune Thrombocytopenia Have Cerebral Microbleeds?
915 - CD8+ TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia
1134 - Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity
2444 - Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review
2447 - Cognitive Impairment in Patients with Immune Thrombocytopenia
2451 - Eltrombopag Causes Cell Cycle Arrest of T Cells through Iron Chelation and Could Modulate the Immune Response in ITP
915 - CD8+ TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia
1134 - Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity
2444 - Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review
2447 - Cognitive Impairment in Patients with Immune Thrombocytopenia
2451 - Eltrombopag Causes Cell Cycle Arrest of T Cells through Iron Chelation and Could Modulate the Immune Response in ITP
Hart, K.
Hart, L.
Harte, S.
Hartel, G.
Hartert, K. T.
1531 - EFS24 Failure, BRD4 Expression, and TP53 Are Linked to Reduced CDKN1A Expression in DLBCL and May be Targeted By Single-Agent Protac ARV-825 or in Synergistic Combination with the CDK4/6 Inhibitor Abemaciclib
2848 - The DLBCL Axis of Low TNFRSF10B Expression, TP53 Loss, and a Cold Immune Microenvironment May be Addressed By the Synergistic Combination of Eprenetapopt and Idasnutlin
2848 - The DLBCL Axis of Low TNFRSF10B Expression, TP53 Loss, and a Cold Immune Microenvironment May be Addressed By the Synergistic Combination of Eprenetapopt and Idasnutlin
Hartford, C.
Hartigan, A. J.
1955 - Engineered Stem Cell Antibody Paired Evasion 1 (ESCAPE-1): Paired HSC Epitope Engineering and Upregulation of Fetal Hemoglobin for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Hemoglobinopathies
4585 - Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease
4585 - Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease
Hartley, J. A.
Hartman, G.
Hartmann, A. M.
Hartmann, B. L.
561 - Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine – a Prospective Cohort Study By the AGMT
4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
Hartmann, G.
Hartmann, M.
Hartmann, T. N.
Hartog, B.
Hartweg, J.
Hartwig, M.
Hartzell, C.
Harvey, R. D.
1406 - Assessment of Midostaurin in Combination with Idarubicin-Based Induction Treatment in Acute Myeloid Leukemia
2667 - Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)
3173 - African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction
2667 - Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)
3173 - African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction
Hasan, M. I.
Hasan, M.
301 - Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia (AML)
1482 - Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2-Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study
3912 - Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia
1482 - Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2-Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study
3912 - Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia
Hasan, M. K.
Hasan, R. A.
Hasan, S. K.
469 - Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant
1869 - Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing
3137 - Targeting Transcriptional Kinase of CDK7 Halts Proliferation of Multiple Myeloma Cells By Modulating the Function of Canonical NF-Kβ Pathway and Cell Cycle Regulatory Proteins
1869 - Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing
3137 - Targeting Transcriptional Kinase of CDK7 Halts Proliferation of Multiple Myeloma Cells By Modulating the Function of Canonical NF-Kβ Pathway and Cell Cycle Regulatory Proteins
Hasan, T.
Hasanali, Z.
Hasegawa, D.
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
Hasegawa, K.
Hasegawa, S.
Hasegawa, T.
Hasegawa, Y.
Hasegawa, Y.
Hasenkamp, J.
Hasenmayer, D.
Haseyama, Y.
321 - Novel Simple Prognostic Index (NJHSG-PI) Can Effectively Predict Prognosis in Patients with Newly Diagnosed DLBCL : A Real World Analysis across 14 Cancer Centers in Japan
324 - Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma
1390 - Clinical Features of Complex Karyotype in Newly Diagnosed Acute Myeloid Leukemia
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
4036 - Prognostic Impact of CEBPA bZIP Domain Mutation in Cytogenetically Normal Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
324 - Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma
1390 - Clinical Features of Complex Karyotype in Newly Diagnosed Acute Myeloid Leukemia
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
4036 - Prognostic Impact of CEBPA bZIP Domain Mutation in Cytogenetically Normal Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
Hashem, A.
Hashiguchi, J.
324 - Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma
1390 - Clinical Features of Complex Karyotype in Newly Diagnosed Acute Myeloid Leukemia
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
1390 - Clinical Features of Complex Karyotype in Newly Diagnosed Acute Myeloid Leukemia
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
Hashii, Y.
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
Hashimoto, C.
Hashimoto, D.
Hashimoto, K.
Hashmi, H.
252 - Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
1862 - Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
3605 - Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
1862 - Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
3605 - Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
Hashmi, S.
Hasipek, M.
Hasiuk, M.
Haskamp, S.
Haskett, G.
Haslam, A.
Hasle, H.
564 - UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
2413 - Association between Fc-Gamma Receptor Polymorphisms and Autoimmune Neutropenia in Early Childhood in Danish Patients
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
2413 - Association between Fc-Gamma Receptor Polymorphisms and Autoimmune Neutropenia in Early Childhood in Danish Patients
Hasle, V.
2779 - Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
4017 - Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
4017 - Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
Haspel, R. L.
Hassan, A.
Hassan, A.
3635 - Neighborhood Disadvantage, Insurance Status, and Molecular Profiling of Patients with Acute Myeloid Leukemia
4863 - A Quality Improvement Initiative to Improve Implementation of Guideline-Concordant Hereditary Myeloid Malignancy Syndrome Evaluation
4953 - Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology
4863 - A Quality Improvement Initiative to Improve Implementation of Guideline-Concordant Hereditary Myeloid Malignancy Syndrome Evaluation
4953 - Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology
Hassan, H.
Hassan, M.
Hassan, S.
Hassanain, H.
Hassane, D. C.
Hasselbalch, H. C.
743 - Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial
1680 - Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms
1717 - Prevalence of the JAK2V617F Mutation in Patients with Ischemic Stroke
3029 - Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera
3043 - Neutrophil-to-Lymphocyte Ratio As a Predictor of All-Cause Mortality in the General Population and Patients with Myeloproliferative Neoplasms
4322 - Interferon-alpha2 Favorably Impacts Deregulated Atherosclerosis Genes in Polycythemia Vera and Related Neoplasms
4345 - Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)
1680 - Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms
1717 - Prevalence of the JAK2V617F Mutation in Patients with Ischemic Stroke
3029 - Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera
3043 - Neutrophil-to-Lymphocyte Ratio As a Predictor of All-Cause Mortality in the General Population and Patients with Myeloproliferative Neoplasms
4322 - Interferon-alpha2 Favorably Impacts Deregulated Atherosclerosis Genes in Polycythemia Vera and Related Neoplasms
4345 - Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)
Hasserjian, R. P.
597 - Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
4803 - A Machine-Learning Derived Red Blood Cell Morphology Tool Enables Differential Diagnosis and Novel Single-Cell Analyses
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
4803 - A Machine-Learning Derived Red Blood Cell Morphology Tool Enables Differential Diagnosis and Novel Single-Cell Analyses
Hasson, D.
Hassoun, H.
100 - Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
251 - Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
752 - Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
992 - Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
3225 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
251 - Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
752 - Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
992 - Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
3225 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
Hastrup, E. K.
Hata, K.
Hathcock, M. A.
768 - Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
4276 - Prognosis Score for Overall Survival with CAR-T Therapy in Aggressive Lymphoma
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
4276 - Prognosis Score for Overall Survival with CAR-T Therapy in Aggressive Lymphoma
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy
Hatic, H.
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort
Hatjiharissi, E.
Hatkar, R.
Hatsell, S.
Hatta, Y.
54 - Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study
2687 - Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study
2687 - Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study
Hatton, C.
Hatton, C.
Hattori, K.
Hatzimichael, E.
Hatzimichael, E.
Haubner, S.
Hauer, J.
Hauer-Jensen, M.
Haug, J.
Hauk, C. I.
Haunstrup, T.
Häupl, B.
1500 - Proteomic Characterization of Acute Myeloid Leukemia
2154 - Breaking the Pump: Targeting the Sodium-Potassium Pump As a Therapeutic Strategy in Acute Myeloid Leukemia
2845 - Alternative Splicing of Bcap (PIK3AP1) Enhances Oncogenic Signaling in Subsets of Activated B-Cell Diffuse Large B-Cell Lymphoma
2154 - Breaking the Pump: Targeting the Sodium-Potassium Pump As a Therapeutic Strategy in Acute Myeloid Leukemia
2845 - Alternative Splicing of Bcap (PIK3AP1) Enhances Oncogenic Signaling in Subsets of Activated B-Cell Diffuse Large B-Cell Lymphoma
Haura, E. B.
Hauser, R. G.
Hausler, R.
Hausman, J. A.
Hausmann, A.
Hausrath, D. J.
Hav, M.
Havenith, K.
1542 - Identification of Predictive Biomarkers for Response of R/R DLBCL Patients Treated with Loncastuximab Tesirine Using Low Pass Whole-Genome Sequencing (WGS)
4192 - CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
4297 - CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling
4584 - Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties
4192 - CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
4297 - CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling
4584 - Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties
Haverkate, N. J.
Haverkos, B. M.
554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
958 - Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas
1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
958 - Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas
1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
Haverman, L.
Havermans, M.
Havlicek, M.
Havranek, O.
1364 - Combinatorial PI3K/AKT Pathway Inhibition As a Therapeutic Approach in Diffuse Large B-Cell Lymphoma
2671 - Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma
2869 - Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma
2671 - Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma
2869 - Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma
Havrilla, H.
Hawken, S.
Hawkes, E.
313 - Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
2938 - First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma
4237 - Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
2938 - First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma
4237 - Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study
Hawkins, E. D.
Hawkins, K. A.
Hawkins, M.
Hawkins, P.
Hawrylecka, D.
Hay, A. E.
1620 - Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP
2714 - Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
2714 - Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
Hay, K. A.
3362 - Clinical Outcomes in Fresh Versus Cryopreserved Hematopoietic Stem Cell Products in British Columbia: A Retrospective Study
3437 - Autologous Stem Cell Transplantation for Treatment with Curative Intent in Adult Patients with Acute Lymphoblastic Lymphoma
4494 - Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma
3437 - Autologous Stem Cell Transplantation for Treatment with Curative Intent in Adult Patients with Acute Lymphoblastic Lymphoma
4494 - Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma
Hayakawa, M.
Hayama, K. L.
1986 - Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy
3288 - iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma
3288 - iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma
Hayashi, M.
Hayashi, R. J.
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
Hayashi, Y.
Hayashida, H.
Hayashida, M.
Hayati, S.
Haydar, D.
Hayden, A.
Hayden, C.
3025 - Real-World Experience of Asciminib: Factors Associated with Response
4332 - Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study
4332 - Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study
Hayden, P. J.
Hayden, P. J.
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
4680 - Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
4680 - Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021
Haydn, A.
Hayek, S.
Hayer, K.
Hayes, C. A.
2042 - Utility of Targeted Neurocognitive Testing in Detecting Early Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CAR T-Cell Therapy
3622 - Patient Reported Outcomes for Patients Receiving a Hematopoietic Stem Cell Transplant: A Longitudinal Assessment with a Dashboard Display
3622 - Patient Reported Outcomes for Patients Receiving a Hematopoietic Stem Cell Transplant: A Longitudinal Assessment with a Dashboard Display
Hayes, K.
Hayes-Lattin, B.
Hayette, S.
1705 - Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.
1777 - Correlation of Clonal Hematopoiesis in Vexas Syndrome with Immunophenotype Alterations in CD34+ HSPCs (Hematopoietic Stem Progenitors Cells): Multiparametric Flow Cytometry Heterogeneity in CD34+CD38- Stem Cells Fraction and Upregulation of CD90 Thy-1 By Unsupervised Strategy Using PCA, Tsnee and Flowsom
1777 - Correlation of Clonal Hematopoiesis in Vexas Syndrome with Immunophenotype Alterations in CD34+ HSPCs (Hematopoietic Stem Progenitors Cells): Multiparametric Flow Cytometry Heterogeneity in CD34+CD38- Stem Cells Fraction and Upregulation of CD90 Thy-1 By Unsupervised Strategy Using PCA, Tsnee and Flowsom
Hayford, C.
Hayman, S. R.
768 - Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma
970 - Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
3177 - Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma
3196 - Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma
3613 - Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes
4492 - Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide
4501 - Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
4523 - Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event
4556 - Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma – MRD Negativity and Survival Outcomes
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy
970 - Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
3177 - Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma
3196 - Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma
3613 - Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes
4492 - Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide
4501 - Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
4523 - Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event
4556 - Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma – MRD Negativity and Survival Outcomes
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy
Hazenberg, M. D.
808 - Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
1426 - Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study
3736 - Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies
4700 - Improved T-Cell Chimerism and Successful Withdrawal of Immunosuppression after Non-Myeloablative Stem Cell Transplantation for Sickle Cell Disease with Azathioprine/Hydroxyurea Preconditioning Added to Alemtuzumab/TBI Conditioning
1426 - Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study
3736 - Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies
4700 - Improved T-Cell Chimerism and Successful Withdrawal of Immunosuppression after Non-Myeloablative Stem Cell Transplantation for Sickle Cell Disease with Azathioprine/Hydroxyurea Preconditioning Added to Alemtuzumab/TBI Conditioning
Hazlehurst, L.
Hazra, R.
He, B.
He, B.
He, B.
He, C.
He, D.
He, D.
He, F.
455 - Transcriptional and Metabolic Profiling Reveals Alpha-Ketoglutarate As a Novel Mediator of Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms
1718 - Comprehensive Profiling of Clinical JAK2 Inhibitors in Myeloproliferative Neoplasms
2993 - Targeting RSK1-Mediated Dependency and Inflammation in Myeloid Malignancies
1718 - Comprehensive Profiling of Clinical JAK2 Inhibitors in Myeloproliferative Neoplasms
2993 - Targeting RSK1-Mediated Dependency and Inflammation in Myeloid Malignancies
He, G.
1250 - Cyclophosphamide Combined with Prednisone for Cyclosporine-Refractory/Relapsed Large Granular Lymphocyte Leukemia-Associated Pure Red Cell Aplasia
2574 - Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study
3888 - Prolonged Use of Eltrombopag in Patients with Severe Aplastic Anemia without Complete Response at 6 Months after Immunosuppressive Therapy
2574 - Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study
3888 - Prolonged Use of Eltrombopag in Patients with Severe Aplastic Anemia without Complete Response at 6 Months after Immunosuppressive Therapy
He, H.
1970 - Cord Derived 8F4CAR-iNKT Cells to Prevent Acute Myeloid Leukemia Relapse and Graft Vs. Host Disease after Allogeneic Stem Cell Transplantation
3290 - Targeting Myeloid Leukemia Using Novel TCR-like Chimeric Antigen Receptor-T Cells Against Cathepsin G
4081 - Humanized T Cell Receptor-like Antibody Hu8F4 Reduces Leukemia By Fc-Mediated Mechanism
3290 - Targeting Myeloid Leukemia Using Novel TCR-like Chimeric Antigen Receptor-T Cells Against Cathepsin G
4081 - Humanized T Cell Receptor-like Antibody Hu8F4 Reduces Leukemia By Fc-Mediated Mechanism
He, H.
He, H.
He, J.
He, N.
278 - Does Race/Ethnicity Impact Umbilical Cord Blood Transplant Outcomes in a Contemporary Era?
763 - Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies – Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113
2054 - International Collaborative Study to Compare the Prognosis for Acute Leukemia Patients Transplanted with Intensified Myeloablative Regimens
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
763 - Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies – Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113
2054 - International Collaborative Study to Compare the Prognosis for Acute Leukemia Patients Transplanted with Intensified Myeloablative Regimens
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
He, Q.
1624 - A Multicenter, Single-Arm, Prospective Phase II Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Dignosed Primary Central Nervous System Lymphoma
2945 - Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma
2945 - Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma
He, R.
He, R.
He, S.
He, X. C.
He, X.
2403 - Role of Vimentin and Alpha7 Nicotinic Acetylcholine Receptor of the Critical Targets in Meningitic Pathogenic Triad Among Blood-Brain Barrier Breakdown
2412 - The Roles of CD44 Membrane Ruffling and Signaling in Leukocyte Transmigration across Cryptococcus Neoformans-Coinfected Blood-Brain Barrier with HIV-1 gp41 in Vitro
2412 - The Roles of CD44 Membrane Ruffling and Signaling in Leukocyte Transmigration across Cryptococcus Neoformans-Coinfected Blood-Brain Barrier with HIV-1 gp41 in Vitro
He, X.
275 - Targeting SAMHD1 Promotes Anti-Tumor Immunity in Acute Myeloid Leukemia
415 - Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia
2152 - Targeting PRMT9 Elicits Cgas-Mediated Anti-Leukemia Immunity
3909 - HDAC8 Disrupts DNA Damage Response By Deacetylation of U2AF1 in Inv(16) Acute Myeloid Leukemia
415 - Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia
2152 - Targeting PRMT9 Elicits Cgas-Mediated Anti-Leukemia Immunity
3909 - HDAC8 Disrupts DNA Damage Response By Deacetylation of U2AF1 in Inv(16) Acute Myeloid Leukemia
He, Y.
1621 - Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial
4227 - DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study
4227 - DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study
He, Y.
3161 - Multiple Myeloma-Derived Mir-27b-3p Facilitates Tumor Progression Via Promoting Tumor Cell Proliferation and Immunosuppressive Microenvironment
3435 - Combination of Cytogenetic Classification and MRD Status Correlates with Outcomes of Autologous Versus Allogeneic Stem Cell Transplantation in Adults with B Cell-Acute Lymphoblastic Leukemia in First Remission
4695 - The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients
3435 - Combination of Cytogenetic Classification and MRD Status Correlates with Outcomes of Autologous Versus Allogeneic Stem Cell Transplantation in Adults with B Cell-Acute Lymphoblastic Leukemia in First Remission
4695 - The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients
He, Y.
He, Y.
2178 - The Role of Metagenomics Next-Generation Sequencing (mNGS) in Early Diagnosis of Bloodstream Infection in Hematologic Patients with Febrile Neutropenia: A Multicenter Prospective Study
2454 - Real-World Study of the Use of Iguratimod to Treat Chronic/Refractory ITP
3872 - Sitagliptin Alleviates Excessive Autophagy in Macrophages in Immune Thrombocytopenia Patients to Promote Megakaryopoiesis Via the AMPK/mTOR Pathway
2454 - Real-World Study of the Use of Iguratimod to Treat Chronic/Refractory ITP
3872 - Sitagliptin Alleviates Excessive Autophagy in Macrophages in Immune Thrombocytopenia Patients to Promote Megakaryopoiesis Via the AMPK/mTOR Pathway
He, Z.
Healey, J.
Healy, E.
Healy, J.
Healy, S.
Heaney, M. L.
626 - Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)
4441 - Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience
4441 - Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience
Heaney, M. L.
Heaton, G.
Heaton, H. A.
Heavican-Foral, T. B.
Hebalkar, R. Y.
Heberling, L.
Hebert, J.
2809 - Identification of Novel Cell Surface Therapeutic Targets for KMT2A-Rearranged Acute Myeloid Leukemia
2816 - IL1R1 Expression Predicts the Benefit from Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Intermediate-Risk Cytogenetics
3976 - Targeting PLZF Enhances Glucocorticoid Sensitivity in Acute Myeloid Leukemia
2816 - IL1R1 Expression Predicts the Benefit from Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Intermediate-Risk Cytogenetics
3976 - Targeting PLZF Enhances Glucocorticoid Sensitivity in Acute Myeloid Leukemia
Hebert, J.
Hebert, N.
3685 - Neutron Spin Echo Spectroscopy Allows an Extremely Precise Evaluation of Hemoglobin S Structure and Dynamics, and Provides Insights on HbF Therapeutic Target
3689 - Fetal Hemoglobin Induced Improvement in Relative Age of Sickle Red Blood Cells Determined through Glycated Hemoglobin Assessment By Flow Cytometry
3689 - Fetal Hemoglobin Induced Improvement in Relative Age of Sickle Red Blood Cells Determined through Glycated Hemoglobin Assessment By Flow Cytometry
Heberton, M.
Hecht, A.
Heck, A. M.
Hecker, J. S.
Heckman, C. A.
46 - Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML
430 - Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia
835 - Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax
2673 - A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma
4799 - The Novel Peptide Drug Conjugate OPDC3 Is Highly Active in Different Hematological Malignancies
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML
430 - Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia
835 - Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax
2673 - A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma
4799 - The Novel Peptide Drug Conjugate OPDC3 Is Highly Active in Different Hematological Malignancies
Heckman, M. G.
593 - Prevalence of Vitamin C Deficiency and Bleeding at a Tertiary Care Center: Mayo Clinic Florida (MCF) Experience
2121 - IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort
2121 - IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort
Hedgepath, C.
Hedges, D.
Heemskerk, M. H.
68 - Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments
196 - High-Dimensional Mass Cytometric Analysis of the Bone Marrow Compartment Identifies a Disease-Specific Immune Cell Network in Aplastic Anemia
808 - Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
1104 - Sars-Cov-2-Specific CD4+ and CD8+ T Cell Responses Can Originate from Cross-Reactive CMV-Specific T Cells
1961 - Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain
1985 - Immunotherapy By Targeting CD45 in Mismatched HLA-DP to Treat Patients after Allogeneic Stem Cell Transplantation
3736 - Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies
4600 - Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia
4625 - T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma
196 - High-Dimensional Mass Cytometric Analysis of the Bone Marrow Compartment Identifies a Disease-Specific Immune Cell Network in Aplastic Anemia
808 - Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
1104 - Sars-Cov-2-Specific CD4+ and CD8+ T Cell Responses Can Originate from Cross-Reactive CMV-Specific T Cells
1961 - Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain
1985 - Immunotherapy By Targeting CD45 in Mismatched HLA-DP to Treat Patients after Allogeneic Stem Cell Transplantation
3736 - Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies
4600 - Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia
4625 - T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma
Heeney, M. M.
887 - Increasing COVID-19 Vaccination Rates Amongst Children with Sickle Cell Disease: A Quality Improvement Project
2377 - Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial
2387 - Ketamine Use for Management of Vaso-Occlusive Pain in Children with Sickle Cell Disease
2393 - Natural History of Pediatric Patients with Sickle Cell Disease and Concurrent Cerebral Vasculopathies: Report of 62 Cases from a Single Institution
2525 - Altered Cellular Sedimentation during Apheresis Impacts Outcomes of Peripheral Blood Stem Cell Collection Efficiency in Patients with Sickle Cell Disease
3525 - Improving Rates of Annual Transcranial Doppler Screening in Children with Sickle Cell Disease: A Quality Improvement Project
4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial
2377 - Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial
2387 - Ketamine Use for Management of Vaso-Occlusive Pain in Children with Sickle Cell Disease
2393 - Natural History of Pediatric Patients with Sickle Cell Disease and Concurrent Cerebral Vasculopathies: Report of 62 Cases from a Single Institution
2525 - Altered Cellular Sedimentation during Apheresis Impacts Outcomes of Peripheral Blood Stem Cell Collection Efficiency in Patients with Sickle Cell Disease
3525 - Improving Rates of Annual Transcranial Doppler Screening in Children with Sickle Cell Disease: A Quality Improvement Project
4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial
Heerema, N. A.
834 - A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
1412 - A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1
1510 - Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children’s Oncology Group Study AALL1331
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
3118 - FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
1412 - A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1
1510 - Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children’s Oncology Group Study AALL1331
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
3118 - FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
Heeren, A.
Heery, C. R.
Hefazi, M.
256 - Targeting a Dominant Negative Splice Variant of TRAIL to Enhance CART Cell Functions
654 - Chimeric Antigen Receptor Engineering of Mesenchymal Stromal Cells (CAR-MSC) Enhance Immunosuppression and Outcomes in Graft Versus Host Disease (GvHD) Preclinical Models
977 - CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy
3862 - Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling
4610 - Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19
654 - Chimeric Antigen Receptor Engineering of Mesenchymal Stromal Cells (CAR-MSC) Enhance Immunosuppression and Outcomes in Graft Versus Host Disease (GvHD) Preclinical Models
977 - CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy
3862 - Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling
4610 - Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19
Hefner, N.
Hegazi, M. M.
Hege, K.
364 - Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
566 - Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
566 - Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Hegel, J.
Heger, J. M.
Heggen, C.
2218 - Advancing CAR T-Cell Care in Relapsed/Refractory Multiple Myeloma: Insights from a Collaborative Quality Improvement Initiative
2225 - Transforming Chronic Lymphocytic Leukemia Care with Real-World Patient and Provider Perspectives: Results from Two Collaborative Patient-Provider Quality Improvement Programs
2233 - Addressing Racial Disparities to Advance Quality Care for Adults with Acute Leukemia: A Health Equity-Focused Quality Improvement Program
2235 - Identifying and Overcoming Racial Disparities in Multiple Myeloma Care: Results from a Large-Scale Equity-Focused Quality Improvement Initiative
2225 - Transforming Chronic Lymphocytic Leukemia Care with Real-World Patient and Provider Perspectives: Results from Two Collaborative Patient-Provider Quality Improvement Programs
2233 - Addressing Racial Disparities to Advance Quality Care for Adults with Acute Leukemia: A Health Equity-Focused Quality Improvement Program
2235 - Identifying and Overcoming Racial Disparities in Multiple Myeloma Care: Results from a Large-Scale Equity-Focused Quality Improvement Initiative
Hehir-Kwa, J. Y.
Hehlmann, R.
390 - Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)
622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
877 - Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
1698 - Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study
4329 - Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
877 - Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
1698 - Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study
4329 - Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
Heibl, S.
336 - Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry
561 - Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine – a Prospective Cohort Study By the AGMT
561 - Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine – a Prospective Cohort Study By the AGMT
Heiblig, M.
1777 - Correlation of Clonal Hematopoiesis in Vexas Syndrome with Immunophenotype Alterations in CD34+ HSPCs (Hematopoietic Stem Progenitors Cells): Multiparametric Flow Cytometry Heterogeneity in CD34+CD38- Stem Cells Fraction and Upregulation of CD90 Thy-1 By Unsupervised Strategy Using PCA, Tsnee and Flowsom
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
Heide, M.
Heidegger, S.
3262 - Immunomodulatory Microbial Metabolites Identified in Allo-SCT Patients Protect from GvHD By Sting Dependent Modulation of Intestinal Tissue Homeostasis
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
4420 - Negative Feedback Regulation of MAPK Signaling Is an Important Driver of CLL Progression
4590 - IFN-Gamma Is Crucial for the Counterbalance of T Cell-Mediated Injury to the Intestinal Stem Cell Compartment By Regulatory T Cells in Mice and Humans
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
4420 - Negative Feedback Regulation of MAPK Signaling Is an Important Driver of CLL Progression
4590 - IFN-Gamma Is Crucial for the Counterbalance of T Cell-Mediated Injury to the Intestinal Stem Cell Compartment By Regulatory T Cells in Mice and Humans
Heidel, F. H.
742 - Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
3036 - Prediction of Resistance to Hydroxyurea Therapy in Patients with Polycythemia Vera: A Machine Learning Study (PV-AIM)
3036 - Prediction of Resistance to Hydroxyurea Therapy in Patients with Polycythemia Vera: A Machine Learning Study (PV-AIM)
Heidel, F. H.
201 - Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia
203 - Pre-Clinical Investigation of a Novel Small Molecule Inhibitor Targeting YBX1 in AML
298 - Functional Role of Histone Variant macroH2A1 (H2AFY) in Acute Myeloid Leukemia (AML)
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
3057 - Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)
3903 - Loss of Cell Fate Determinant LLGL1 Impairs Leukemia Development in Acute Myeloid Leukemia
4359 - Diagnosis and Treatment of MPN in Real Life – Interim-Analysis of an Exploratory Chart Review on 960 ET and MF Patients in Germany
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study
203 - Pre-Clinical Investigation of a Novel Small Molecule Inhibitor Targeting YBX1 in AML
298 - Functional Role of Histone Variant macroH2A1 (H2AFY) in Acute Myeloid Leukemia (AML)
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
3057 - Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)
3903 - Loss of Cell Fate Determinant LLGL1 Impairs Leukemia Development in Acute Myeloid Leukemia
4359 - Diagnosis and Treatment of MPN in Real Life – Interim-Analysis of an Exploratory Chart Review on 960 ET and MF Patients in Germany
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study
Heidenreich, O.
Heijboer, H.
Heijmans, J.
Heikal, N.
Heikamp, E. B.
Heilbronner, C.
Heilpern-Mallory, D.
108 - Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy
354 - Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
354 - Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
Heim, D.
Heimlich, J. B.
Heinäniemi, M.
46 - Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia
209 - Genetic and Pharmacological Inhibition of BTK Increases Dasatinib Sensitivity in Vitro and In Vivo Including CNS-Infiltrating E2A-PBX1+/Pre-BCR+ ALL Cells
1506 - A Human iPSC Model Reveals Specific Upregulation of Linker Histone H1‑0 in ETV6::RUNX1+ Preleukemia and B Cell Precursor Acute Lymphoblastic Leukemia
3734 - Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers
209 - Genetic and Pharmacological Inhibition of BTK Increases Dasatinib Sensitivity in Vitro and In Vivo Including CNS-Infiltrating E2A-PBX1+/Pre-BCR+ ALL Cells
1506 - A Human iPSC Model Reveals Specific Upregulation of Linker Histone H1‑0 in ETV6::RUNX1+ Preleukemia and B Cell Precursor Acute Lymphoblastic Leukemia
3734 - Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers
Heinicke, T.
877 - Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
Heinrich, P.
3262 - Immunomodulatory Microbial Metabolites Identified in Allo-SCT Patients Protect from GvHD By Sting Dependent Modulation of Intestinal Tissue Homeostasis
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
Heinz Montoya, R.
1269 - Traceable Mouse Models for Tracking p53-Mutant Subclones in Acute Myeloid Leukemia
2610 - Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia
2643 - Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage
2610 - Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia
2643 - Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage
Heinze, K. G.
Heinzlmeir, S.
Heise, R.
Heisterkamp, N.
Heitmüller, C.
977 - CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy
2811 - Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells
4185 - Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis
2811 - Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells
4185 - Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis
Heitner, S. B.
Heitzer, A. M.
Heizer, T.
Hejazi, A.
Hekmati, A.
Helal, M.
Helbig, G.
1388 - A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL – a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)
2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
3448 - Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
4732 - Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT
2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
3448 - Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
4732 - Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT
Held, N.
Helenowski, I.
Hellenbrand, D.
Heller, M.
Hellmann, I.
2743 - Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice – a Prospective Analysis from the Revive Study
4058 - Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment – a Real-World Prospective Analysis from the Revive Study Group
4058 - Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment – a Real-World Prospective Analysis from the Revive Study Group
Hellmich, C.
351 - Malignant Plasma Cell Derived Mitochondrial Damps Activate Macrophages Via Sting Signalling to Promote Myeloma Development
2548 - LC3-Associated Phagocytosis Is Impaired in Bone Marrow Macrophages during Ageing Leading to Defective Processing of Apoptotic Cells and Suppression of Sting Activation
- Characterizing Mitochondrial Changes in the Aged HSC
2548 - LC3-Associated Phagocytosis Is Impaired in Bone Marrow Macrophages during Ageing Leading to Defective Processing of Apoptotic Cells and Suppression of Sting Activation
- Characterizing Mitochondrial Changes in the Aged HSC
Hellmich, C.
Hellou, T.
Hellström, M.
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
Hellström-Lindberg, E.
2418 - Somatic Mutations in T Cells in Patients with Hematological Diseases
3068 - Long-Term Clonal Inversion in an MDS-RS Case with Dual SF3B1 Mutations
3070 - Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)
3097 - Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes
3737 - Comprehensive Exploration of NK Cell Education in ADCC Triggered By a Monoclonal Antibody or a Bispecific Killer Engager Molecule (BiKE)
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
4405 - Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases
3068 - Long-Term Clonal Inversion in an MDS-RS Case with Dual SF3B1 Mutations
3070 - Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)
3097 - Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes
3737 - Comprehensive Exploration of NK Cell Education in ADCC Triggered By a Monoclonal Antibody or a Bispecific Killer Engager Molecule (BiKE)
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
4405 - Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases
Hellwig, K.
Helma-Smets, J.
Helman, K.
Helman, S. L.
Helmig-Mason, J.
15 - PRMT5 Inhibition Reduces Autoinflammation in a Murine Model of Secondary Hemophagocytic Lymphohistiocytosis
1341 - Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways
1347 - PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease
1348 - PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds
1341 - Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways
1347 - PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease
1348 - PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds
Helton, D.
Helton, N. M.
Helvaci, D. G.
Hem, J.
Hemar, C.
Hematti, P.
2024 - Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)
2025 - Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)
2025 - Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)
Hemmaway, C.
218 - FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial
431 - Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
431 - Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
Henary, H.
Henden, A. S.
Hendershot, T.
Henderson, J.
550 - B-Cell Receptor Signaling Modulates Cholesterol Biosynthesis in Diffuse Large B-Cell Lymphoma
703 - Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient Tumor Suppressor in Lymphoma
708 - DTX1 Controls Germinal Center B-Cell Development and Lymphomagenesis
1963 - Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy
3948 - Crebbp Kat Domain Missense Mutations Alter Its Dynamic Loading Onto Chromatin and Create a Transcription Factor Sink
703 - Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient Tumor Suppressor in Lymphoma
708 - DTX1 Controls Germinal Center B-Cell Development and Lymphomagenesis
1963 - Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy
3948 - Crebbp Kat Domain Missense Mutations Alter Its Dynamic Loading Onto Chromatin and Create a Transcription Factor Sink
Henderson, R.
Henderson, S.
Henderson, T. O.
Hendrickson, J. E.
32 - Antibody-Mediated Antigen Loss Can Switch an Augmented Immune Response to Antibody-Mediated Immunosuppression
885 - A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease
2520 - SRSF2 or TET2 Mutations in Patients with MDS Predict Increased Red Blood Cell Alloimmunization
885 - A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease
2520 - SRSF2 or TET2 Mutations in Patients with MDS Predict Increased Red Blood Cell Alloimmunization
Hendrie, P. C.
496 - Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)
1385 - Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse
2694 - Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison
2708 - Time to Count Recovery after Post-Remission Chemotherapy in AML Patients
4057 - Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
1385 - Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse
2694 - Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison
2708 - Time to Count Recovery after Post-Remission Chemotherapy in AML Patients
4057 - Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
Heneghan, M. M.
Hengeveld, P.
Henitz, E.
2859 - Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory Versus Newly Diagnosed Patients Using Single FFPE Slides
2874 - Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial
2874 - Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial
Henne, P.
Hennessey, K.
Henninger, J.
Henningsson, R.
Henrich, J. A.
Henrich, S. E.
Henriksen, A. C.
Henry, C. J.
3982 - Lyt-200, a Humanized Anti-Galectin-9 Antibody, Exhibits Preclinical Efficacy in Models of Hematological Malignancies
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
Henry, N.
874 - Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
3695 - A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
3695 - A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
Henschler, R.
Henskens, Y. M.
Hentea, C.
Hentemann, M.
Hentges, L. D.
Hentrich, T.
Hentzen, S.
Heras, I.
2918 - Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin’s Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party
3397 - Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)
3397 - Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)
Herault, O.
Herbaux, C.
542 - Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
616 - Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)
767 - Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
1575 - Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)
1793 - Functional Anti-Apoptotic Protein Dependence and Its Relation to Genomic Prognostic Markers and Response to Treatment in Chronic Lymphocytic Leukemia
1836 - EZH2 Targeting Induces CD38 Upregulation and Response to Anti-CD38 Antibodies in Multiple Myeloma
2866 - Ironomycin Induces Mantle Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction
4484 - Targeting Iron Homeostasis As a Therapeutic Strategy in Multiple Myeloma
4814 - Development of a Robust BH3 Profiling Toolkit for Precision Medicine in Hematologic Malignancies
616 - Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)
767 - Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
1575 - Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)
1793 - Functional Anti-Apoptotic Protein Dependence and Its Relation to Genomic Prognostic Markers and Response to Treatment in Chronic Lymphocytic Leukemia
1836 - EZH2 Targeting Induces CD38 Upregulation and Response to Anti-CD38 Antibodies in Multiple Myeloma
2866 - Ironomycin Induces Mantle Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction
4484 - Targeting Iron Homeostasis As a Therapeutic Strategy in Multiple Myeloma
4814 - Development of a Robust BH3 Profiling Toolkit for Precision Medicine in Hematologic Malignancies
Herbst, J.
Herbst, R.
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
Heredia, Á.
Herek, T. A.
Hergalant, S.
Herhaus, P.
622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
729 - Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
729 - Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
Herishanu, Y.
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
Herishanu, Y.
1658 - Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
2910 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
3121 - The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge
2910 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
3121 - The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge
Herling, M.
1481 - Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation
1829 - Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia
2099 - Outcomes Following Hypomethylating Agent / Venetoclax Combination-Therapy for MDS or AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
2103 - Outcomes of Patients with Acute Myeloid Leukemia Receiving a Second Allogeneic Stem Cell Transplantation
3364 - Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes – No Association of Clonal Hematopoiesis (CH) with Manufacturing Success
3449 - Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
4756 - Prognostic Impact of the 2022 European Leukemia Net Risk Classification in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
1829 - Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia
2099 - Outcomes Following Hypomethylating Agent / Venetoclax Combination-Therapy for MDS or AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
2103 - Outcomes of Patients with Acute Myeloid Leukemia Receiving a Second Allogeneic Stem Cell Transplantation
3364 - Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes – No Association of Clonal Hematopoiesis (CH) with Manufacturing Success
3449 - Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
4756 - Prognostic Impact of the 2022 European Leukemia Net Risk Classification in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
Herman, V.
Hermand-Tournamille, P.
Hermann, F.
Hermanova, I.
Hermans, C.
1113 - Predictive Value of Platelet Sequestration Studies in Splenectomy Response
1127 - Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid
3794 - Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor
1127 - Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid
3794 - Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor
Hermans, C.
Hermans, M.
Hermans, S. J.
Hermansen, E.
Hermansen, J. U.
Hermanson, D. L.
Hermes, P.
Hermine, O.
722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma
767 - Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
804 - Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study
957 - Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
2619 - Metabolic Plasticity Reveals a Targetable Vulnerability in Leukemia
3643 - In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis
3659 - Investigations into the Mechanisms and Clinical Implications of Modulation of Hepcidin Levels By Luspatercept in TD MDS and TD b-Thalassemia
3671 - Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β‑Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis
767 - Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
804 - Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study
957 - Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
2619 - Metabolic Plasticity Reveals a Targetable Vulnerability in Leukemia
3643 - In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis
3659 - Investigations into the Mechanisms and Clinical Implications of Modulation of Hepcidin Levels By Luspatercept in TD MDS and TD b-Thalassemia
3671 - Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β‑Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis
Hermine, O.
Hermine, O.
Hermiston, M. L.
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
2033 - Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
4662 - Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
2033 - Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
4662 - Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
Hermiston, T. W.
Hernáez, M.
Hernandez Boluda, J. C.
339 - Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
1708 - Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
2996 - Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
3376 - Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
4759 - Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis
1708 - Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
2996 - Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
3376 - Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
4759 - Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis
Hernandez, B. N.
1039 - Functionality of a Peripheral Blood Derived Microglia-like Cell System for Drug Discovery to Treat Sickle Cell Related Chronic Pain
2366 - GBT021601 Increases Hemoglobin and Improves Red Blood Cell Deformability without Rebound Hyperviscosity upon Drug Clearance in a Sickle Mouse Model
3470 - Characterization of Hemoglobin Variants Due to in-Frame Deletions in the β-Globin Gene from CRISPR/Cas9 Gene Correction for Sickle Cell Disease
2366 - GBT021601 Increases Hemoglobin and Improves Red Blood Cell Deformability without Rebound Hyperviscosity upon Drug Clearance in a Sickle Mouse Model
3470 - Characterization of Hemoglobin Variants Due to in-Frame Deletions in the β-Globin Gene from CRISPR/Cas9 Gene Correction for Sickle Cell Disease
Hernandez, C.
1682 - Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial
1711 - Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
1711 - Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
Hernandez, C.
Hernandez, E. F.
Hernandez, F. M.
Hernandez, G. H.
Hernández, J. M.
Hernandez, J. A.
Hernandez, J. A.
Hernandez, L.
Hernández, M.
Hernández, M. T.
118 - Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
866 - Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
3241 - Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
866 - Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
3241 - Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
Hernandez, P. M.
Hernandez Perez, A. P.
Hernandez, Q.
Hernandez, R.
Hernández Sánchez, A.
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
339 - Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
339 - Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
Hernández-Hernández, J. A.
Hernandez-Ibarburu, G.
Hernandez-Ilizaliturri, F.
655 - Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
2262 - The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
2881 - Evaluation of Antibody and T Cell Responses to COVID-19 Vaccination in Patients with Lymphoid Malignancies Receiving B Cell-Depleting Agents
3293 - Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax
3989 - Enhanced Anti-Tumor Activity with Exposure to BCL-2 and BRD4 Inhibitors in Mantle Cell Lymphoma
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4615 - CD180 As a Putative Target for Immunotherapy in Aggressive Mature B Cell Lymphomas
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
2262 - The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
2881 - Evaluation of Antibody and T Cell Responses to COVID-19 Vaccination in Patients with Lymphoid Malignancies Receiving B Cell-Depleting Agents
3293 - Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax
3989 - Enhanced Anti-Tumor Activity with Exposure to BCL-2 and BRD4 Inhibitors in Mantle Cell Lymphoma
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4615 - CD180 As a Putative Target for Immunotherapy in Aggressive Mature B Cell Lymphomas
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort
Hernandez-Lopez, I.
Hernández-Oliveros, F.
Hernández-Rivas, J. M.
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
339 - Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
460 - Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
1784 - NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted
1786 - TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia
1790 - Chemotherapy-Based Regimes Increase Karyotype Complexity of Del(11q) CLL Cells and Impact the Response to Subsequent Ibrutinib Treatment
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
2727 - Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
2822 - IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial
4377 - Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
- Impact of Real-World Evidence on Research and Clinical Care: Priorities from EU HARMONY Alliance (1)
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
339 - Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
460 - Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
1784 - NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted
1786 - TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia
1790 - Chemotherapy-Based Regimes Increase Karyotype Complexity of Del(11q) CLL Cells and Impact the Response to Subsequent Ibrutinib Treatment
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
2727 - Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
2822 - IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial
4377 - Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
- Impact of Real-World Evidence on Research and Clinical Care: Priorities from EU HARMONY Alliance (1)
Hernandez-Rivas, J. A.
1584 - Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I+BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting
3241 - Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
3241 - Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
Hernández-Rivas, J. Á.
460 - Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
3619 - Comprehensive Geriatric Assessment Is a Useful Tool for Predicting the Outcome of Elderly Patients with Hematologic Malignancies in Real Life
4208 - Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo
4377 - Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
4926 - Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
3619 - Comprehensive Geriatric Assessment Is a Useful Tool for Predicting the Outcome of Elderly Patients with Hematologic Malignancies in Real Life
4208 - Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo
4377 - Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
4926 - Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021
Hernandez-Sanchez, M.
Hernani, R.
155 - Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy
269 - Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
658 - Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
764 - Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
269 - Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
658 - Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
764 - Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
Herne, C. A.
1558 - Innate Immune Microenvironment of Indolent B Cell Splenic Lymphomas: Role in Diagnosis and Treatment
1794 - Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment
1814 - Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions
1794 - Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment
1814 - Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions
Herold, S.
Herold, T.
386 - Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
1479 - Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia
2129 - Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation
4018 - Acute Myeloid Leukemia with Isolated Trisomy 4 Is Characterized By Frequent Mutations of TET2 and a Distinct DNA Methylation Signature
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
1479 - Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia
2129 - Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation
4018 - Acute Myeloid Leukemia with Isolated Trisomy 4 Is Characterized By Frequent Mutations of TET2 and a Distinct DNA Methylation Signature
Herr, W.
1350 - Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response
1464 - Cohesin-STAG2 Mutations Alter Chromatin Structure and Gene Regulation in Human Acute Myeloid Leukemia
2084 - Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd
2863 - Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity
3262 - Immunomodulatory Microbial Metabolites Identified in Allo-SCT Patients Protect from GvHD By Sting Dependent Modulation of Intestinal Tissue Homeostasis
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
1464 - Cohesin-STAG2 Mutations Alter Chromatin Structure and Gene Regulation in Human Acute Myeloid Leukemia
2084 - Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd
2863 - Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity
3262 - Immunomodulatory Microbial Metabolites Identified in Allo-SCT Patients Protect from GvHD By Sting Dependent Modulation of Intestinal Tissue Homeostasis
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
Herraez, M. R.
Herraez, R.
Herraiz, M. A.
Herrejon Chavez, F.
Herrera, A. M.
Herrera, A. F.
316 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti–PD-1 Treatment
318 - Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma
442 - Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
490 - A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma
542 - Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
795 - Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2910 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
4192 - CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
4239 - Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
- Incorporating Novel Agents in Frontline Treatment of HL
318 - Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma
442 - Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
490 - A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma
542 - Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
795 - Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2910 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
4192 - CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
4239 - Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
- Incorporating Novel Agents in Frontline Treatment of HL
Herrera Arroyo, C.
Herrera, P.
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Herrera Puente, P.
Herrero, A.
2264 - Real-World Evidence of Collecting Quality of Life (QoL) and Symptoms Perception Using the HM-PRO© Tool As a Patient-Reported Outcome Measure (PROM) in Patients with Lymphoma While Receiving Intravenous Chemotherapy
3614 - End-of-Life Care in Hospitalized Patients with Hematologic Malignancies: A Retrospective Unicentric Study
4936 - Feasibility of Electronic Patient-Reported Outcome (ePRO) Measurement Using PRO-CTCAE® Questionnaire to Improve Quality of Life Assessment and Healthcare Resources Management in Patients with Lymphoma Receiving Intravenous Chemotherapy
3614 - End-of-Life Care in Hospitalized Patients with Hematologic Malignancies: A Retrospective Unicentric Study
4936 - Feasibility of Electronic Patient-Reported Outcome (ePRO) Measurement Using PRO-CTCAE® Questionnaire to Improve Quality of Life Assessment and Healthcare Resources Management in Patients with Lymphoma Receiving Intravenous Chemotherapy
Herrero, J.
715 - The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)
1311 - The Hematopoietic Transcription Factor GATA3 Is the Main Activator of Enhancer-Mediated Activation of Oncogenic TAL1 in T-ALL
4540 - Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma
1311 - The Hematopoietic Transcription Factor GATA3 Is the Main Activator of Enhancer-Mediated Activation of Oncogenic TAL1 in T-ALL
4540 - Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma
Herrero-Martín, S.
Herrman, E.
Herrmann, L.
Herrmann, L.
Herrmann, S. M.
Hershberger, C. E.
Hershenfeld, S. A.
Hershkovitz-Rokah, O.
Hertenstein, B.
116 - Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
2782 - Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
2782 - Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
Herter, S.
1360 - RG6333 (CD19-CD28), a CD19-Targeted Affinity-Optimized CD28 Bispecific Antibody, Enhances and Prolongs the Anti-Tumor Activity of Glofitamab (CD20-TCB) in Preclinical Models
3981 - Pharmacologic Inhibitors of STAT3 or BCL6 Transcriptional Function Sensitize Lymphoma Cells to the Novel PD-1 Cis-Targeted PD1-IL2v Immunocytokine in a Murine Model
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
3981 - Pharmacologic Inhibitors of STAT3 or BCL6 Transcriptional Function Sensitize Lymphoma Cells to the Novel PD-1 Cis-Targeted PD1-IL2v Immunocytokine in a Murine Model
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Hertlein, E.
Hertlein, E.
305 - Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia
1440 - Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
1451 - A Novel Inhibitor of FLT3 and Its Drug-Resistant Mutants with Superior Activity to Gilteritinib in Molm-13 Preclinical Acute Myeloid Leukemia Xenograft Model
2586 - A Novel Ptpn11E76K/Npm1cA Murine Model of AML Identifies a Unique Immune Population Relevant to Human Disease
4798 - Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
1440 - Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
1451 - A Novel Inhibitor of FLT3 and Its Drug-Resistant Mutants with Superior Activity to Gilteritinib in Molm-13 Preclinical Acute Myeloid Leukemia Xenograft Model
2586 - A Novel Ptpn11E76K/Npm1cA Murine Model of AML Identifies a Unique Immune Population Relevant to Human Disease
4798 - Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy
Hertzberg, M.
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
4381 - Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment
4381 - Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment
Hertzberg, M.
441 - Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
3080 - In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
3080 - In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
Herzog, E.
Herzog, R. W.
126 - Combination Therapy to Enable AAV Re-Dosing and Mitigate Transgene Immunity in Liver-Targeted Gene Therapy
399 - Antigen Trafficking and Possibly Intrinsic Immunostimulatory Properties Shape High Immunogenicity of Factor VIII
2150 - Key Role of Kupffer Cells in IL-1 Dependent Activation of CD8+ T Cell Responses to AAV Transgene Product in Liver
399 - Antigen Trafficking and Possibly Intrinsic Immunostimulatory Properties Shape High Immunogenicity of Factor VIII
2150 - Key Role of Kupffer Cells in IL-1 Dependent Activation of CD8+ T Cell Responses to AAV Transgene Product in Liver
Herzog, S.
Heslop, H. E.
167 - CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma
984 - Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
3338 - Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
984 - Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
3338 - Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
Heslop, K.
Hess, A. S.
Hess, B. T.
154 - Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2960 - Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
4230 - Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2960 - Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial
4230 - Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
Hess, G.
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
4627 - A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
4627 - A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
Hess, J. R.
Hess, J. M.
Hess, S. M.
Hestdal, K.
Hester, L. L.
Hetherington, M. J.
Heuck, C.
157 - Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
1925 - MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
3243 - MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
1925 - MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
3243 - MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
Heugel, M.
Heuschmann, P.
Heuser, M.
223 - Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo+AZA in the AGILE Study
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
340 - TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis
832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
836 - Macs - a Leukemic Stem Cell- Based Predictor of Clinical Response to Venetoclax and Other BH3 Mimetics for Acute Myeloid Leukemia
1437 - Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
1466 - Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
2155 - DEK-NUP214 Acute Myeloid Leukemia Depends on CRM1 In Vivo
2704 - Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients
2782 - Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients
3306 - Single and Combinational Multiplex Base-Edited ‘Universal’ CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
340 - TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis
832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
836 - Macs - a Leukemic Stem Cell- Based Predictor of Clinical Response to Venetoclax and Other BH3 Mimetics for Acute Myeloid Leukemia
1437 - Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
1466 - Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
2155 - DEK-NUP214 Acute Myeloid Leukemia Depends on CRM1 In Vivo
2704 - Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients
2782 - Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients
3306 - Single and Combinational Multiplex Base-Edited ‘Universal’ CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
Heußner, P.
Heuston, E. F.
Hevenor, L.
102 - Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1837 - In Situ Characterization of Chromatin Landscape in Progression of Smoldering Precursor Stage to Multiple Myeloma
1854 - Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
4457 - Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1837 - In Situ Characterization of Chromatin Landscape in Progression of Smoldering Precursor Stage to Multiple Myeloma
1854 - Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
4457 - Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma
Hewitt, K. J.
Hexner, E. O.
426 - Real World Effectiveness of “7 + 3” Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia
770 - Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
1710 - An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety
2016 - Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy
4862 - Fried’s Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
770 - Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
1710 - An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety
2016 - Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy
4862 - Fried’s Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Heydendael, W.
Heyerdahl, H.
Heyman, M.
1294 - Single-Cell Multi-Omics Analysis Reveals Hematopoiesis of Aberrant Mast Cells in Systemic Mastocytosis
1513 - The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia
2688 - High-Dose Methotrexate-Related Toxicity in Children with Acute Lymphoblastic Leukemia
4006 - Pharmacokinetics and Immunogenicity of the First Doses of Peg-Asparaginase -an Alltogether Pilot Study
1513 - The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia
2688 - High-Dose Methotrexate-Related Toxicity in Children with Acute Lymphoblastic Leukemia
4006 - Pharmacokinetics and Immunogenicity of the First Doses of Peg-Asparaginase -an Alltogether Pilot Study
Heymans, M. W.
Heyn, H.
Heyne, K.
Hibbitts, E.
901 - The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children’s Oncology Group Study
1412 - A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1
1412 - A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1
Hicheri, Y.
50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
2735 - Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study
2738 - Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
2735 - Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study
2738 - Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
Hickey, C. L.
Hickman, A.
3192 - Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma
4509 - A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma
4509 - A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma
Hickman, H. D.
Hickman, J.
Hicks, A.
Hicks, B.
4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
Hicks, L. K.
129 - Toxicity Reporting Is Inconsistent and Incomplete, and Subjective Minimizing Language Is Common in Acute Leukemia Clinical Trials: A Systematic Review of Randomized Controlled Trials Presented at ASH between 2017-2021
2216 - Inconsistent Adverse Event Reporting: A Systematic Review of Phase 3 Lymphoma or Myeloma Trials Presented at ASH Annual Meetings between 2017-2021
2216 - Inconsistent Adverse Event Reporting: A Systematic Review of Phase 3 Lymphoma or Myeloma Trials Presented at ASH Annual Meetings between 2017-2021
Hicks, S. M.
Hidaka, D.
1390 - Clinical Features of Complex Karyotype in Newly Diagnosed Acute Myeloid Leukemia
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
Hidalgo, A.
Hidalgo Soto, M.
Hidalgo-Miranda, A.
Hidalgo-Vargas, M.
Hidalgo-Vargas, M. J.
Hiddemann, W.
280 - Secondary Neoplasms in AML Long-Term Survivors: Even More Cancer to Come?
386 - Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])
388 - German AMLCG-Survivorship Study: Anxiety and Depression Symptoms in AML Long-Term Survivors
1479 - Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia
2319 - Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study
386 - Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])
388 - German AMLCG-Survivorship Study: Anxiety and Depression Symptoms in AML Long-Term Survivors
1479 - Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia
2319 - Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study
Hideshima, T.
148 - Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma
241 - BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells
642 - Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma
859 - Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients
1822 - Super-Enhancer-Driven PIM Kinase Upregulation in Multiple Myeloma Maintains the Plasma Cell-Specific Oncogenic and Microenvironmental Circuits, and Can be Efficiently Targeted By the Pan-PIM Inhibitor MEN1703
3165 - Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma
241 - BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells
642 - Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma
859 - Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients
1822 - Super-Enhancer-Driven PIM Kinase Upregulation in Multiple Myeloma Maintains the Plasma Cell-Specific Oncogenic and Microenvironmental Circuits, and Can be Efficiently Targeted By the Pan-PIM Inhibitor MEN1703
3165 - Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma
Hiemeyer, F.
1576 - Population Pharmacokinetics and Exposure–Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma
2882 - Pooled Safety Analysis from Phase I–III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib
2882 - Pooled Safety Analysis from Phase I–III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib
Hiemstra, I. H.
Hiemstra, P. S.
Hiergeist, A.
Hiew, H. J.
27 - Characteristics and Bleeding Behavior of Females with Mild Hemophilia A: Longitudinal Study from Picnichealth Hemophilia A Database
192 - Real-World Safety of Emicizumab: Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database
1170 - Characteristics and Healthcare Utilization of Patients with Mild or Moderate Hemophilia A in the US - an Analysis from the Picnichealth Cohort
4288 - Characterizing Diffuse Large B Cell Lymphoma (DLBCL) Disease Biology Features and Survival Outcomes By Patient Racial Groups Using Real World Data
192 - Real-World Safety of Emicizumab: Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database
1170 - Characteristics and Healthcare Utilization of Patients with Mild or Moderate Hemophilia A in the US - an Analysis from the Picnichealth Cohort
4288 - Characterizing Diffuse Large B Cell Lymphoma (DLBCL) Disease Biology Features and Survival Outcomes By Patient Racial Groups Using Real World Data
Higashi, M. K.
Higashi, R. M.
Higgins, A.
Higgins, J. M.
Higgins, K.
1567 - Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial
3133 - Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
3133 - Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Higgins, M.
Higgins, S. J.
Higgs, B.
2859 - Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory Versus Newly Diagnosed Patients Using Single FFPE Slides
2874 - Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial
2874 - Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial
Higgs, D. R.
Highfill, S.
2015 - Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India
2408 - Extended Detection in Peripheral Blood Following Infusion of Chronic Granulomatous Disease Patient Autologous Granulocytes Corrected By mRNA Transfection in Patients with Chronic Granulomatous Disease
3310 - T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma
3372 - Allogeneic Peripheral Blood Stem Cell Transplantation for Bone Marrow Failure Syndromes Using CD34+-Selected Progenitor Cells Co-Infused with a Reduced Number of Non-Mobilized T-Cells
2408 - Extended Detection in Peripheral Blood Following Infusion of Chronic Granulomatous Disease Patient Autologous Granulocytes Corrected By mRNA Transfection in Patients with Chronic Granulomatous Disease
3310 - T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma
3372 - Allogeneic Peripheral Blood Stem Cell Transplantation for Bone Marrow Failure Syndromes Using CD34+-Selected Progenitor Cells Co-Infused with a Reduced Number of Non-Mobilized T-Cells
Hikima, M. S.
674 - Progressive Silent Cerebral Infarcts Are Prevalent in Adults with Sickle Cell Anemia but Moderate-Severe Cognitive Abnormalities Are Independent of Preexisting Silent Cerebral Infarcts
2395 - Rationale and Design of a Randomized Controlled Double-Blind Internal Pilot Trial for Prevention of Recurrent Ischemic Priapism in Men with Sickle Cell Disease (PIN Trial)
2395 - Rationale and Design of a Randomized Controlled Double-Blind Internal Pilot Trial for Prevention of Recurrent Ischemic Priapism in Men with Sickle Cell Disease (PIN Trial)
Hilal, T.
Hilberink, J. R.
523 - M2 Macrophages Drive Resistance to Phagocytosis and Improve Mitochondrial Metabolism in Acute Myeloid Leukemia Facilitating Leukemic Transformation and In Vivo Engraftment
3960 - Functional Drug Screen Identifies Thiostrepton, NAMPT Inhibitors and Metformin As Potential Candidates to Target the Macrophage Tumor Microenvironment in Acute Myeloid Leukemia
3960 - Functional Drug Screen Identifies Thiostrepton, NAMPT Inhibitors and Metformin As Potential Candidates to Target the Macrophage Tumor Microenvironment in Acute Myeloid Leukemia
Hilberink, J. R.
Hildebrandt, F.
Hildebrandt, F.
Hildebrandt, G. C.
714 - Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)
3416 - Complex Restrictive Lung Disease Patterns Affecting Survival and Outcomes in Patients Undergoing Allogeneic Stem Cell Transplant: A Single-Institution Retrospective Analysis
3416 - Complex Restrictive Lung Disease Patterns Affecting Survival and Outcomes in Patients Undergoing Allogeneic Stem Cell Transplant: A Single-Institution Retrospective Analysis
Hilden, V.
Hildenbrand, A. K.
Hilder, B.
157 - Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
Hilgendorf, I.
Hilgendorf, I.
Hilger, J.
962 - A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data
1529 - Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies
4201 - A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data
1529 - Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies
4201 - A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data
Hilinski, G.
Hill, B. T.
156 - Outcomes of DLBCL Patients Achieving Complete Remission after R-ICE Chemoimmunotherapy
554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
656 - Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
765 - Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
847 - Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study
2032 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
2037 - Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers
2221 - Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab
3319 - ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
3345 - Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4908 - Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study
554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
656 - Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
765 - Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
847 - Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study
2032 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
2037 - Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers
2221 - Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab
3319 - ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
3345 - Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4908 - Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study
Hill, B. Y.
Hill, G. R.
861 - Regulatory T Cell Depletion during Stem Cell Mobilization Enhances Anti-Myeloma Immunity after Experimental Autologous Stem Cell Transplantation
3258 - Lithium Attenuates Graft-Versus-Host Disease Via Effects on the Intestinal Stem Cell Niche
3418 - Pilot Trial of IFN-γ and Donor Lymphocyte Infusion to Treat Relapsed AML and MDS after Allogeneic Hematopoietic Stem Cell Transplantation
3258 - Lithium Attenuates Graft-Versus-Host Disease Via Effects on the Intestinal Stem Cell Niche
3418 - Pilot Trial of IFN-γ and Donor Lymphocyte Infusion to Treat Relapsed AML and MDS after Allogeneic Hematopoietic Stem Cell Transplantation
Hill, Jr., J. M.
2042 - Utility of Targeted Neurocognitive Testing in Detecting Early Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CAR T-Cell Therapy
3622 - Patient Reported Outcomes for Patients Receiving a Hematopoietic Stem Cell Transplant: A Longitudinal Assessment with a Dashboard Display
3622 - Patient Reported Outcomes for Patients Receiving a Hematopoietic Stem Cell Transplant: A Longitudinal Assessment with a Dashboard Display
Hill, K.
Hill, K.
Hill, M.
2181 - Non-Invasive Optical Characterization of Tissue Hemodynamics in Sickle Cell Patients Undergoing Treatment with Isoquercetin
3699 - Targeting Thrombophilia in Sickle Cell Disease with Isoquercetin: Results of a Fixed Dose, Single Center, Phase II Randomized Clinical Trial
3700 - Effects of Isoquercetin on Plasma Protein Disulfide Isomerase Activity and Extracellular Vesicle Tissue Factor Antigen/Activity in Sickle Cell Disease
3699 - Targeting Thrombophilia in Sickle Cell Disease with Isoquercetin: Results of a Fixed Dose, Single Center, Phase II Randomized Clinical Trial
3700 - Effects of Isoquercetin on Plasma Protein Disulfide Isomerase Activity and Extracellular Vesicle Tissue Factor Antigen/Activity in Sickle Cell Disease
Hill, M. M.
Hill, Q. A.
31 - Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study
2325 - Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States
2325 - Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States
Hillengass, J.
3175 - Physical Activity in Patients with Monoclonal Gammopathies – a Healthtree Cure Hub Study
3240 - Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
4506 - A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders
4566 - A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
3240 - Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
4506 - A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders
4566 - A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Hillengass, M.
Hillier, K.
Hillis, C. M.
Hillje, R.
Hillmen, P.
91 - MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
94 - Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
3125 - High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses
- Clinical/Translational Science
LBA-6 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
94 - Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
3125 - High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses
- Clinical/Translational Science
LBA-6 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
Hiltenbrand, R.
Hilton, L. K.
546 - Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL
555 - Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia
721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
726 - Exploring Splicing Factor Aberrations As a Therapeutic Target in Mature B-Cell Malignancies
1518 - Towards a Unified Genetic Classification System for Diffuse Large B-Cell Lymphoma (DLBCL)
2836 - Genetic Determinants of Isolated and Systemic Testicular Diffuse Large B-Cell Lymphoma Highlight a Disease Spectrum
4160 - Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas
4166 - Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
555 - Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia
721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
726 - Exploring Splicing Factor Aberrations As a Therapeutic Target in Mature B-Cell Malignancies
1518 - Towards a Unified Genetic Classification System for Diffuse Large B-Cell Lymphoma (DLBCL)
2836 - Genetic Determinants of Isolated and Systemic Testicular Diffuse Large B-Cell Lymphoma Highlight a Disease Spectrum
4160 - Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas
4166 - Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
Himberlin, C.
2737 - Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)
2738 - Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
2738 - Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
Himburg, H. A.
Himmat, M.
Hinderlie, P.
Hindley, C. J.
Hinds, M. T.
Hines, D. M.
Hines, J.
Hines, K.
Hines, P. C.
Hines, P. C.
Hing, Z. A.
Hinkle, J.
Hinman, K.
Hino, M.
Hinson, E. L.
218 - FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial
431 - Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
431 - Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
Hinterschied, C.
Hinton, P. R.
2632 - CD123 Directed IgM Antibody-based T-cell Engager, IGM-2537, Demonstrates Potent in vitro and in vivo Activity with Minimal Cytokine Release
2678 - Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile
2678 - Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile
Hippen, K. L.
Hirabayashi, S.
Hirabayashi, S.
Hirabayashi, S.
Hiraga, J.
Hirakawa, A.
Hiramatsu, Y.
Hiramoto, N.
Hiramoto, N.
Hirata, J.
542 - Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
951 - A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
2958 - Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
951 - A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
2958 - Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
Hirata, T.
Hiregoudar, S.
Hironaka, D.
Hirsch, P.
Hirschbühl, K.
336 - Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry
2129 - Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation
2129 - Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation
Hirst, M.
Hisada, Y.
Hitchcock, I.
Hitchens, T. K.
Hitchinson, L.
Hivert, B.
Hiwase, D.
606 - A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
1252 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
1754 - Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
2133 - Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
2806 - Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
3080 - In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4383 - Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
4730 - Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
1252 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
1754 - Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
2133 - Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
2806 - Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
3080 - In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4383 - Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
4730 - Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
Hixon, J.
Hizukuri, Y.
Hlavackova, A.
Hlozkova, K.
Hlubi, T.
3216 - Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
Ho, A. Y.
3386 - Sequential Use of Flamsa, FLAG, CLAG or TEC-Based Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasia Patients: 15 Year Follow-up of the Multicenter Study in Singapore
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4711 - Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4711 - Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore
Ho, A. D.
Ho, B.
Ho, C.
Ho, J. J. D.
Ho, J. M.
Ho, L.
314 - Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)
4230 - Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
4230 - Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
Ho, P. J.
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
1857 - Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
1857 - Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
Ho, P. Y.
Ho, S.
Ho, S. J.
234 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
3232 - An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
3232 - An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
Ho, T. C.
Ho, V.
377 - Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study
2097 - Allogeneic Stem Cell Cryopreservation Is Associated with Equivalent Survival and Relapse Rates with Lower Rate of Severe Chronic Gvhd
2097 - Allogeneic Stem Cell Cryopreservation Is Associated with Equivalent Survival and Relapse Rates with Lower Rate of Severe Chronic Gvhd
Ho, V. T.
479 - The DNA-Sensor AIM2 Promotes BCR-Activated B Cells in Chronic Graft-Versus-Host-Disease
880 - Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial
2078 - Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL Targets
4004 - Intensity of Induction Regimen and Outcomes Among Adults with Ph+ ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
880 - Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial
2078 - Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL Targets
4004 - Intensity of Induction Regimen and Outcomes Among Adults with Ph+ ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Ho, Y. Y.
3014 - Population Pharmacokinetics in Hepatic and Renal Impairment and PBPK Drug-Drug Interaction Simulations of Asciminib, a Novel Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia in Chronic Phase
3023 - Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML-CP) with and without the T315I Mutation
3023 - Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML-CP) with and without the T315I Mutation
Hoagland, B.
Hoang, D. H.
Hoang, N. M.
Hoang-Xuan, K.
Hobbelink, M. G.
Hobbs, G. S.
236 - Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
1425 - A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
1435 - Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults
1716 - Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
3030 - Trends in All-Cause and Cardiovascular Mortality Among Patients with Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis
3047 - Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections
4372 - Risk Factors for Major Adverse Cardiac Events and Bleeding in Patients with Myeloproliferative Neoplasms Admitted for Myocardial Infarction
4841 - Development of Consensus Guidelines for Hematology Fellow Competency in Peripheral Blood Smear Review Utilizing Nominal Group Technique
1425 - A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
1435 - Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults
1716 - Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
3030 - Trends in All-Cause and Cardiovascular Mortality Among Patients with Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis
3047 - Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections
4372 - Risk Factors for Major Adverse Cardiac Events and Bleeding in Patients with Myeloproliferative Neoplasms Admitted for Myocardial Infarction
4841 - Development of Consensus Guidelines for Hematology Fellow Competency in Peripheral Blood Smear Review Utilizing Nominal Group Technique
Hobbs, K. A.
Hobbs, L. M.
Hobbs, M. A.
970 - Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma
3177 - Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma
3613 - Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes
4492 - Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide
4501 - Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
4523 - Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event
4556 - Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma – MRD Negativity and Survival Outcomes
3177 - Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma
3613 - Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes
4492 - Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide
4501 - Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
4523 - Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event
4556 - Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma – MRD Negativity and Survival Outcomes
Hobbs, W.
Hobohm, L.
Hoch, M.
3014 - Population Pharmacokinetics in Hepatic and Renal Impairment and PBPK Drug-Drug Interaction Simulations of Asciminib, a Novel Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia in Chronic Phase
3023 - Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML-CP) with and without the T315I Mutation
4334 - ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors
3023 - Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML-CP) with and without the T315I Mutation
4334 - ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors
Hochberg, B.
Hochberg, J. C.
1056 - A Phase II Study to Evaluate the Safety and Efficacy of Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome (IND 127812)
2734 - Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia
3455 - Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL
2734 - Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia
3455 - Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL
Hochhaus, A.
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
332 - ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase
336 - Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry
390 - Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
742 - Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
877 - Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
2316 - Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
2786 - Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
3008 - Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
3012 - ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
3018 - First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies
3021 - ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
4334 - ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors
4339 - Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN
332 - ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase
336 - Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry
390 - Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
742 - Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
877 - Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
2316 - Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
2786 - Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
3008 - Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
3012 - ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
3018 - First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies
3021 - ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
4334 - ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors
4339 - Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN
Hochman, M. J.
597 - Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification
1468 - Post-Remission Outcomes in Patients with Acute Myeloid Leukemia (AML) Are Similar between Hypomethylating Agent/Venetoclax Therapy and Intensive Chemotherapy after Accounting for Measurable Residual Disease (MRD) Status
1468 - Post-Remission Outcomes in Patients with Acute Myeloid Leukemia (AML) Are Similar between Hypomethylating Agent/Venetoclax Therapy and Intensive Chemotherapy after Accounting for Measurable Residual Disease (MRD) Status
Hochwald, A. P.
Hock, H. R.
Hock, S.
Hockaday, A.
94 - Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
762 - Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) – Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation
762 - Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) – Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation
Hod, E. A.
Hoda, D.
4673 - Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4724 - Reduced Incidence of Cytokine Release Syndrome and Improved Outcomes with Earlier Initiation of Immunosuppressive Therapy in Haploidentical Stem Cell Transplant
4856 - Successful Outpatient Treatment and Monitoring Following Administration of Various Anti-CD19 Chimeric Antigen Receptor Therapies in B-Cell Lymphomas
- Reducing Overtesting and Overdiagnosis of Clostrdioides Dificile Infection in the Setting of an HSCT Unit
4724 - Reduced Incidence of Cytokine Release Syndrome and Improved Outcomes with Earlier Initiation of Immunosuppressive Therapy in Haploidentical Stem Cell Transplant
4856 - Successful Outpatient Treatment and Monitoring Following Administration of Various Anti-CD19 Chimeric Antigen Receptor Therapies in B-Cell Lymphomas
- Reducing Overtesting and Overdiagnosis of Clostrdioides Dificile Infection in the Setting of an HSCT Unit
Hodder, A.
1418 - Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
Hodge, D.
Hodges, E.
Hodges, H. C.
Hodges, P.
Hodgson, D.
Hodgson, D. C.
313 - Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
1597 - Treatment Patterns and Outcomes in Adolescent and Young Adults with Nodular Lymphocyte Predominant Hodgkin Lymphoma: An Impact Cohort Population-Based Study
1642 - Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study
2921 - Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331
1597 - Treatment Patterns and Outcomes in Adolescent and Young Adults with Nodular Lymphocyte Predominant Hodgkin Lymphoma: An Impact Cohort Population-Based Study
1642 - Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study
2921 - Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331
Hodgson, K.
Hodi, S.
Hoefer, I.
Hoeg, R. T.
265 - Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
769 - Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
2764 - A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia
3538 - Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records
4024 - Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens
4252 - A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
769 - Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
2764 - A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia
3538 - Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records
4024 - Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens
4252 - A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
Hoehn, D.
Hoeijmakers, J. H.
Hoekstra, O. S.
Hoekx, M.
Hoenemann, D.
Hoepting, M.
Hoering, A.
Hoermann, G.
228 - AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages?
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
3861 - Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
3861 - Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression
Hoeynck, B.
Hof, W. V.
Hofbauer, L. C.
Hofer, M.
Höfer, T.
Hoff, F. W.
2072 - Post-Transplant Cyclophosphamide Associated with Increased Early Mixed Donor Chimerism in Myeloid Malignancies; A Single-Center Experience
2785 - Targeting Vimentin (VIM) in Acute Myelogenous Leukemia (AML)
2825 - RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome
3603 - Real World Patient Reported Outcomes Evaluating the Impact of Hematologic Malignancies on Patient Quality of Life
2785 - Targeting Vimentin (VIM) in Acute Myelogenous Leukemia (AML)
2825 - RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome
3603 - Real World Patient Reported Outcomes Evaluating the Impact of Hematologic Malignancies on Patient Quality of Life
Hoffman, C.
Hoffman, H. M.
Hoffman, J. E.
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
4515 - Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
4547 - The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients
4555 - Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
4562 - Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)
4515 - Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
4547 - The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients
4555 - Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
4562 - Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)
Hoffman, R.
249 - Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy
327 - Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis
1323 - Pharmacological Disruption of the Interplay between HDM2-p53 and NFκB Depletes Myelofibrosis Progenitor/Stem Cells and Dampens the Accompanying Inflammatory Milieu
1709 - Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
1735 - Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119
3040 - Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera
3662 - ATR Inhibitor Camonsertib (RP-3500) Suppresses Early Stage Erythroblasts By Mediating Ferroptosis
3877 - Co-Cultivation of MF CD34+ Cells with Microenvironmental Cells Has a Profound Effect on MF Hematopoiesis and Responses to Drug Therapy
4312 - Transcriptional and Epigenetic Dysregulation Drives Erythroid and Megakaryocyte Differentiation Bias in the Spleens of Patients with Advanced Myelofibrosis
327 - Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis
1323 - Pharmacological Disruption of the Interplay between HDM2-p53 and NFκB Depletes Myelofibrosis Progenitor/Stem Cells and Dampens the Accompanying Inflammatory Milieu
1709 - Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
1735 - Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119
3040 - Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera
3662 - ATR Inhibitor Camonsertib (RP-3500) Suppresses Early Stage Erythroblasts By Mediating Ferroptosis
3877 - Co-Cultivation of MF CD34+ Cells with Microenvironmental Cells Has a Profound Effect on MF Hematopoiesis and Responses to Drug Therapy
4312 - Transcriptional and Epigenetic Dysregulation Drives Erythroid and Megakaryocyte Differentiation Bias in the Spleens of Patients with Advanced Myelofibrosis
Hoffmann, M.
229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
4264 - Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
4264 - Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma
Hoffmann, P.
Hoffmann, S.
Hoffmann, S.
Hoffmeister, L.
Hofland, M. A.
Hofman, I. J.
Hofmann, A.
Hofmann, M.
Hofmann, S. L.
Hofmann, W. K.
390 - Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)
1316 - Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms
1727 - Response and Resistance to Cladribine in Patients with Advanced Systemic Mastocytosis: A Registry-Based Analysis
1744 - Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models
3971 - The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML
4380 - ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes
4416 - Inter-Modality Variance of Blast Quantification in Patients with Myelodysplastic Syndrome (MDS) and Its Impact on Risk Stratification and Overall Survival
1316 - Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms
1727 - Response and Resistance to Cladribine in Patients with Advanced Systemic Mastocytosis: A Registry-Based Analysis
1744 - Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models
3971 - The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML
4380 - ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes
4416 - Inter-Modality Variance of Blast Quantification in Patients with Myelodysplastic Syndrome (MDS) and Its Impact on Risk Stratification and Overall Survival
Hofmans, M.
Hofmeister, C. C.
98 - Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders
162 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
1884 - Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1
1931 - The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma
2301 - Chronic Opioid Use Is Highly Prevalent and Associated with Inferior Survival in Myeloma Patients in Remission after Autologous Transplant
2667 - Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)
3173 - African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction
3247 - Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance
3250 - Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
4652 - Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
162 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
1884 - Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1
1931 - The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma
2301 - Chronic Opioid Use Is Highly Prevalent and Associated with Inferior Survival in Myeloma Patients in Remission after Autologous Transplant
2667 - Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)
3173 - African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction
3247 - Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance
3250 - Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
4652 - Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
Hofsink, Q.
Hofste Op Bruinink, D.
Hofste op Bruinink, D.
Hofstetter, L.
Hogan, F. L.
Hogan, G. J.
322 - MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design
984 - Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
1519 - Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP
984 - Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
1519 - Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP
Hogan, W. J.
537 - Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
770 - Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
1715 - Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013
2121 - IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort
3056 - Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
770 - Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
1715 - Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013
2121 - IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort
3056 - Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
Hogeling, S. M.
2593 - Functional and Molecular Characterisation of Prospectively Isolated Subclones in Individual AML Patients Reveals Distinct Gene Regulatory Networks Linked to Targetable Metabolic Vulnerabilities
2637 - Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia
3970 - Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2-Mutant Acute Myeloid Leukemia
2637 - Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia
3970 - Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2-Mutant Acute Myeloid Leukemia
Hogg, G.
Hogg, M.
Hogg, S.
Hogg, S. J.
Hoglund, P.
Hoglund, V.
Hohaus, S.
731 - Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study
1580 - Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study
1580 - Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study
Hohmann, H.
Hoiness, J.
Højlund Nielsen, P.
Holanda, A. C. R.
Holbrook, E.
Holden, K. A.
Holderried, M.
Holderried, T. A.
713 - Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens
1480 - Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion
3554 - The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation
1480 - Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion
3554 - The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation
Holinstat, M.
Hollaender, N.
Holland, C.
Holland, H. K.
491 - Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant
2070 - Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus
2120 - Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype
3368 - Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center
3404 - Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide
3444 - HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)
4252 - A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
4763 - TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia
4944 - Transition from Initial Therapy to Hematopoietic Cell Transplantation for Non-Favorable Risk Acute Leukemia and MDS Patients in the Era of Haploidentical Donor Availability: Assessment of Efficacy, Barriers and Racial Disparities in 269 Consecutive Patients Treated in an Integrated Leukemia/HCT Program
2070 - Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus
2120 - Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype
3368 - Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center
3404 - Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide
3444 - HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)
4252 - A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
4763 - TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia
4944 - Transition from Initial Therapy to Hematopoietic Cell Transplantation for Non-Favorable Risk Acute Leukemia and MDS Patients in the Era of Haploidentical Donor Availability: Assessment of Efficacy, Barriers and Racial Disparities in 269 Consecutive Patients Treated in an Integrated Leukemia/HCT Program
Holland, S. M.
Hollander, S.
Holle, L. A.
Hollenhorst, M. A.
Hollenkamp, C. R.
Höller, C.
Holler, E.
Holler, E.
1945 - Harnessing the Expression of TNFR2 on Tregs to Prevent Agvhd
3262 - Immunomodulatory Microbial Metabolites Identified in Allo-SCT Patients Protect from GvHD By Sting Dependent Modulation of Intestinal Tissue Homeostasis
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
4590 - IFN-Gamma Is Crucial for the Counterbalance of T Cell-Mediated Injury to the Intestinal Stem Cell Compartment By Regulatory T Cells in Mice and Humans
3262 - Immunomodulatory Microbial Metabolites Identified in Allo-SCT Patients Protect from GvHD By Sting Dependent Modulation of Intestinal Tissue Homeostasis
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
4590 - IFN-Gamma Is Crucial for the Counterbalance of T Cell-Mediated Injury to the Intestinal Stem Cell Compartment By Regulatory T Cells in Mice and Humans
Holley, R. J.
Hollifield, M.
Hollingsworth, R.
666 - A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-Shelf Cancer Immunotherapy
1983 - Development of Next-Generation NK Cell Optimized Chimeric Antigen Receptors (CARs) for iPSC-Derived NK Cell Therapies Targeting Both Solid and Liquid Tumors
1983 - Development of Next-Generation NK Cell Optimized Chimeric Antigen Receptors (CARs) for iPSC-Derived NK Cell Therapies Targeting Both Solid and Liquid Tumors
Holloway, K.
Holloway Melo, R.
Holmberg, L. A.
Holmes, H.
Holmes, H.
738 - Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
4257 - A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)
4257 - A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)
Holmqvist, A. S.
Holmstrøm, M.
Holopainen, A.
Holot, N.
804 - Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study
3671 - Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β‑Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis
3671 - Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β‑Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis
Holowiecki, J.
2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
Holstein, S. A.
473 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN
565 - Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
3238 - Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
4054 - Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients' Function and Health-Related Quality of Life Change with Treatment?
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
4560 - An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
- Beyond the Cell: Novel Non-Cellular Immunotherapy Approaches to Multiple Myeloma
565 - Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
3238 - Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
4054 - Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients' Function and Health-Related Quality of Life Change with Treatment?
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
4560 - An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
- Beyond the Cell: Novel Non-Cellular Immunotherapy Approaches to Multiple Myeloma
Holt, K. R.
Holt, M.
Holt-Martyn, J.
Holtan, S. G.
114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
3389 - Radiation Sparing Reduced Intensity Conditioning for Allogeneic Cell Transplantation in Patients with Dyskeratosis Congenita Comparable to Standard of Care: A Phase III Single Institution Trial
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
4708 - Chronic Gvhd Following Steroid Sensitive, Dependent, and Refractory Acute Gvhd: Incidence and Clinical Outcomes
4709 - Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
3389 - Radiation Sparing Reduced Intensity Conditioning for Allogeneic Cell Transplantation in Patients with Dyskeratosis Congenita Comparable to Standard of Care: A Phase III Single Institution Trial
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
4708 - Chronic Gvhd Following Steroid Sensitive, Dependent, and Refractory Acute Gvhd: Incidence and Clinical Outcomes
4709 - Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
Holte, H.
448 - Reproduktiv Patterns Among Non-Hodgkin Lymphoma Survivors By Subtype in Sweden, Denmark and Norway
548 - Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
614 - Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial
734 - Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study
2853 - Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma
2864 - Characterization and Clinical Impact of the Tumor Microenvironment of Post-Transplant Large B-Cell Lymphoma
4170 - Exploring New Prognostic Biomarkers in Mantle Cell Lymphoma: The Best RNA Based Risk Score
548 - Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
614 - Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial
734 - Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study
2853 - Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma
2864 - Characterization and Clinical Impact of the Tumor Microenvironment of Post-Transplant Large B-Cell Lymphoma
4170 - Exploring New Prognostic Biomarkers in Mantle Cell Lymphoma: The Best RNA Based Risk Score
Holter, W.
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
2964 - Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL – First Data from the Austrian CAR-T Network
2964 - Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL – First Data from the Austrian CAR-T Network
Holter-Chakrabarty, J.
Holthoff, M. M.
Holtick, U.
998 - Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
2002 - Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
3554 - The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation
4670 - CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
2002 - Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
3554 - The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation
4670 - CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
Holtzman, N. G.
Holzhauer, S. L.
Holzhauer, S.
Holzmann, K.
Homan, C.
Homburg, C.
Honda, H.
Honders, M. W.
Hong, H. Y.
Hong, J.
Hong, J.
Hong, J. Y.
Hong, J.
36 - A Prospective Randomized Study for Optimal Red Blood Cell Use Patients with Acute Myeloid Leukemia Receiving Dose Intensive Chemotherapy
39 - Programmed Death-1 Homolog (PD-1H/VISTA) Blockade Confers a Synergistic Anti-Leukemia Effect with PD-1 Blockade
3647 - Serum Erythropoietin As an Early Marker for Hidden Hematologic Malignancy in Anemia of Unknown Etiology
39 - Programmed Death-1 Homolog (PD-1H/VISTA) Blockade Confers a Synergistic Anti-Leukemia Effect with PD-1 Blockade
3647 - Serum Erythropoietin As an Early Marker for Hidden Hematologic Malignancy in Anemia of Unknown Etiology
Hong, K. T.
Hong, M.
Hong, R.
Hong, S. D.
Hong, S. G.
Hong, S.
Hong, X.
Hong, X.
Hong, Y.
Hong, Y.
Hong, Y.
Hong, Z.
83 - Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
2021 - The Safety and Efficacy of p CAR-19B, a Scfv Humanized CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL
2021 - The Safety and Efficacy of p CAR-19B, a Scfv Humanized CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL
Hongeng, S.
2348 - Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials
3665 - Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia
3665 - Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia
Hongying, Y.
Hood, A. M.
Hood, T.
1463 - Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study
2639 - SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents
2639 - SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents
Hoogenboezem, R.
37 - Oncogene EVI1 Drives Acute Myeloid Leukemia Via a Targetable EVI1-CtBP1/2 Interaction and By Repressing Myeloid Regulator CEBPA
648 - Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification
1818 - Stromal Cell-Activated Bone Marrow Neutrophils Provide BAFF in Newly Diagnosed and Treated Multiple Myeloma
4452 - MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course
648 - Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification
1818 - Stromal Cell-Activated Bone Marrow Neutrophils Provide BAFF in Newly Diagnosed and Treated Multiple Myeloma
4452 - MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course
Hoogenboom, J.
Hoogenboom, J. D.
Hoogendoorn, G. M.
Hoogendoorn, M.
Hoogerbrugge, P. M.
215 - Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders
1409 - ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010
1503 - Mutational Mechanisms in Pediatric Acute Lymphoblastic Leukemia with Multiple Relapses
1513 - The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia
2730 - Variable Immune Response Following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Patients with Hematological Malignancies Under Treatment
1409 - ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010
1503 - Mutational Mechanisms in Pediatric Acute Lymphoblastic Leukemia with Multiple Relapses
1513 - The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia
2730 - Variable Immune Response Following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Patients with Hematological Malignancies Under Treatment
Hoogeveen, P. G.
Hoogewijs, D.
Hoogland, A. I.
Hoogland, A. I.
Hook, C. C.
Hookeri, N.
Hoopmann, M. R.
Hoover, A.
114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
2055 - Phase II Study Optimizing Engraftment in Radiation-Sparing Myeloablative Umbilical Cord Blood Transplant for Hematologic Malignancies in Infants
3530 - The Cost of Cellular Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis
2055 - Phase II Study Optimizing Engraftment in Radiation-Sparing Myeloablative Umbilical Cord Blood Transplant for Hematologic Malignancies in Infants
3530 - The Cost of Cellular Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis
Hope, K.
Hopfner, K. P.
Hopkins, B.
Hopkins, D.
153 - Impact of Double Expression of MYC and BCL-2 on Outcomes in Primary CNS Lymphoma: A UK Multicentre Analysis
732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
4298 - R-DA-EPOCH Treatment Is Highly Effective Therapy for Primary Mediastinal Large B-Cell Lymphoma: A Real-World Multi-Centre Retrospective Evaluation
732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
4298 - R-DA-EPOCH Treatment Is Highly Effective Therapy for Primary Mediastinal Large B-Cell Lymphoma: A Real-World Multi-Centre Retrospective Evaluation
Hoppe, C.
Hoppe, R.
730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
2872 - Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
2872 - Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
Hoppensteadt, D.
Hopper, M. A.
Hoppman, N. L.
Hoppmann, A.
Horacek, J. M.
Horak, I. D.
984 - Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
3338 - Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
3338 - Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
Horan, J. T.
111 - Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial
3407 - Abatacept for the Prevention of Gvhd in Pediatric and Adult Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis
3407 - Abatacept for the Prevention of Gvhd in Pediatric and Adult Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis
Horgan, C.
Horgan, R.
Horibe, K.
54 - Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
1522 - Prognostic Impact of Minimal Disseminated Disease By Digital PCR for Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
4114 - Prognosis of Pediatric Acute Myeloid Leukemia with KMT2A-MLLT3 According to DNA Methylation Patterns: Jccg JPLSG AML-05 Study
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
1522 - Prognostic Impact of Minimal Disseminated Disease By Digital PCR for Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
4114 - Prognosis of Pediatric Acute Myeloid Leukemia with KMT2A-MLLT3 According to DNA Methylation Patterns: Jccg JPLSG AML-05 Study
Horick, N. K.
262 - Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel
3239 - A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
3239 - A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
Horiguchi, H.
324 - Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
4812 - A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
4812 - A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02
Horioka, K.
1120 - Platelet-Derived Microvesicles Promote Selective Cell Viability in Hepatocellular Carcinoma: Differences in Properties between Normal Platelets and Tumor Educated Platelets
2435 - Bioprotective Role of Platelet-Derived Microvesicles in Hypothermia: Insights from the Differential Characteristics of Peripheral and Splenic Platelets
2435 - Bioprotective Role of Platelet-Derived Microvesicles in Hypothermia: Insights from the Differential Characteristics of Peripheral and Splenic Platelets
Hormaechea-Agulla, D.
Horn, B. N.
986 - Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)
Hornburger, H.
Horne, D. A.
Horne, G.
Horneff, R.
Horneman, H.
Horny, H. P.
Horodniceanu, E.
Horowitz, E.
102 - Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1854 - Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
4457 - Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1854 - Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
4457 - Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma
Horowitz, M. M.
4731 - Quality of Life in Patients Undergoing Double Umbilical Cord Blood Vs. Haploidentical Marrow Transplantation: A QOL Analysis Report of BMT CTN 1101
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
Horowitz, N. A.
738 - Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
2907 - Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia
4299 - Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
2907 - Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia
4299 - Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
Horowitz, S. B.
Horrigan, S.
Horst, D.
Horstmann, M. A.
Horton, M.
Horton, S. J.
Horton, T. M.
66 - Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
2785 - Targeting Vimentin (VIM) in Acute Myelogenous Leukemia (AML)
2825 - RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
4138 - High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children’s Oncology Group Trial AALL1231
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
2785 - Targeting Vimentin (VIM) in Acute Myelogenous Leukemia (AML)
2825 - RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
4138 - High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children’s Oncology Group Trial AALL1231
Horvat, A.
Horvath, C. J.
691 - Pre-Clinical Characterization of VGA039, an Anti-Protein S Monoclonal Antibody Being Developed As a Universal Hemostatic Agent for Various Bleeding Disorders
3722 - Characterization of ELA026, a Clinical-Stage Monoclonal Antibody That Rapidly and Potently Depletes Myeloid Cells and T Lymphocytes
3722 - Characterization of ELA026, a Clinical-Stage Monoclonal Antibody That Rapidly and Potently Depletes Myeloid Cells and T Lymphocytes
Horvath, N.
2133 - Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
4460 - Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma
4460 - Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma
Horvath, S.
Horwitz, M. E.
Horwitz, S. M.
613 - Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
1592 - Identifying Primary Refractory Disease and Early Relapses in Peripheral T-Cell Lymphoma Using Baseline Characteristics, Minimal Residual Disease, and Mutational Profiling
1593 - Outcomes for Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma in the 21st Century By Relapse Status, Salvage Therapy, and Receipt of Allogeneic Transplant
1608 - Emapalumab for Malignancy-Associated Hemophagocytic Lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center Experience
2917 - Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified: Characterization of a Large Cohort with Long-Term Outcomes Shows Disparate Outcomes By Body Region Involvement
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
4222 - Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation
4225 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis
4229 - Tub-010, a Novel Antibody-Drug-Conjugate with Reduced Nonspecific Toxicity Profile Based on Tub-Tag Technology Widens the Therapeutic Window for the Treatment of CD30+ Malignancies
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
1592 - Identifying Primary Refractory Disease and Early Relapses in Peripheral T-Cell Lymphoma Using Baseline Characteristics, Minimal Residual Disease, and Mutational Profiling
1593 - Outcomes for Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma in the 21st Century By Relapse Status, Salvage Therapy, and Receipt of Allogeneic Transplant
1608 - Emapalumab for Malignancy-Associated Hemophagocytic Lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center Experience
2917 - Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified: Characterization of a Large Cohort with Long-Term Outcomes Shows Disparate Outcomes By Body Region Involvement
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
4222 - Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation
4225 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis
4229 - Tub-010, a Novel Antibody-Drug-Conjugate with Reduced Nonspecific Toxicity Profile Based on Tub-Tag Technology Widens the Therapeutic Window for the Treatment of CD30+ Malignancies
Hosahalli Vasanna, S.
Hose, D.
Hosing, C.
168 - Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma
489 - High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas
777 - Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial
848 - Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with Overall Survival (OS) and 1-Year Mortality in Patients (pts) with Relapsed or Refractory (r/r) Large B Cell Lymphoma (LBCL) Treated with CD19 Directed Autologous Chimeric Antigen Receptor T (CART) Cell Therapies
875 - First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
960 - Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
2024 - Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)
2128 - HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT
3341 - Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30
3405 - Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
3426 - Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond
489 - High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas
777 - Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial
848 - Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with Overall Survival (OS) and 1-Year Mortality in Patients (pts) with Relapsed or Refractory (r/r) Large B Cell Lymphoma (LBCL) Treated with CD19 Directed Autologous Chimeric Antigen Receptor T (CART) Cell Therapies
875 - First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
960 - Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
2024 - Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)
2128 - HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT
3341 - Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30
3405 - Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
3426 - Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond
Hosking, M.
Hosoi, H.
Hosokawa, K.
Hosokawa, Y.
Hosono, N.
1460 - Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)–Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)
4812 - A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02
4812 - A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02
Hosoya, H.
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
640 - Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4807 - Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study
640 - Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4807 - Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study
Hospital, M. A.
2737 - Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
4413 - Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
4413 - Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351
Hossack, K.
Hossain, F.
Hosseini, M.
Hossian, A. K. M. N.
Hosszu, K.
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
4645 - An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
4645 - An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Hoster, E.
1 - Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
544 - Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial
998 - Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
1528 - Genotyping and Minimal Residual Disease (MRD) Assessment in cfDNA By the Euroclonality-NGS DNA Capture (EC-NDC) Panel in Mantle Cell Lymphoma (MCL)
544 - Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial
998 - Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
1528 - Genotyping and Minimal Residual Disease (MRD) Assessment in cfDNA By the Euroclonality-NGS DNA Capture (EC-NDC) Panel in Mantle Cell Lymphoma (MCL)
Hou, H. A.
853 - Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
1106 - Conditional Knock-out of Phf6 Decreases CD44 Expression on Naïve CD4+ T Cells and Skews the Differentiation Toward Regulatory T Cells in Mice
3082 - Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients
1106 - Conditional Knock-out of Phf6 Decreases CD44 Expression on Naïve CD4+ T Cells and Skews the Differentiation Toward Regulatory T Cells in Mice
3082 - Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients
Hou, H. A.
56 - Prognostic Relevance of Adult Acute Myeloid Leukemia Patients According to the 2022 European Leukemianet Risk Stratification
458 - A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia
629 - Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis
1331 - Strategies for Alleviating Tyrosine Kinase Resistance in Acute Myeloid Leukemia By Modulating p53 Signaling Pathway with Small Molecules
4867 - Healthcare Resource Utilization and Costs Associated with AL Amyloidosis: A Retrospective Matched Cohort Study
458 - A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia
629 - Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis
1331 - Strategies for Alleviating Tyrosine Kinase Resistance in Acute Myeloid Leukemia By Modulating p53 Signaling Pathway with Small Molecules
4867 - Healthcare Resource Utilization and Costs Associated with AL Amyloidosis: A Retrospective Matched Cohort Study
Hou, J.
1414 - Venetoclax in Combination with Homoharringtonine and Cytarabine in the Treatment of Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukaemia: A Single Arm, Multicenter, Prospective, Phase II, Pilot Trial
4573 - Bortezomib-Decp Alternating with Daratumumab-Vpd Plus Stem Cell Transplantation, Followed By Maintenance with VP in Ultra-High Risk (UHiR) Newly Diagnosed Multiple Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): A Multicenter, Prospective Phase 2 Pilot Trial (DRAGON CATCHER TRIAL)
4573 - Bortezomib-Decp Alternating with Daratumumab-Vpd Plus Stem Cell Transplantation, Followed By Maintenance with VP in Ultra-High Risk (UHiR) Newly Diagnosed Multiple Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): A Multicenter, Prospective Phase 2 Pilot Trial (DRAGON CATCHER TRIAL)
Hou, J. Z.
612 - Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL
2736 - Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1st Induction Regimen
4055 - Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A
2736 - Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1st Induction Regimen
4055 - Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A
Hou, K.
Hou, L.
2020 - SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up
4622 - Clinical Efficacy Observation of Humanized BCMA-CAR-T in the Treatment of Relapsed/Refractory Multiple Myeloma Complicated with Extramedullary Lesions
4622 - Clinical Efficacy Observation of Humanized BCMA-CAR-T in the Treatment of Relapsed/Refractory Multiple Myeloma Complicated with Extramedullary Lesions
Hou, M.
Hou, M.
1994 - Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
2443 - Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial
3764 - Rapamycin Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction in Immune Thrombocytopenia
2443 - Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial
3764 - Rapamycin Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction in Immune Thrombocytopenia
Hou, Y.
3762 - Low-Dose Rhein Sensitizes Platelet Production to Thrombopoietin Receptor Agonists (TPO-RA) in Immune Thrombocytopenia
3764 - Rapamycin Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction in Immune Thrombocytopenia
3767 - Eltrombopag Plus Diacerein Versus Eltrombopag in Adult Primary Immune Thrombocytopenia: Interim Analysis of a Multicenter, Randomized, Controlled, Phase 2 Trial
3764 - Rapamycin Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction in Immune Thrombocytopenia
3767 - Eltrombopag Plus Diacerein Versus Eltrombopag in Adult Primary Immune Thrombocytopenia: Interim Analysis of a Multicenter, Randomized, Controlled, Phase 2 Trial
Hough, R.
214 - High Dose Methotrexate Does Not Reduce the Risk of CNS Relapse in Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma. Results of the Randomised Phase III Study UKALL 2011
997 - Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure
1418 - Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia
4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL
4663 - CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
997 - Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure
1418 - Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia
4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL
4663 - CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Hough, S.
Houghton, D. E.
1185 - Validation of Natural Language Processing for the Identification of Venous Thromboembolism in Radiologic Reports
2491 - Accuracy and Prediction of D-Dimers for Pulmonary Embolism in Patients with COVID-19 Infection
3817 - Development of a Machine Learning Model Using Electrocardiogram Signals to Determine Acute Pulmonary Embolism
3833 - Clinical Characteristics of Cohort of 113 Patients with Cancer-Associated Non Bacterial Thrombotic Endocarditis
3834 - No Difference in Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations
2491 - Accuracy and Prediction of D-Dimers for Pulmonary Embolism in Patients with COVID-19 Infection
3817 - Development of a Machine Learning Model Using Electrocardiogram Signals to Determine Acute Pulmonary Embolism
3833 - Clinical Characteristics of Cohort of 113 Patients with Cancer-Associated Non Bacterial Thrombotic Endocarditis
3834 - No Difference in Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations
Houillier, C.
Houk, A.
Hounkpe, B. W.
Houot, R.
767 - Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
2035 - French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
3356 - Efficacy of CAR-T Cells in Primary Central Nervous System Lymphomas: The French Experience of the National LOC Network
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
2035 - French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
3356 - Efficacy of CAR-T Cells in Primary Central Nervous System Lymphomas: The French Experience of the National LOC Network
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Houot, R.
166 - Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study
553 - Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry
1652 - Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry
2026 - CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry
553 - Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry
1652 - Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry
2026 - CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry
Hourcade-Potelleret, F.
Hourigan, C. S.
597 - Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification
4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
- Achieving MRD Negativity in AML: How Important Is This and How Do We Get There?
4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
- Achieving MRD Negativity in AML: How Important Is This and How Do We Get There?
Hourigan, C. S.
714 - Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)
1470 - Pre- and Post-Transplant Measurable Residual IDH Mutations Are Not Associated with Relapse in Patients with IDH-Mutated AML
1487 - Spatial-Temporal Multiomic Analysis of Tumor-Immune Interactions in Patients with AML Receiving Pembrolizumab and Decitabine
2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
1470 - Pre- and Post-Transplant Measurable Residual IDH Mutations Are Not Associated with Relapse in Patients with IDH-Mutated AML
1487 - Spatial-Temporal Multiomic Analysis of Tumor-Immune Interactions in Patients with AML Receiving Pembrolizumab and Decitabine
2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
Houshyar, S.
Houston, B. L.
Houston, D. S.
Houston, R.
330 - Jak2V617F Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms (MPNs)
2992 - The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)
2992 - The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)
Houtsmuller, A. B.
Houvras, Y.
4555 - Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
4896 - Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)
4896 - Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)
Houx, L.
Houy, A.
Hovanky, V.
640 - Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
Hovestadt, V.
Hovig, E.
Hoving, V.
Hovorkova, L.
How, J.
452 - Mutant Srsf2 Diminishes Jak2V617F-Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2-Mutant MPN
3030 - Trends in All-Cause and Cardiovascular Mortality Among Patients with Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis
3047 - Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections
3030 - Trends in All-Cause and Cardiovascular Mortality Among Patients with Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis
3047 - Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections
Howard, C.
Howard, C.
Howard, M.
Howard, T. E.
1188 - The Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) 353 R>q in the Coagulation Factor VII (FVII) Gene, F7, is Associated with Decreased Plasma FVII Levels and a Decreased Risk of Coronary Heart Disease (CHD) in Mexican Americans of South Texas
3829 - A Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) in TFPI, the Gene Encoding Tissue Factor Pathway Inhibitor (TFPI), is Pleiotropically Associated with Increased Plasma TFPI Levels and a Decreased Risk of Type 2 Diabetes (T2D) in Mexican Americans of South Texas
3829 - A Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) in TFPI, the Gene Encoding Tissue Factor Pathway Inhibitor (TFPI), is Pleiotropically Associated with Increased Plasma TFPI Levels and a Decreased Risk of Type 2 Diabetes (T2D) in Mexican Americans of South Texas
Howell, H.
Hoye, K.
Hoyt, S. B.
Hrachovinova, I.
Hradilova, I.
Hrustincova, A.
Hshieh, T. T.
Hsi, E. D.
1520 - Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
1539 - Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
2838 - Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site
1539 - Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
2838 - Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site
Hsia, C. C.
Hsieh, C. L.
Hsieh, E. M.
Hsieh, M. M.
Hsing, A. W.
Hsu, A.
Hsu, C. J.
Hsu, C. A.
Hsu, C. L.
Hsu, C. C.
Hsu, J.
3375 - Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial
3396 - Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation
3396 - Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation
Hsu, J. I.
825 - Genome-Wide CRISPR Screen Reveals Dependency of PPM1D-mutant Cells on DNA Repair
927 - Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis
3857 - Clonal Competition: Cisplatin Treatment Drives Dominance of TP53- over Tet2-Mutant Stem Cell Clones
927 - Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis
3857 - Clonal Competition: Cisplatin Treatment Drives Dominance of TP53- over Tet2-Mutant Stem Cell Clones
Hsu, K. C.
Hsu, K.
Hsu, L. L.
Hsu, L. Y.
Hsu, T. C.
Hsu, Y. C.
Htut, M.
364 - Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
2019 - Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
2019 - Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Htut, T. W.
3569 - Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy
4891 - Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy
4891 - Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy
Hu, B.
234 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
617 - Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
617 - Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
Hu, B.
Hu, B.
447 - Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy
450 - T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments
2967 - Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
450 - T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments
2967 - Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
Hu, B.
26 - Characterization of Bleeding and Laboratory Phenotype of Carriers of Hemophilia and Trends of Utilization of Factor Concentrates and Hemostatic Therapies: Analysis of the National Athndataset
1152 - Risk of Intracranial Hemorrhage in US Patients with Hemophilia a: Real-World Retrospective Cohort Study Using the Athndataset
1152 - Risk of Intracranial Hemorrhage in US Patients with Hemophilia a: Real-World Retrospective Cohort Study Using the Athndataset
Hu, C.
Hu, C.
558 - Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker
4293 - Efficacy and Safety of Zanubrutinib Combined with R-CHOP Regimen in the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma with Extranodal Involvement: A Single-Arm, Prospective Phase II Trial
4293 - Efficacy and Safety of Zanubrutinib Combined with R-CHOP Regimen in the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma with Extranodal Involvement: A Single-Arm, Prospective Phase II Trial
Hu, D.
Hu, H.
Hu, J.
2758 - A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2767 - A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2893 - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies
2767 - A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2893 - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies
Hu, J.
Hu, J.
335 - Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study
1361 -
1694 - Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
1968 - Valproic Acid Increased CAR T Cell Cytotoxicity Against Acute Myeloid Leukemia
2443 - Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial
2894 - Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis
3357 - Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
4121 - Minimal Residual Disease after the 2nd Induction Course Predicted Outcomes in Chinese Children with Acute Myeloid Leukaemia Treated According to the C-Huanan-AML 15 Protocol
4328 - Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia
4335 - A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy
1361 -
Ferroptosis Patterns Predicting Prognosis and Drug Resistance in Acute Lymphoblastic Leukemia
1694 - Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
1968 - Valproic Acid Increased CAR T Cell Cytotoxicity Against Acute Myeloid Leukemia
2443 - Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial
2894 - Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis
3357 - Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
4121 - Minimal Residual Disease after the 2nd Induction Course Predicted Outcomes in Chinese Children with Acute Myeloid Leukaemia Treated According to the C-Huanan-AML 15 Protocol
4328 - Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia
4335 - A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy
Hu, J.
531 - Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
3984 - Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Dasatinib and Ponatinib in Lck-Activated T-Cell Acute Lymphoblastic Leukemia
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
3984 - Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Dasatinib and Ponatinib in Lck-Activated T-Cell Acute Lymphoblastic Leukemia
Hu, J.
Hu, J.
1767 - Incorporation of Mutations and Bone Marrow Fibrosis into the Revised International Prognostic Scoring System in Patients with Myelodysplastic Syndromes
2059 - Metagenomic Next-Generation Sequencing for Pathogens in Bronchoalveolar Lavage Fluid Improve the Survival of Patients with Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation
2113 - A Phase IV, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) As a Myeloablative Conditioning Regimen in Chinese Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
2635 - Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia through Ubiquitination and Degradation of PML-RARα
3394 - Phase I Study of SHR0302, a Selective JAK1 Inhibitor, Combined with Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease after Allo-HSCT
4694 - Fludarabine, Busulfan and Melphalan Based Conditioning Reduced Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myeloid Malignancies: A Multicenter Retrospective Analysis
4697 - Low-Dose Antithymocyte Globulin Plus Low-Dose Post-Transplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after Haploidentical Peripheral Blood Stem Cell Transplants: A Large Sample, Long-Term Follow-up Retrospective Study
2059 - Metagenomic Next-Generation Sequencing for Pathogens in Bronchoalveolar Lavage Fluid Improve the Survival of Patients with Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation
2113 - A Phase IV, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) As a Myeloablative Conditioning Regimen in Chinese Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
2635 - Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia through Ubiquitination and Degradation of PML-RARα
3394 - Phase I Study of SHR0302, a Selective JAK1 Inhibitor, Combined with Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease after Allo-HSCT
4694 - Fludarabine, Busulfan and Melphalan Based Conditioning Reduced Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myeloid Malignancies: A Multicenter Retrospective Analysis
4697 - Low-Dose Antithymocyte Globulin Plus Low-Dose Post-Transplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after Haploidentical Peripheral Blood Stem Cell Transplants: A Large Sample, Long-Term Follow-up Retrospective Study
Hu, K.
1657 - Effects of BMI, Albumin and NRS 2002 Changes on Prognosis in Patients with Hematological Malignancies during CAR T Treatment
3311 - Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma
3359 - Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities
4266 - Daratumumab-Primed Venetoclax Combined with Cage for Refractory/Relapsed T-Lymphoblastic Leukemia/Lymphoma Patients: Single-Arm, Open-Label, Phase I Study
4661 - Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy
4675 - Interpreting Immune Reconstitution and Clinical Outcome By Single-Cell Transcriptomic Analysis in T-ALL Patients Undergoing Donor-Derived CD7 CAR-T Immunotherapy
3311 - Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma
3359 - Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities
4266 - Daratumumab-Primed Venetoclax Combined with Cage for Refractory/Relapsed T-Lymphoblastic Leukemia/Lymphoma Patients: Single-Arm, Open-Label, Phase I Study
4661 - Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy
4675 - Interpreting Immune Reconstitution and Clinical Outcome By Single-Cell Transcriptomic Analysis in T-ALL Patients Undergoing Donor-Derived CD7 CAR-T Immunotherapy
Hu, K. N.
Hu, S.
2733 - Pediatric Acute Lymphoblastic Leukemia with Pdgfrb Fusions: A Multicenter Retrospective Study
3398 - Association between Haploidentical Hematopoietic Stem Cell Transplantation Combined with an Umbilical Cord Blood Unit and Graft-Versus-Host Disease in Pediatric Patients with Acquired Severe Aplastic Anemia
3933 - Anagrelide Represents a Potential Therapeutic Therapy for Acute Myeloid Leukemia Cells Based on Phosphodiesterase 3A Expression
4691 - Improved Grfs Observed in a Multicenter Prospective Study of Tcrαβ- and CD45RA-Depleted Haploidentical Transplant in Children with Acute Leukemia
4723 - The Association of pDC Dose in Graft with CMV and EBV Infection after Allo-HSCT in Pediatric Patients: A Single-Center Experience
3398 - Association between Haploidentical Hematopoietic Stem Cell Transplantation Combined with an Umbilical Cord Blood Unit and Graft-Versus-Host Disease in Pediatric Patients with Acquired Severe Aplastic Anemia
3933 - Anagrelide Represents a Potential Therapeutic Therapy for Acute Myeloid Leukemia Cells Based on Phosphodiesterase 3A Expression
4691 - Improved Grfs Observed in a Multicenter Prospective Study of Tcrαβ- and CD45RA-Depleted Haploidentical Transplant in Children with Acute Leukemia
4723 - The Association of pDC Dose in Graft with CMV and EBV Infection after Allo-HSCT in Pediatric Patients: A Single-Center Experience
Hu, S.
1721 - Clinical Features and Outcomes of Pre-Fibrotic Primary Myelofibrosis Patients with Triple-Negative, JAK2V617F and Calr Mutations
4333 - Targeted Next-Generation Sequencing Identifies Additional Mutations Other Than BCR-ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study
4333 - Targeted Next-Generation Sequencing Identifies Additional Mutations Other Than BCR-ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study
Hu, S.
Hu, S.
Hu, T.
Hu, W.
Hu, X.
485 - Engineered Hypoimmune CAR T Cells Provide Lasting Tumor Control in Fully Immunocompetent Allogeneic Humanized Mice
1988 - A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape
3168 - BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models
1988 - A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape
3168 - BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models
Hu, X.
Hu, X.
2020 - SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up
4622 - Clinical Efficacy Observation of Humanized BCMA-CAR-T in the Treatment of Relapsed/Refractory Multiple Myeloma Complicated with Extramedullary Lesions
4622 - Clinical Efficacy Observation of Humanized BCMA-CAR-T in the Treatment of Relapsed/Refractory Multiple Myeloma Complicated with Extramedullary Lesions
Hu, X.
Hu, Y.
Hu, Y.
Hu, Y.
2826 - Genomic and Transcriptomic Profiling Reveal the Mechanism and Risk Factors of CD19-Negative Relapse after CAR-T Cell Therapy
3336 - High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study
3417 - Muticenter Retrospective Comparable Study of Prophylactic Versus Preemptive Modified Donor Lymphocyte Infusion for Patients with High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
4642 - Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial
3336 - High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study
3417 - Muticenter Retrospective Comparable Study of Prophylactic Versus Preemptive Modified Donor Lymphocyte Infusion for Patients with High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
4642 - Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial
Hu, Y.
257 - Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies
1133 - Different Biomarkers and a Novel Scoring Model for the Prediction of ITP Patients Treated with Corticosteroid Versus TPO-Ras
2443 - Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial
3758 - Bile Acid Reduces Thrombosis Risk By Inhibiting Noncatalytic Region of Tyrosine Kinase in Platelets
4636 - Single-Cell Profiling Reveals Contribution of IFITM1 Expression to Severe CRS in CAR-T-Treated B-ALL
1133 - Different Biomarkers and a Novel Scoring Model for the Prediction of ITP Patients Treated with Corticosteroid Versus TPO-Ras
2443 - Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial
3758 - Bile Acid Reduces Thrombosis Risk By Inhibiting Noncatalytic Region of Tyrosine Kinase in Platelets
4636 - Single-Cell Profiling Reveals Contribution of IFITM1 Expression to Severe CRS in CAR-T-Treated B-ALL
Hu, Y.
1998 - Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
2007 - Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies
3286 - Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy
4626 - BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System
2007 - Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies
3286 - Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy
4626 - BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System
Hu, Z. H.
765 - Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
2022 - Real-World Bridging Therapy (BT) of Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Systematic Literature Review (SLR) and Meta-Analysis
3345 - Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
4284 - Minority Patients in the US Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy: A SEER-Based Simulation on Representation and Impact of Proximity to Authorized Treatment Center (ATC)
2022 - Real-World Bridging Therapy (BT) of Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Systematic Literature Review (SLR) and Meta-Analysis
3345 - Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
4284 - Minority Patients in the US Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy: A SEER-Based Simulation on Representation and Impact of Proximity to Authorized Treatment Center (ATC)
Hu, Z.
Hu, Z.
Hua, L.
Hua, V. M.
Hua, W. K.
Huanfeng, L.
Huang, A.
Huang, A. Y.
Huang, A. C.
Huang, A.
Huang, B. J.
357 - Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-β2 As an Immunotherapeutic Target
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
1467 - Transcriptome Analysis and Machine Learning Prioritize Therapeutic Strategies for High-Risk Pediatric AML Patients of the KMT2A-Fusion Subgroup
1471 - Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia
2659 - Opposing Effects of KDM6A and JDP2 on Glucocorticoid Sensitivity in T-ALL
4133 - A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
1467 - Transcriptome Analysis and Machine Learning Prioritize Therapeutic Strategies for High-Risk Pediatric AML Patients of the KMT2A-Fusion Subgroup
1471 - Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia
2659 - Opposing Effects of KDM6A and JDP2 on Glucocorticoid Sensitivity in T-ALL
4133 - A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
Huang, C. C.
69 - High-Plex Imaging and Cellular Neighborhood Spatial Analysis Reveals Multiple Immune Escape and Suppression Patterns in DLBCL
724 - Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
4156 - Molecular Landscape of Primary Refractory DLBCL
724 - Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
4156 - Molecular Landscape of Primary Refractory DLBCL
Huang, C.
Huang, C.
1621 - Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial
4227 - DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study
4227 - DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study
Huang, C.
Huang, C. Y.
250 - Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy
1866 - Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease
2236 - Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma
2286 - Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy
3529 - Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation
1866 - Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease
2236 - Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma
2286 - Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy
3529 - Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation
Huang, C.
3394 - Phase I Study of SHR0302, a Selective JAK1 Inhibitor, Combined with Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease after Allo-HSCT
4697 - Low-Dose Antithymocyte Globulin Plus Low-Dose Post-Transplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after Haploidentical Peripheral Blood Stem Cell Transplants: A Large Sample, Long-Term Follow-up Retrospective Study
4697 - Low-Dose Antithymocyte Globulin Plus Low-Dose Post-Transplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after Haploidentical Peripheral Blood Stem Cell Transplants: A Large Sample, Long-Term Follow-up Retrospective Study
Huang, C. E.
Huang, F.
1713 - MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis
3037 - MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
3037 - MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
Huang, G.
Huang, H.
Huang, H.
Huang, H.
253 - MEK Inhibition in CAR-T Cells Prevents Exhaustion and Terminal Differentiation Via Downregulating C-Fos and JunB
1327 - C/EBPα-p30 Confers AML Cell Susceptibility to the Terminal Unfolded Protein Response and Resistance to Venetoclax By Activating DDIT3 Transcription
2102 - MRD Monitoring of Non-DTA Genes By Digital Droplet PCR in the Early Period after Allogeneic Hematopoietic Stem Cell Transplantation Can Effectively Predict Patients at High Risk of Relapse
2826 - Genomic and Transcriptomic Profiling Reveal the Mechanism and Risk Factors of CD19-Negative Relapse after CAR-T Cell Therapy
2989 - A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data
3202 - Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma
3223 - High Serum IL-17A Is Associated with Bone Destruction in Newly Diagnosed Multiple Myeloma Patients
3311 - Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma
3336 - High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study
3380 - Double Filtration Plasmapheresis for Desensitization during Haploidentical Stem Cell Transplantation in Patients with Positive Donor-Specific Anti-HLA Antibodies
3417 - Muticenter Retrospective Comparable Study of Prophylactic Versus Preemptive Modified Donor Lymphocyte Infusion for Patients with High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
4642 - Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial
4713 - JAK/Rock Inhibitor TQ05105 for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Preliminary Analysis Results of a Phase 1b/2 Study
4757 - Comparable Outcomes Following Non-First-Degree and First-Degree Related Donor Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia Patients in Complete Remission: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
1327 - C/EBPα-p30 Confers AML Cell Susceptibility to the Terminal Unfolded Protein Response and Resistance to Venetoclax By Activating DDIT3 Transcription
2102 - MRD Monitoring of Non-DTA Genes By Digital Droplet PCR in the Early Period after Allogeneic Hematopoietic Stem Cell Transplantation Can Effectively Predict Patients at High Risk of Relapse
2826 - Genomic and Transcriptomic Profiling Reveal the Mechanism and Risk Factors of CD19-Negative Relapse after CAR-T Cell Therapy
2989 - A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data
3202 - Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma
3223 - High Serum IL-17A Is Associated with Bone Destruction in Newly Diagnosed Multiple Myeloma Patients
3311 - Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma
3336 - High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study
3380 - Double Filtration Plasmapheresis for Desensitization during Haploidentical Stem Cell Transplantation in Patients with Positive Donor-Specific Anti-HLA Antibodies
3417 - Muticenter Retrospective Comparable Study of Prophylactic Versus Preemptive Modified Donor Lymphocyte Infusion for Patients with High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
4642 - Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial
4713 - JAK/Rock Inhibitor TQ05105 for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Preliminary Analysis Results of a Phase 1b/2 Study
4757 - Comparable Outcomes Following Non-First-Degree and First-Degree Related Donor Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia Patients in Complete Remission: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Huang, H.
Huang, H.
Huang, H.
Huang, H.
Huang, H. T.
Huang, H.
610 - Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
Huang, H.
Huang, H.
Huang, H.
Huang, H.
955 - Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study
1621 - Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial
2916 - XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study
2941 - A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma
4213 - Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) – Preliminary Results of Phase II CHESS Clinical Trial
4227 - DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study
1621 - Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial
2916 - XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study
2941 - A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma
4213 - Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) – Preliminary Results of Phase II CHESS Clinical Trial
4227 - DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study
Huang, H.
1627 - Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1632 - Combination of Mitoxantrone Hydrochloride Liposome with Cyclophosphamide, Vincristine and Prednisone (CMOP) in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial
4206 - Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
1632 - Combination of Mitoxantrone Hydrochloride Liposome with Cyclophosphamide, Vincristine and Prednisone (CMOP) in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial
4206 - Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
Huang, I. J.
Huang, J.
1721 - Clinical Features and Outcomes of Pre-Fibrotic Primary Myelofibrosis Patients with Triple-Negative, JAK2V617F and Calr Mutations
3770 - Efficiency and Safety of Avatrombopag in the Management of Thrombocytopenia with TPO or Tpora Ineffective：a Prospective, Single Arm, Exploratory Clinical Study
4333 - Targeted Next-Generation Sequencing Identifies Additional Mutations Other Than BCR-ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study
3770 - Efficiency and Safety of Avatrombopag in the Management of Thrombocytopenia with TPO or Tpora Ineffective：a Prospective, Single Arm, Exploratory Clinical Study
4333 - Targeted Next-Generation Sequencing Identifies Additional Mutations Other Than BCR-ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study
Huang, J.
335 - Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study
1694 - Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
4328 - Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia
4335 - A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy
1694 - Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
4328 - Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia
4335 - A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy
Huang, J.
Huang, J.
Huang, J.
Huang, J.
Huang, J.
Huang, J.
Huang, J.
Huang, J.
Huang, K. C.
Huang, Sr., K.
Huang, K.
Huang, L.
Huang, L.
Huang, L.
1568 - A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe
1990 - Allogeneic CAR-T Therapy Enabled By Base Editing of Lck to Resist Dasatinib Used to Prevent Rejection Mediated through Both T and NK in Host
2012 - Be Cautious to Adopt a Second CAR T-Cell Infusion after Failure of CD19/CD22 Cocktail CAR T-Cell Therapy in Relapsed/Refractory B-NHL
2021 - The Safety and Efficacy of p CAR-19B, a Scfv Humanized CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL
3298 - A Novel Platform to Manufacture High-Efficient “Off-the-Shelf” CAR-NK Products from Peripheral Blood Mononuclear Cells (PBMC)
3758 - Bile Acid Reduces Thrombosis Risk By Inhibiting Noncatalytic Region of Tyrosine Kinase in Platelets
4243 - Outcomes of PD-1 Inhibitors Treatment of Chronic Active Epstein Barr Virus Infection : A Single Center Retrospective Analysis
4386 - High Expression of Plasma IL-1β Levels and Transition of Regulatory T-Cell Subsets Correlate with Disease Progression in Myelodysplastic Syndrome
4611 - MIP3α As an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR T-Cell Cocktail Therapy
4632 - Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse/Refractory Aggressive B-Cell Lymphoma
1990 - Allogeneic CAR-T Therapy Enabled By Base Editing of Lck to Resist Dasatinib Used to Prevent Rejection Mediated through Both T and NK in Host
2012 - Be Cautious to Adopt a Second CAR T-Cell Infusion after Failure of CD19/CD22 Cocktail CAR T-Cell Therapy in Relapsed/Refractory B-NHL
2021 - The Safety and Efficacy of p CAR-19B, a Scfv Humanized CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL
3298 - A Novel Platform to Manufacture High-Efficient “Off-the-Shelf” CAR-NK Products from Peripheral Blood Mononuclear Cells (PBMC)
3758 - Bile Acid Reduces Thrombosis Risk By Inhibiting Noncatalytic Region of Tyrosine Kinase in Platelets
4243 - Outcomes of PD-1 Inhibitors Treatment of Chronic Active Epstein Barr Virus Infection : A Single Center Retrospective Analysis
4386 - High Expression of Plasma IL-1β Levels and Transition of Regulatory T-Cell Subsets Correlate with Disease Progression in Myelodysplastic Syndrome
4611 - MIP3α As an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR T-Cell Cocktail Therapy
4632 - Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse/Refractory Aggressive B-Cell Lymphoma
Huang, L. L.
Huang, L.
Huang, L.
Huang, M.
337 - Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib
1733 - Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib
4348 - Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
1733 - Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib
4348 - Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
Huang, P.
799 - Let-7 Inhibits HIC2 to Control BCL11A Transcription and Hemoglobin Switching
802 - Examining the Role of Individual Baf Chromatin Remodeling Complex Components in Globin Gene Regulation
1041 - Regulation of Fetal Hemoglobin Production in Adult Erythroid Cells By Protein Phosphatase 6C (PPP6C)
2361 - Mechanisms of Polycomb Group Protein-Mediated Fetal Hemoglobin Silencing
802 - Examining the Role of Individual Baf Chromatin Remodeling Complex Components in Globin Gene Regulation
1041 - Regulation of Fetal Hemoglobin Production in Adult Erythroid Cells By Protein Phosphatase 6C (PPP6C)
2361 - Mechanisms of Polycomb Group Protein-Mediated Fetal Hemoglobin Silencing
Huang, P.
Huang, P.
1098 - A2 Astrocytes Counteract the Blood-Brain Barrier Dysfunction Via α7nAChR/JAK2/STAT3 Signaling in HIV-Associated Neurocognitive Disorders
2409 - Microglia Regulating Neuronal Apoptosis Via Alpha7 Nicotinic Acetylcholine Receptor in HIV-Associated Neurocognitive Disorders
2412 - The Roles of CD44 Membrane Ruffling and Signaling in Leukocyte Transmigration across Cryptococcus Neoformans-Coinfected Blood-Brain Barrier with HIV-1 gp41 in Vitro
2409 - Microglia Regulating Neuronal Apoptosis Via Alpha7 Nicotinic Acetylcholine Receptor in HIV-Associated Neurocognitive Disorders
2412 - The Roles of CD44 Membrane Ruffling and Signaling in Leukocyte Transmigration across Cryptococcus Neoformans-Coinfected Blood-Brain Barrier with HIV-1 gp41 in Vitro
Huang, Q.
Huang, Q.
Huang, R.
3317 - Off-the-Shelf CD33 CAR-NK Cell Therapy for Relapse/Refractory AML: First-in-Human, Phase I Trial
3406 - Phase II Multicenter, Randomized Controlled Study on Infusion of MSCs at 45 Days after Haplo-Hematopoietic Stem Cell Transplantation in the Prophylaxis of Gvhd
3475 - Amplifying Sting Activation By Bio-Inspired Nanomedicine for Targeted Acute Myeloid Leukemia Chemo- and Immunotherapy
3406 - Phase II Multicenter, Randomized Controlled Study on Infusion of MSCs at 45 Days after Haplo-Hematopoietic Stem Cell Transplantation in the Prophylaxis of Gvhd
3475 - Amplifying Sting Activation By Bio-Inspired Nanomedicine for Targeted Acute Myeloid Leukemia Chemo- and Immunotherapy
Huang, R.
Huang, R.
Huang, S.
Huang, S.
Huang, S.
Huang, S.
Huang, S.
Huang, S.
Huang, T.
Huang, T.
Huang, T.
Huang, W. H.
Huang, W.
Huang, W.
1568 - A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe
1613 - Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas
4565 - Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
1613 - Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas
4565 - Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
Huang, W.
1559 - Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study
1901 - A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma
2009 - CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study
2898 - R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma
3327 - Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial
4749 - A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma
1901 - A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma
2009 - CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study
2898 - R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma
3327 - Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial
4749 - A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma
Huang, X.
Huang, X.
Huang, X. J.
335 - Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study
780 - Development and Validation of a Prognostic Model Based on Clinical Biomarkers for Heart Failure in Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
1393 - Prognostic Impact of WT1 Mutation on AML of Different Risk Groups Based on 2022 European Leukemianet (ELN) Risk Classification
1431 - Interferon-α-2b As a Maintenance Therapy Gain a High Rate of MRD Negative Conversion and Improve RFS in Patients with Favorable-Risk Acute Myeloid Leukemia---- a Prospective, Single-Arm Study
1443 - Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
1694 - Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
1951 - Distinct Immune Homeostasis Remodeling Patterns after HLA-Matched and Haploidentical Transplantation
2051 - Thrombopoietin Levels Predict the Response to Avatrombopag Treatment in Patients with Persistent Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplantation
2081 - Efficacy and Safety of MSCs Plus Basiliximab for the Treatment of Steroid-Resistant aGVHD after Haploidentical Stem Cell Transplantation: A Multicenter, Randomized, Open-Label Trial
2107 - Mutations of TP53 Gene in Acute Lymphoblastic Leukemia Do Not Affect the Survival Outcomes after Haploidentical Stem Cell Transplantation
2178 - The Role of Metagenomics Next-Generation Sequencing (mNGS) in Early Diagnosis of Bloodstream Infection in Hematologic Patients with Febrile Neutropenia: A Multicenter Prospective Study
2454 - Real-World Study of the Use of Iguratimod to Treat Chronic/Refractory ITP
3270 - Exploring the Effects of G-CSF Mobilization on the Immune Function of Mucosal-Associated Invariant T Cell Subsets By Single-Cell RNA-Seq
3423 - The FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in AML Patients with FLT3-ITD after Allo-HSCT: A Retrospective Propensity-Score Matching Study
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4090 - Phase I Study of TQB3455, a Selective Inhibitor of IDH2 with Favorable Safety and More Potent Efficacy to IDH2-R172K Mutation, for Acute Myeloid Leukemia and Myelodysplastic Syndrome
4325 - Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
4328 - Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia
4335 - A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy
4772 - A Prospective Study of Short-Term Chemotherapy Bridging Allogeneic-SCT in High Risk Peripheral T-Cell Lymphoma
780 - Development and Validation of a Prognostic Model Based on Clinical Biomarkers for Heart Failure in Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
1393 - Prognostic Impact of WT1 Mutation on AML of Different Risk Groups Based on 2022 European Leukemianet (ELN) Risk Classification
1431 - Interferon-α-2b As a Maintenance Therapy Gain a High Rate of MRD Negative Conversion and Improve RFS in Patients with Favorable-Risk Acute Myeloid Leukemia---- a Prospective, Single-Arm Study
1443 - Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
1694 - Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
1951 - Distinct Immune Homeostasis Remodeling Patterns after HLA-Matched and Haploidentical Transplantation
2051 - Thrombopoietin Levels Predict the Response to Avatrombopag Treatment in Patients with Persistent Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplantation
2081 - Efficacy and Safety of MSCs Plus Basiliximab for the Treatment of Steroid-Resistant aGVHD after Haploidentical Stem Cell Transplantation: A Multicenter, Randomized, Open-Label Trial
2107 - Mutations of TP53 Gene in Acute Lymphoblastic Leukemia Do Not Affect the Survival Outcomes after Haploidentical Stem Cell Transplantation
2178 - The Role of Metagenomics Next-Generation Sequencing (mNGS) in Early Diagnosis of Bloodstream Infection in Hematologic Patients with Febrile Neutropenia: A Multicenter Prospective Study
2454 - Real-World Study of the Use of Iguratimod to Treat Chronic/Refractory ITP
3270 - Exploring the Effects of G-CSF Mobilization on the Immune Function of Mucosal-Associated Invariant T Cell Subsets By Single-Cell RNA-Seq
3423 - The FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in AML Patients with FLT3-ITD after Allo-HSCT: A Retrospective Propensity-Score Matching Study
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4090 - Phase I Study of TQB3455, a Selective Inhibitor of IDH2 with Favorable Safety and More Potent Efficacy to IDH2-R172K Mutation, for Acute Myeloid Leukemia and Myelodysplastic Syndrome
4325 - Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
4328 - Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia
4335 - A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy
4772 - A Prospective Study of Short-Term Chemotherapy Bridging Allogeneic-SCT in High Risk Peripheral T-Cell Lymphoma
Huang, X. Z.
Huang, X. J.
957 - Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3424 - Machine Learning Algorithm As a Prognostic Tool for Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation
3424 - Machine Learning Algorithm As a Prognostic Tool for Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation
Huang, X. J.
81 - A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China
83 - Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
1394 - A Novel Risk Stratification Model for Cytogenetically Normal Acute Myeloid Leukemia with FLT3-ITD Mutation
2064 - Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr
83 - Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
1394 - A Novel Risk Stratification Model for Cytogenetically Normal Acute Myeloid Leukemia with FLT3-ITD Mutation
2064 - Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr
Huang, X.
Huang, X.
942 - Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed
1099 - Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Prospective, Single-Center, Single-Arm, Phase 2 Clinical Trial
1414 - Venetoclax in Combination with Homoharringtonine and Cytarabine in the Treatment of Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukaemia: A Single Arm, Multicenter, Prospective, Phase II, Pilot Trial
1450 - Venetoclax Plus “2 + 5” Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis
1099 - Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Prospective, Single-Center, Single-Arm, Phase 2 Clinical Trial
1414 - Venetoclax in Combination with Homoharringtonine and Cytarabine in the Treatment of Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukaemia: A Single Arm, Multicenter, Prospective, Phase II, Pilot Trial
1450 - Venetoclax Plus “2 + 5” Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis
Huang, X.
213 - Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
4043 - The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
4043 - The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
Huang, Y.
Huang, Y.
Huang, Y.
Huang, Y. J.
Huang, Y.
Huang, Y.
834 - A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
1771 - Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL
1812 - Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
3118 - FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
1771 - Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL
1812 - Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
3118 - FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
Huang, Y.
Huang, Y. S. V.
Huang, Y.
Huang, Y.
Huang, Y.
Huang, Y.
Huang, Y. H.
Huang, Y.
Huang, Y.
Huang, Y.
Huang, Y.
Huang, Z.
Huang, Z.
Huang, Z.
257 - Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies
1998 - Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
3286 - Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy
1998 - Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
3286 - Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy
Huang, Z.
1509 - Prognostic Significance of Epigenetic Modifiers Gene Mutations in Adult Acute Lymphoblastic Leukemia at Diagnosis
2830 - Metabolic Feature Profiling and Metabolic Vulnerability Targeting in B-Cell Lymphoblastic Leukemia
4149 - Dynamics of Minimal Residual Disease Defines a Novel Risk-Classification and the Role of Allo-HSCT in Adult Ph-Negative B Cell Acute Lymphoblastic Leukemia
2830 - Metabolic Feature Profiling and Metabolic Vulnerability Targeting in B-Cell Lymphoblastic Leukemia
4149 - Dynamics of Minimal Residual Disease Defines a Novel Risk-Classification and the Role of Allo-HSCT in Adult Ph-Negative B Cell Acute Lymphoblastic Leukemia
Huard, J.
Hubbeling, H.
557 - Initial Treatment Response Is Prognostic and Predictive of Relapse Patterns: Outcomes of >500 Patients Treated for Primary CNS Lymphoma
1573 - “Big Boom” (4 Gy x 1) Radiation Treatment (RT) Versus “Big Boom” (2 Gy x 2) for Non-Hodgkin Lymphoma (NHL)
2854 - Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma
2974 - Radiotherapy for Secondary CNS Lymphoma: Patterns of Utilization and Clinical Outcomes
4292 - Safety and Efficacy of Splenic Irradiation for Non-Hodgkin Lymphoma
1573 - “Big Boom” (4 Gy x 1) Radiation Treatment (RT) Versus “Big Boom” (2 Gy x 2) for Non-Hodgkin Lymphoma (NHL)
2854 - Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma
2974 - Radiotherapy for Secondary CNS Lymphoma: Patterns of Utilization and Clinical Outcomes
4292 - Safety and Efficacy of Splenic Irradiation for Non-Hodgkin Lymphoma
Hubben, A. K.
Huber, B.
Huber, J.
Huber, S.
228 - AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages?
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
Huber, W.
745 - A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21R110
1793 - Functional Anti-Apoptotic Protein Dependence and Its Relation to Genomic Prognostic Markers and Response to Treatment in Chronic Lymphocytic Leukemia
1793 - Functional Anti-Apoptotic Protein Dependence and Its Relation to Genomic Prognostic Markers and Response to Treatment in Chronic Lymphocytic Leukemia
Huberman, K.
Huberty, P.
Hubka, K. M.
Hubner, S.
Huck, I.
691 - Pre-Clinical Characterization of VGA039, an Anti-Protein S Monoclonal Antibody Being Developed As a Universal Hemostatic Agent for Various Bleeding Disorders
3722 - Characterization of ELA026, a Clinical-Stage Monoclonal Antibody That Rapidly and Potently Depletes Myeloid Cells and T Lymphocytes
3722 - Characterization of ELA026, a Clinical-Stage Monoclonal Antibody That Rapidly and Potently Depletes Myeloid Cells and T Lymphocytes
Hudecek, M.
1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
3146 - Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
3146 - Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma
Hudson, B.
Hudson, C. A.
1498 - CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children’s Oncology Group AAML1031 Protocol
2168 - A Novel Multi-Analytic Clinical Diagnostic Assay to Detect HLA Loss of Heterozygosity in Post-Hematopoietic Cell Transplant Relapse Patients
2168 - A Novel Multi-Analytic Clinical Diagnostic Assay to Detect HLA Loss of Heterozygosity in Post-Hematopoietic Cell Transplant Relapse Patients
Hudson, K. E.
32 - Antibody-Mediated Antigen Loss Can Switch an Augmented Immune Response to Antibody-Mediated Immunosuppression
33 - Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels
1023 - Iron Overload and Iron-Induced Microbiome Changes May Affect Lymphoid Levels Post Bone Marrow Transplant and Graft-Versus-Host Disease Survival in Mice
33 - Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels
1023 - Iron Overload and Iron-Induced Microbiome Changes May Affect Lymphoid Levels Post Bone Marrow Transplant and Graft-Versus-Host Disease Survival in Mice
Hudson, M. M.
Huebel, K.
Huehn, J.
Huelgas, G.
Huen, A.
1631 - Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial
4233 - Prognostic Significance of Cutaneous Angioimmunoblastic T-Cell Lymphoma: Correlation of Clinical, Histologic and Immunophenotypic Features with Response
4245 - Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers
4233 - Prognostic Significance of Cutaneous Angioimmunoblastic T-Cell Lymphoma: Correlation of Clinical, Histologic and Immunophenotypic Features with Response
4245 - Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers
Huen, M. S. Y.
Huenecke, S.
Hueneman, K.
Huerga Domínguez, S.
Huerga Encabo, H.
Huff, C. A.
2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
3233 - Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
3233 - Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Huggins, W.
Hughes, D.
Hughes, J. R.
Hughes, M. K.
Hughes, M.
Hughes, M. E.
Hughes, S.
Hughes, T. P.
79 - Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML – Interim Results from ALLG CML13 Ascend-CML
80 - Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA
331 - Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors
1354 - PTPN11 Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph+ ALL Cells, but Are Sensitive to the Combination
1704 - Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML
3008 - Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
3012 - ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
3018 - First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies
3027 - Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia
4327 - A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income
4383 - Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm
- Treatment of TKI resistant chronic phase CML
80 - Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA
331 - Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors
1354 - PTPN11 Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph+ ALL Cells, but Are Sensitive to the Combination
1704 - Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML
3008 - Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
3012 - ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
3018 - First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies
3027 - Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia
4327 - A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income
4383 - Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm
- Treatment of TKI resistant chronic phase CML
Huguet, F.
50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
1405 - Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study
2724 - Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study
2727 - Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
3016 - Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" in Patients with TKI-Resistant or Intolerant CML
4343 - Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
1405 - Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study
2724 - Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study
2727 - Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
3016 - Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" in Patients with TKI-Resistant or Intolerant CML
4343 - Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis
Huguet, M.
Huh, J.
4232 - Interim PET-CT Scan to Improve Risk Modeling for Patients with Extranodal Natural Killer/T-Cell Lymphoma Treated with Non-Anthracycline Containing L-Asparaginase Based Regimen
4273 - Prognostic Stratification of Patients with Primary Central Nervous System Lymphoma Using Serum β2-Microglobulin Levels
4273 - Prognostic Stratification of Patients with Primary Central Nervous System Lymphoma Using Serum β2-Microglobulin Levels
Huhn, J.
Huhn, J.
Huhn, S.
860 - Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
968 - Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
4487 - Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma
4499 - The Landscape of Small Nucleolar RNA Expression in Multiple Myeloma
968 - Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
4487 - Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma
4499 - The Landscape of Small Nucleolar RNA Expression in Multiple Myeloma
Hui, S. K. (.
Hui, S.
Hui, Y.
Hui, Z.
4212 - An Open-Label, Multicenter,Single-Arm, Phase I Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of XNW5004 in Patients with Relapsed or Refractory Hematologic Malignancies
4291 - Thiotepa, Orelabrutinib, and Methotrexate Combined with or without the Rituximab Regimens in the Treatment of Patients with Central Nervous System Lymphoma
4291 - Thiotepa, Orelabrutinib, and Methotrexate Combined with or without the Rituximab Regimens in the Treatment of Patients with Central Nervous System Lymphoma
Huisman, A.
Huisman, F.
Huisman, M. V.
Huitema, A. D.
Hulbert, M. L.
Hulett, T.
Hulin, C.
160 - Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
472 - Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
569 - A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
1880 - Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study
1910 - What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort
1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
3174 - Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study
3245 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
4553 - Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
4559 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
472 - Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
569 - A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
1880 - Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study
1910 - What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort
1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
3174 - Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study
3245 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
4553 - Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
4559 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
Huls, G. A.
55 - Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial
523 - M2 Macrophages Drive Resistance to Phagocytosis and Improve Mitochondrial Metabolism in Acute Myeloid Leukemia Facilitating Leukemic Transformation and In Vivo Engraftment
535 - 10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
1645 - First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study
2593 - Functional and Molecular Characterisation of Prospectively Isolated Subclones in Individual AML Patients Reveals Distinct Gene Regulatory Networks Linked to Targetable Metabolic Vulnerabilities
2655 - Targeting PIP4K2 Lipid Kinases through Thz-P1-2 Reveals Vulnerabilities Related to Mitochondrial Homeostasis and Autophagy in Acute Leukemia
2787 - High MN1 Expression Is Associated with an Lspc-Enriched Phenotype and Glycolysis Representing a New Vulnerability in Acute Myeloid Leukemia
3329 - An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
3960 - Functional Drug Screen Identifies Thiostrepton, NAMPT Inhibitors and Metformin As Potential Candidates to Target the Macrophage Tumor Microenvironment in Acute Myeloid Leukemia
3970 - Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2-Mutant Acute Myeloid Leukemia
4117 - Full Spectrum 40-Parameter Single-Tube Flow Cytometry Analysis for Longitudinal Immunophenotyping and Tracing of Clonal Heterogeneity in AML
523 - M2 Macrophages Drive Resistance to Phagocytosis and Improve Mitochondrial Metabolism in Acute Myeloid Leukemia Facilitating Leukemic Transformation and In Vivo Engraftment
535 - 10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
1645 - First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study
2593 - Functional and Molecular Characterisation of Prospectively Isolated Subclones in Individual AML Patients Reveals Distinct Gene Regulatory Networks Linked to Targetable Metabolic Vulnerabilities
2655 - Targeting PIP4K2 Lipid Kinases through Thz-P1-2 Reveals Vulnerabilities Related to Mitochondrial Homeostasis and Autophagy in Acute Leukemia
2787 - High MN1 Expression Is Associated with an Lspc-Enriched Phenotype and Glycolysis Representing a New Vulnerability in Acute Myeloid Leukemia
3329 - An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
3960 - Functional Drug Screen Identifies Thiostrepton, NAMPT Inhibitors and Metformin As Potential Candidates to Target the Macrophage Tumor Microenvironment in Acute Myeloid Leukemia
3970 - Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2-Mutant Acute Myeloid Leukemia
4117 - Full Spectrum 40-Parameter Single-Tube Flow Cytometry Analysis for Longitudinal Immunophenotyping and Tracing of Clonal Heterogeneity in AML
Hulshof, A. M.
Hultcrantz, M.
100 - Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
103 - Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
251 - Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
646 - Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
752 - Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
992 - Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
3049 - Patterns of Childbirth in Women with Myeloproliferative Neoplasms
3225 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
3246 - Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
4549 - Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study
103 - Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
251 - Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
646 - Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
752 - Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
992 - Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
3049 - Patterns of Childbirth in Women with Myeloproliferative Neoplasms
3225 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
3246 - Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
4549 - Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study
Hultquist, A.
Humbert, M.
Humbert, P. O.
Hummel, M.
Humphrey, D.
Humphrey, J.
874 - Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
3695 - A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
4592 - The Pharmacokinetic and Pharmacodynamic Characterization of Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate for Targeted Conditioning Prior to Transplant, in Nonhuman Primates
3695 - A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
4592 - The Pharmacokinetic and Pharmacodynamic Characterization of Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate for Targeted Conditioning Prior to Transplant, in Nonhuman Primates
Humphrey, K.
74 - Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma
441 - Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment
737 - Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study
441 - Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment
737 - Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study
Humphreys, J.
Humphries, R. K.
Hunault, M.
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
2735 - Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study
4407 - Prevalence of Osteoporosis in Myelodysplastic Syndrome Patients and Association with Cytopenias
2735 - Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study
4407 - Prevalence of Osteoporosis in Myelodysplastic Syndrome Patients and Association with Cytopenias
Hundemer, M.
Hunger, S. P.
411 - Rare Deleterious TCF3 Germline Variants and Predisposition to Acute Lymphoblastic Leukemia in Children
1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
Hunger, S. P.
531 - Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
718 - Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis
901 - The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children’s Oncology Group Study
1412 - A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1
1510 - Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children’s Oncology Group Study AALL1331
2725 - A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
718 - Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis
901 - The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children’s Oncology Group Study
1412 - A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1
1510 - Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children’s Oncology Group Study AALL1331
2725 - A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations
Hungria, V. T.
1859 - Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study
1897 - A Brazilian Real-Life Experience of Multiple Myeloma Patients: Final Results from the Mmybrave Multi-Center Study
3253 - Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
3428 - Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS
1897 - A Brazilian Real-Life Experience of Multiple Myeloma Patients: Final Results from the Mmybrave Multi-Center Study
3253 - Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
3428 - Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS
Hunsucker, S. A.
Hunt, B. J.
Hunt, J.
Hunter, A.
Hunter, A. M.
82 - Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1714 - A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)
4358 - INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study
1714 - A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)
4358 - INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study
Hunter, B.
2032 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
4724 - Reduced Incidence of Cytokine Release Syndrome and Improved Outcomes with Earlier Initiation of Immunosuppressive Therapy in Haploidentical Stem Cell Transplant
4856 - Successful Outpatient Treatment and Monitoring Following Administration of Various Anti-CD19 Chimeric Antigen Receptor Therapies in B-Cell Lymphomas
4724 - Reduced Incidence of Cytokine Release Syndrome and Improved Outcomes with Earlier Initiation of Immunosuppressive Therapy in Haploidentical Stem Cell Transplant
4856 - Successful Outpatient Treatment and Monitoring Following Administration of Various Anti-CD19 Chimeric Antigen Receptor Therapies in B-Cell Lymphomas
Hunter, T.
Hunter, Z. R.
231 - Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
723 - Multi-Omic Analysis of 253 Untreated Patients with Waldenström’s Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
1538 - Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
723 - Multi-Omic Analysis of 253 Untreated Patients with Waldenström’s Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
1538 - Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
Huntington, J. A.
Huntington, S. F.
130 - Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia
1424 - Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia
2208 - Treatment Utilization Patterns, Health Resource Use, Costs, and Survival in Mantle Cell Lymphoma: A Real-World Analysis of a National Sample of Medicare Beneficiaries
2209 - Real-World Analysis of Adverse Event Rates after Initiation of Ibrutinib Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia By Ibrutinib Discontinuation Status
2890 - Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)
3542 - Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study
4857 - Real-World Treatment Patterns, Healthcare Resource Utilization, Costs, and Survival Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL)
4859 - Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis
4899 - Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis
4943 - Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib
1424 - Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia
2208 - Treatment Utilization Patterns, Health Resource Use, Costs, and Survival in Mantle Cell Lymphoma: A Real-World Analysis of a National Sample of Medicare Beneficiaries
2209 - Real-World Analysis of Adverse Event Rates after Initiation of Ibrutinib Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia By Ibrutinib Discontinuation Status
2890 - Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)
3542 - Real-World Treatment Patterns and Outcomes after Ibrutinib Discontinuation Among Elderly Medicare Beneficiaries with Chronic Lymphocytic Leukemia: An Observational Study
4857 - Real-World Treatment Patterns, Healthcare Resource Utilization, Costs, and Survival Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL)
4859 - Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis
4899 - Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis
4943 - Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib
Huntley, K.
Huntly, B.
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
295 - HOXA9 Nucleates a Repressive Chromatin Complex with Nuclear Matrix-Associated Protein- Safb to Maintain Acute Myeloid Leukemia
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
2316 - Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
3025 - Real-World Experience of Asciminib: Factors Associated with Response
- Building Real-World Research and Collaborative Practice Networks for Malignant Hematology
295 - HOXA9 Nucleates a Repressive Chromatin Complex with Nuclear Matrix-Associated Protein- Safb to Maintain Acute Myeloid Leukemia
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
2316 - Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
3025 - Real-World Experience of Asciminib: Factors Associated with Response
- Building Real-World Research and Collaborative Practice Networks for Malignant Hematology
Huo, S.
Huppunen, M. E.
Hur, E. H.
Hurd, D. D.
1919 - A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell–Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
Hurley, P.
Hurren, R.
1289 - Intracellular IL-23 Receptor (IL-23R) Is Necessary for AML Viability and Regulates Mitotic Spindle and Centrosome Formation
3925 - Inhibiting the Mitochondrial RNA Degradosome Complex SUV3 and Pnpase Increases dsRNA in the Cytoplasm, Triggers a Viral Mimicry Response and Kills AML Cells and Progenitors
3925 - Inhibiting the Mitochondrial RNA Degradosome Complex SUV3 and Pnpase Increases dsRNA in the Cytoplasm, Triggers a Viral Mimicry Response and Kills AML Cells and Progenitors
Hurst, K. E.
Hurtado Martinez, J. A. H.
Hurtz, C.
Hurwitz, M.
Hurwitz, S.
Hurwitz, S. N.
Hus, M.
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
4348 - Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
4348 - Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
Husain, J.
Husby, S.
Huselton, E. J.
132 - A Patient-Centered Communication Tool for Older Patients with Acute Myeloid Leukemia, Their Caregivers, and Oncologists: A Single Arm Pilot Study
1761 - Therapeutic Modulation of the Marrow Microenvironment in MDS: A Phase I Trial of Abaloparatide and Bevacizumab
4868 - Adaptation of the Serious Illness Care Program for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
1761 - Therapeutic Modulation of the Marrow Microenvironment in MDS: A Phase I Trial of Abaloparatide and Bevacizumab
4868 - Adaptation of the Serious Illness Care Program for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
Huskey, A. L.
Husnain, M.
Hussain, F. A.
Hussain, M.
2259 - Inpatient Burden and Clinical Outcomes of Febrile Neutropenia in Cancer Patients: A National Inpatient Sample Database Analysis
3604 - Impact of Sociodemographic and Socioeconomic Factors on Diffuse Large B-Cell Lymphoma (DLBCL)-Specific Mortality in the United States – a SEER PLUS Database Analysis Spanning 20 Years
3606 - Association of Socioeconomic and Sociodemographic Determinants on Mortality in Hodgkin’s Lymphoma in United States: A 20 Year SEER PLUS Retrospective Analysis
3604 - Impact of Sociodemographic and Socioeconomic Factors on Diffuse Large B-Cell Lymphoma (DLBCL)-Specific Mortality in the United States – a SEER PLUS Database Analysis Spanning 20 Years
3606 - Association of Socioeconomic and Sociodemographic Determinants on Mortality in Hodgkin’s Lymphoma in United States: A 20 Year SEER PLUS Retrospective Analysis
Hussain, M.
Hussain, N.
674 - Progressive Silent Cerebral Infarcts Are Prevalent in Adults with Sickle Cell Anemia but Moderate-Severe Cognitive Abnormalities Are Independent of Preexisting Silent Cerebral Infarcts
2395 - Rationale and Design of a Randomized Controlled Double-Blind Internal Pilot Trial for Prevention of Recurrent Ischemic Priapism in Men with Sickle Cell Disease (PIN Trial)
2395 - Rationale and Design of a Randomized Controlled Double-Blind Internal Pilot Trial for Prevention of Recurrent Ischemic Priapism in Men with Sickle Cell Disease (PIN Trial)
Hussaini, M.
Hussaini, M. O.
1484 - Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1-Mutated AML
1491 - The Prognostic Impact of FLT3 in NPM1-Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes
2794 - Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia
1491 - The Prognostic Impact of FLT3 in NPM1-Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes
2794 - Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia
Hussaini, P.
Hussein, M. A.
Hust, M.
Hutani, F.
Hutchings, M.
1 - Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
76 - Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial
441 - Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
1659 - Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma
4251 - Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
4817 - CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89Zr-Crefmirlimab Berdoxam
76 - Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial
441 - Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
1659 - Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma
4251 - Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
4817 - CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89Zr-Crefmirlimab Berdoxam
Hutchins, C.
Hutchinson, A.
4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
Hutchinson, L.
2547 - Natural History of Patients with Clonal Hematopoiesis Seen in Hematology Clinics
2792 - Prognostic Discrimination within a Heterogeneous Population of TP53-Aberrant Myelodysplastic Syndromes and Acute Myeloid Leukemia
4122 - Impaired Clearance of DNMT3A/TET2/ASXL1-Mutant Clones with Hypomethylating Agent or Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Acute Myeloid Leukemia
2792 - Prognostic Discrimination within a Heterogeneous Population of TP53-Aberrant Myelodysplastic Syndromes and Acute Myeloid Leukemia
4122 - Impaired Clearance of DNMT3A/TET2/ASXL1-Mutant Clones with Hypomethylating Agent or Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Acute Myeloid Leukemia
Hutchison, A.
Hutchison, B.
Huth, R.
Hutson, A.
Hutter, S.
228 - AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages?
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
790 - Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases
856 - Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS
1281 - RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
1477 - IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
2823 - Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
3487 - Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
4118 - Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup?
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
790 - Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases
856 - Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS
1281 - RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
1477 - IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
2823 - Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
3487 - Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
4118 - Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup?
Hütter-Krönke, M. L.
Hüttmann, A.
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
319 - External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
4173 - The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma
319 - External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
4173 - The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma
Huuhtanen, J.
Huw, L. Y.
1630 - Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
2871 - Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study
2871 - Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study
Huynh, A.
Huynh, A.
50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
112 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France
985 - Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS
2126 - Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis
112 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France
985 - Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS
2126 - Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis
Huynh, L.
1806 - Patient Characteristics, Treatment Patterns, and Outcomes Following Covalent Btki Discontinuation in a Contemporary Cohort of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients
4343 - Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis
4343 - Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis
Huynh, T.
256 - Targeting a Dominant Negative Splice Variant of TRAIL to Enhance CART Cell Functions
654 - Chimeric Antigen Receptor Engineering of Mesenchymal Stromal Cells (CAR-MSC) Enhance Immunosuppression and Outcomes in Graft Versus Host Disease (GvHD) Preclinical Models
977 - CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy
1981 - Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial
3862 - Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling
4610 - Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19
654 - Chimeric Antigen Receptor Engineering of Mesenchymal Stromal Cells (CAR-MSC) Enhance Immunosuppression and Outcomes in Graft Versus Host Disease (GvHD) Preclinical Models
977 - CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy
1981 - Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial
3862 - Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling
4610 - Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19
Huynh, V. T.
Huynh-Tran, Q.
Hwa, J.
Hwa, Y. L.
970 - Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma
3177 - Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma
3613 - Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes
4492 - Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide
4501 - Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
4523 - Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event
4556 - Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma – MRD Negativity and Survival Outcomes
3177 - Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma
3613 - Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes
4492 - Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide
4501 - Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
4523 - Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event
4556 - Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma – MRD Negativity and Survival Outcomes
Hwang, A. E.
Hwang, G.
1430 - Is Renal Function Equally Impacted By Hypomethylating Agents during Acute Myelogenous Leukemia Induction Therapy?
3617 - Predictors of Inferior Survival in African American Patients with Diffuse Large B-Cell Lymphoma
4028 - A Real-World Single-Institution Experience with Hypomethylating Agents Plus BCL-2 Inhibitor for the Treatment of Acute Myeloid Leukemia
4070 - Dexamethasone during Leukemia Induction Therapy to Reduce Incidence of Acute Myelogenous Leukemia Relapse
3617 - Predictors of Inferior Survival in African American Patients with Diffuse Large B-Cell Lymphoma
4028 - A Real-World Single-Institution Experience with Hypomethylating Agents Plus BCL-2 Inhibitor for the Treatment of Acute Myeloid Leukemia
4070 - Dexamethasone during Leukemia Induction Therapy to Reduce Incidence of Acute Myelogenous Leukemia Relapse
Hwang, H.
95 - Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
3341 - Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30
3341 - Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30
Hwang, S. R.
Hwang, S. R.
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
4437 - Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
4437 - Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
Hwang, T. H.
Hwang, W. T.
Hwang, W. Y.
325 - A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia
2052 - Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back Reduces Chronic Graft-Versus-Host Disease and Results in Favourable Gvhd-Relapse Free Survival: 5-Year Follow-up of 107 Patients Treated in a Multicenter Study in Singapore
3386 - Sequential Use of Flamsa, FLAG, CLAG or TEC-Based Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasia Patients: 15 Year Follow-up of the Multicenter Study in Singapore
4711 - Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore
2052 - Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back Reduces Chronic Graft-Versus-Host Disease and Results in Favourable Gvhd-Relapse Free Survival: 5-Year Follow-up of 107 Patients Treated in a Multicenter Study in Singapore
3386 - Sequential Use of Flamsa, FLAG, CLAG or TEC-Based Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasia Patients: 15 Year Follow-up of the Multicenter Study in Singapore
4711 - Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore
Hyacinth, H. I.
175 - Neuroinflammation Underlies the Development of Social Stress Induced Cognitive Deficit in Sickle Cell Disease
674 - Progressive Silent Cerebral Infarcts Are Prevalent in Adults with Sickle Cell Anemia but Moderate-Severe Cognitive Abnormalities Are Independent of Preexisting Silent Cerebral Infarcts
2374 - Quantifying Dilated Perivascular Spaces in Children with Sickle Cell Disease
674 - Progressive Silent Cerebral Infarcts Are Prevalent in Adults with Sickle Cell Anemia but Moderate-Severe Cognitive Abnormalities Are Independent of Preexisting Silent Cerebral Infarcts
2374 - Quantifying Dilated Perivascular Spaces in Children with Sickle Cell Disease
Hyde, R. K.
Hydren, J. R.
3194 - A Retrospective Comparison of the Side Effect Prevalence and Severity of Multiple Myeloma Triplet Vs Quadruplet Induction Therapy
3543 - Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study
4915 - The Top Concerns at and Since Diagnosis: Standard v. High Risk Myeloma Patients
3543 - Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study
4915 - The Top Concerns at and Since Diagnosis: Standard v. High Risk Myeloma Patients
Hylkema, T. A.
Hymes, K. B.
Hyseni, S.
Hyter, S.